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Evaluation Of 15
1
-Hydroxypurpurin-7-Lactone (G2) Derivatives, 
Boron Dipyrromethene (Bodipy) And Rosamine Analogues As 
Photosensitisers For Photodynamic Cancer Therapy  
Abstract 
 
Photodynamic therapy (PDT) is a therapeutic strategy that utilises the administration of 
a photosensitiser along with light irradiation to generate reactive singlet oxygen that 
destruct pathological lesions. However, the current clinically approved photosensitisers 
for the treatment of cancer present several limitations such as a lack in ideal 
photophysical and photochemical properties, poor solubility and adverse effects i.e. 
prolonged photosensitisation or pain following PDT.  Therefore, it is necessary to 
discover and develop new classes of photosensitiser with more ideal properties. From 
our earlier data, we had shown that 15
1
-hydroxypurpurin-7-lactone dimethyl ester (G2), 
a semisynthetic cyclic-tetrapyrrole, was a potent photosensitiser. In this study, aspartyl 
and lysyl amino acids conjugated G2 analogues were prepared and evaluated with the 
aim to further improve its PDT efficacies. Also included in this study, were two series 
of non-tetrapyrrolic photosensitisers: boron difluoride dipyrromethene (BODIPY) and 
rosamine photosensitisers.   Both classes of compounds have many characteristics of an 
ideal photosensitiser and their syntheses are relatively easy to perform and scale-up. For 
the G2 analogues, results from the study indicated that conjugation of aspartyl or lysyl 
amino acids was able to modify its properties including light absorption coefficient, 
singlet oxygen quantum yield, cellular uptake and intracellular localisation. Both 
conjugations were able to improve the aqueous solubility but resulted in reduced in vitro 
PDT potency. Further evaluation showed that G2-aspartyl (G2-Asp)  was able to 
achieve similar potency compared to G2 in terms of vasculature occlusion efficiency in 
chorioallantoic membrane (CAM) model and tumour growth inhibition in a syngeneic 
mouse model. Meanwhile for the BODIPYs, in vitro data indicated that BODIPY with 
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iodinated core exhibited potent photo-induced cytotoxicity at sub-micromolar IC50 
concentrations. Further studies on a lead BODIPY showed exclusive mitochondria 
localisation, induction of G2/M-phase cell cycle block and onset of apoptosis. The 
BODIPY molecules also extensively occluded the vasculature of the CAM model. 
Conversely for the rosamines, they were found to be minimally photoactive, even 
though several of the derivatives exhibited potent cytotoxicity (average IC50 < 0.5 μM) 
which was found to be associated with their ability to compromise mitochondrial 
membrane potential and to inhibit the oxidative phosphorylation complexes primarily 
the ATP synthase. Preliminary in vivo studies on 4T1 murine breast cancer-bearing 
female BALB/c mice indicated that treatment with a lead rosamine in a single dosing of 
5 mg/kg or a scheduled dosing of 3 mg/kg once every two day for six times (q2d×6) 
exhibited only minimal tumour growth delay. In conclusion, G2-Asp given its 
hydrophilic nature, is a pharmaceutically advantageous candidate to be developed into a 
clinical photosensitiser as it can be formulated easily for administration. Meanwhile for 
the non-tetrapyrrolic photosensitisers, BODIPY with an iodinated core structure may 
have potential as new PDT agents for cancer, while the rosamine analogues may be 
further developed as mitochondrial targeting agents that either directly kill or deliver 
cytotoxic drugs to selectively kill cancer cells.  
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Evaluasi Derivatif 15
1
-Hidroksipurpurin-7-Lakton (G2), Boron 
Dipyrromethane (BODIPY) dan Rosamin Sebagai Fotosensitiser 
Untuk Terapi Kanser Secara Fotodinamik  
 
 
Abstrak 
Terapi fotodinamik (PDT) merupakan strategi terapeutik yang melibatkan 
penggunaan molekul fotosensitif (fotosensitiser) bersama-sama dengan penyinaran 
cahaya untuk menjana molekul oksigen singlet yang reaktif yang berupaya 
memusnahkan lesi patologi. Walau bagaimanapun, fotosensitiser semasa yang 
diluluskan untuk rawatan klinikal kanser mempunyai beberapa batasan contohnya; 
kekurangan ciri-ciri fotofizikal and fotokimia yang ideal, tahap kelarutan yang rendah 
dan kehadiran kesan sampingan seperti fotosensitiviti yang berpanjangan dan kesakitan 
berikutan PDT. Oleh itu, penemuan kelas fotosensitiser yang baru dengan ciri-ciri yang 
lebih ideal harus diberi keutamaan. Kajian terdahulu kami telah menunjukkan bahawa 
15
1
-hidroksipurpurin-7-lakton dimetil ester (G2) merupakan fotosensitiser tetrapirol 
bersiklik separa sintetik yang poten. Dalam kajian ini, analog G2 yang dikonjugasikan 
dengan asid amino seperti asid aspartik dan lisin telah disediakan dan diuji dengan 
tujuan meningkatkan keberkesanan PDT. Kajian ini juga merangkumi dua siri 
fotosensitiser bukan tetrapirol iaitu boron difluoride dipyrromethene (BODIPY) dan 
rosamin. Kedua-dua kelas sebatian ini mempunyai ciri-ciri fotosensitiser yang ideal dan 
kaedah sintesis mereka adalah mudah untuk melaksanakan. Hasilan daripada kajian ini 
menunjukkan G2 yang dikonjugasi dengan asid aspartik atau lisin mengubah parameter 
termasuk koefisian molar penyerapan, kuantum penghasilan oksigen singlet, penyerapan 
sel dan intra-selular lokalisasi. Kedua-dua konjugasi ini berupaya meningkatkan 
kelarutan akueus tetapi dengan pengurangan potensi PDT in vitro. Kajian selanjutnya 
menunjukkan bahawa G2-aspartil (G2-Asp) mampu mencapai potensi yang sama 
berbanding dengan G2 dari segi efikasi oklusi vaskular dalam model membrane 
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korioalantoik (CAM) model dan perencatan pertumbuhan tumor dalam model mencit 
syngenik. Sementara itu, bagi sebatian BODIPY, data in vitro menunjukkan bahawa 
BODIPY berteraskan iodin mempamerkan foto-sitotoksiksiti yang tinggi dengan nilai 
IC50 pada kepekatan sub-mikromolar. Kajian lanjutan keatas BODIPY pilihan 
menunjukkan lokalisasi mitokondria secara eksklusif, menghalang kitaran sel pada fasa 
G2/M dan apoptosis. Molekul BODIPY ini juga menyebabkan oklusi vaskular CAM 
secara menyeluruh. Sebaliknya, rosamin didapati mempamerkan fotoaktiviti yang 
minima, tetapi beberapa terbitannya menunjukkan sitotoksiksiti yang tinggi (purata IC50 
< 0.5 μM). Aktiviti ini dikaitkan dengan keupayaan mereka untuk mengkompromasikan 
potensi membran mitokondria dan merencat kompleks pemfosforilan oksidatif 
terutamanya ATP sintase. Kajian awalan in vivo menggunakan mencit BALB/c betina 
yang diinokulasi dengan kanser payudara 4T1 menunjukkan bahawa rawatan rosamin 
utama dengan dos individu (5 mg/kg) atau dos berkala (3 mg/kg sekali setiap dua hari 
untuk enam kali, q2d×6) melewatkan pertumbuhan tumor hanya pada kadar yang  
minimum. Kesimpulannya, G2-Asp yang bersifat hidrofilik, adalah calon farmaseutikal 
yang berpotensi untuk dibangunkan sebagai fotosensitiser klinikal kerana ia boleh 
diformulasikan dengan mudah untuk pentadbiran. Sementara itu, bagi fotosensitiser 
bukan tetrapirol, BODIPY dengan struktur berteraskan iodin mempunyai potensi 
sebagai agen baru PDT untuk kanser, manakala analog rosamin boleh terus 
dibangunkan sebagai agen sasaran mitokondria yang sama ada secara langsung 
membunuh atau sebagai agen penghantaran sebatian sitotoksik untuk membunuh sel-sel 
kanser. 
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CHAPTER 1 
 
Introduction 
 
1.1 Overview 
Photodynamic therapy (PDT) is a therapeutic strategy that utilises the administration of 
a photosensitiser along with irradiation of light to generate reactive singlet oxygen that 
destruct pathological lesions.  PDT is a clinical modality approved mainly for palliative 
and curative treatment of some forms of cancers (superficial and luminal carcinomas), 
precancerous lesions and the treatment of age-related macular degeneration. The 
advantages of PDT over conventional treatment such as surgery, chemotherapy or 
radiotherapy are their potential for dual selectivity i.e. preferential accumulation of 
photosensitisers in diseased over normal tissues, and focusing of light to confine 
damage to the targeted region thus minimising collateral damage to normal tissues 
(Dolmans et al. 2003; Castano et al. 2004; Agostinis et al. 2011). So far, there are only 
five photosensitisers, namely Photofrin
®
, Levulan
®
, Foscan
®
, Laserphyrin
®
 and 
Photolon
®
 that have been approved for PDT treatment of cancer and they are all cyclic-
tetrapyrroles. However, these photosensitisers have several limitations such as lack of 
long and strong light absorbance which is essential for effective light penetration into 
tissues, poor solubility and prolonged photosensitisation or pain following PDT.  
Furthermore, the majority of photosensitisers being investigated in clinical trials 
share a common cyclic-tetrapyrrole structure, probably due to the fact that modern PDT 
has evolved from the naturally derived cyclic-tetrapyrroles such as haematoporphyrin 
(Nyman and Hynninen 2004; Wainwright 2009). However, challenges in synthesis and 
purification of cyclic-tetrapyrroles have restricted modulation of their photophysical and 
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biological properties through chemical derivatisation during drug development. For 
example, functionalisation of tetrapyrrole is often limited to meso-position with 
unsatisfactory yields that required laborious chromatographic separation (Feng and 
Senge 2001). Hence, there is an interest among photodynamic research groups in 
discovering other cyclic-tetrapyrrole or non-tetrapyrrole photosensitisers that might be 
synthetically more accessible.  
We had previously shown that 15
1
-hydroxypurpurin-7-lactone dimethyl ester 
(G2), a semisynthetic cyclic-tetrapyrrole, was a potent photosensitiser and was found to 
be a promising clinical PDT candidate (Lim et al. 2011). However, like many 
tetrapyrrole photosensitisers, G2 is highly conjugated and therefore its solubility in 
aqueous media is poor. To overcome this, hydrophilic amino acids conjugated G2 
analogues had been prepared with the aim to improve its solubility and efficacies. In 
this study, these G2 analogues were evaluated for their photophysical properties, in vitro 
photo-killing efficacy, single oxygen generation quantum yield, photobleaching, 
intracellular uptake and subcellular localisation. The most promising G2 analogue was 
further evaluated in a mouse tumour allograft model to establish its in vivo efficacies. 
Additionally, two alternative classes of non-tetrapyrrole photosensitisers, 
namely boron difluoride dipyrromethene (BODIPY) and rosamine were also evaluated 
as potential PDT agents.  Both BODIPY and rosamine are widely used as fluorescence 
imaging probe and have many characteristics of an ideal photosensitiser including, high 
extinction coefficients, high quantum efficiencies of fluorescence, relative insensitivity 
to the environment and resistance to photobleaching (Gorman et al. 2004).  The 
synthesis of BODIPY and rosamine analogues is relatively straightforward, thus 
facilitating compound series preparation and scale-up (Loudet and Burgess 2007; Wu 
and Burgess 2008b). The capability for derivatisation is crucial in improving the 
selectivity and therapeutic efficacy of photosensitiser as this process may change their 
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photosensitising properties and their pharmacology/pharmacokinetic profiles by altering 
the hydrophilic/lipophilic balance. In terms of photodynamic action, only a few 
examples of BODIPYs and rosamines have been investigated even though a great range 
of derivatives could be easily synthesised. 
In the initial part of this study, BODIPYs and rosamines were screened for their 
in vitro photocytotoxicity efficacy  and their structure-activity relationship was 
analysed.  The effects of the most promising candidates from both classes of compounds 
were further investigated in intracellular localisation, cell cycle arrest and onset of 
apoptosis experiments. Subsequently for the BODIPY series, their photosensitising 
properties were evaluated in terms of their PDT-induced vascular occlusion efficacy in a 
preclinical model using the chick chorioallantoic membrane (CAM). Meanwhile, due to 
the poor photo-induced cell killing of the rosamines and their selective accumulation in 
mitochondria, these compounds were further evaluated as a mitochondria targeting 
drug. As potential mitochondrial drugs, the effects of rosamines on cellular redox 
systems in terms of induction of mitochondrial transmembrane potential loss and 
oxidative phosphorylation enzymes inhibition were evaluated. The in vivo antitumour 
activity of the most potent rosamine was then investigated in a syngeneic mouse tumour 
model. Selected rosamines were also tested in the NCI-60 cell lines panel of the 
National Cancer Institute’s (NCI) Developmental Therapeutics Program in their in vitro 
screening platform.  
The overall strategies used to evaluate the three different classes of 
photosensitiser were slightly different as they have unique design features to enhance 
PDT efficacy. For example, G2 was not tested for its ability to induce cell cycle arrest 
or apoptosis as both the experiments had been previously reported (Lim et al. 2011). 
Instead, this work is a continuation to evaluate the effects of ionic amino acid 
conjugation on the solubility of G2 where experiments such as Log D, photostability 
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and cellular uptake studies were carried out. As for the rosamines which were found to 
be cytotoxic, a different approach was used to study their effects on mitochondrial 
transmembrane potential and oxidative phosphorylation enzymes activities. NCI-60 
screening was also performed on the rosamines to elucidate their possible mechanism(s) 
of action. While the in vitro experiments were done using human-derived cancer cell 
lines, the in vivo experiments were carried out using 4T1-mouse mammary carcinoma in 
syngeneic BALB/c mouse model instead. The reason is because BALB/c syngeneic 
model has intact systemic immunity which is lacking in nude mice xenograft, and 
therefore, it is relevant for interrogating the activation of the immune system by PDT in 
the future. Furthermore, PDT is not known to have species-specific effects as the 
cytotoxic agents of PDT are reactive singlet oxygen.  
 
1.2 Aim and Objectives 
The main aim of the study is to investigate the in vitro and in vivo PDT efficiencies of 
hydrophilic amino acids conjugated G2 analogues and two series of non-tetrapyrrole 
photosensitisers namely BODIPY and rosamines. Rosamines were later evaluated for 
non-PDT antitumour activities given their interesting antitumour potency and lack of 
photodynamic activity. The specific objectives of this study are as follows: 
 
1) To compare the PDT efficacies of a series of hydrophilic amino acids conjugated G2 
in terms of their: 
a) photophysical properties such as molar extinction coefficient, absorption 
maxima and fluorescence quantum yield, as well as their photochemical 
properties such as singlet oxygen generation, distribution coefficiency (Log 
D in octanol/PBS pH 7.4) and photostability. 
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b) in vitro bioactivities such as cellular uptake, intracellular localisation and 
photo-induced cytotoxicity. 
c) in ovo PDT-induced vasculature occlusion efficiency using CAM model and 
in vivo PDT antitumour efficacy in BALB/c mice bearing 4T1-mouse 
mammary tumour. 
2) To evaluate the PDT efficacies of differently substituted BODIPYs in terms of their: 
a) photophysical properties such as molar extinction coefficient, absorption 
maxima and fluorescence quantum yield, as well as their photochemical 
property such as singlet oxygen generation. 
b) in vitro bioactivities such as photo-induced cytotoxicity potency, 
intracellular localisation, cell cycle arrest and onset of apoptosis. 
c) in ovo PDT-induced vasculature occlusion efficiency using CAM model. 
3) To investigate the PDT/antitumour efficacies of cyclic-amine substituted rosamine 
in terms of their: 
a) photophysical properties such as molar extinction coefficient, absorption 
maxima and fluorescence quantum yield. 
b) in vitro bioactivities such as photo-induced cytotoxicity potency, 
intracellular localisation, cell cycle arrest and onset of apoptosis. 
c) effect on the cellular redox systems, namely mitochondrial transmembrane 
potential and oxidative phosphorylation enzymes activity. 
d) in vivo antitumour efficacy in BALB/c mice bearing 4T1-mouse mammary 
tumour. 
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CHAPTER 2 
 
Literature Review 
 
2.1 Photodynamic Therapy 
Photodynamic therapy (PDT) is a well-recognised and an approved modality for the 
palliative and curative treatment of some forms of cancers (refer to Table 2.1), 
premalignant lesions such as actinic keratosis and the treatment of neovascularisation-
related disorders such as age-related macular degeneration (Dolmans et al. 2003).  The 
application of PDT requires three key components, namely a non-toxic photosensitising 
drug, known as photosensitiser, non-damaging light and tissular oxygen. PDT is a two-
step procedure (Figure 2.1) involving the administration of photosensitiser either 
topically or systematically, in which the photosensitiser will selectively accumulate in 
the tumour after a period of systemic distribution. The tumour lesions are then focally 
irradiated with light at a specific wavelength (mostly in red or far-red, 600-800 nm 
region) to activate the photosensitiser.  Through a series of photochemical reaction, 
highly reactive singlet oxygen molecules are generated from molecular oxygen by the 
activated photosensitiser that subsequently cause damage to lesion tissues (Dolmans et 
al. 2003; Agostinis et al. 2011). This effect is highly localised given the short half-life of 
singlet oxygen ~0.6 µs (Moan and Berg 1991).  In cancer treatment, PDT is capable of 
inducing cellular death of tumour, the shutting down of blood vessels feeding the 
tumour and the activation of immunological responses against tumour cells (Juarranz et 
al. 2008).  These detailed mechanisms of tumour ablation induced by PDT will be 
discussed in Section 2.5.2. 
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Figure 2.1 Treatment protocol of PDT. PDT is a two-step procedure, where a drug 
known as photosensitiser is first injected into the patient body and allowed to 
accumulate at the tumour site. In the second step, the tumour site is irradiated with light 
in order to activate the photosensitiser to selectively destroy the tumour. 
 
The main attribute of PDT is the potential for dual selectivity, i.e. preferential 
accumulation of photosensitiser in diseased over normal tissues, and focusing of light to 
confine damage to the targeted region thereby minimising collateral damage to normal 
tissue (Castano et al. 2004).  This makes PDT less invasive compared to conventional 
treatments such as surgery, by preserving tissue structure and retaining anatomical 
functions and mechanical integrity of hollow organs such as tongue, larynx and bladder. 
PDT is a suitable modality for treating patients with tumour occurring in complex 
regional anatomy or close proximity to vital structures which is often inoperable with 
surgery (Lou et al. 2004). Besides that, the excellent post-treatment cosmesis outcome 
i.e. minimal scarring, makes PDT the preferred modality for treating skin cancers 
(Wang et al. 2001).  
Unlike chemotherapy and radiotherapy, PDT has no cumulative toxicity as 
photosensitisers are non-toxic in the absence of light. None of the clinically approved 
photosensitisers accumulate in cell nuclei, thereby eliminating DNA damage that can 
Administration 
of 
photosensitiser 
Photosensitiser 
allow to 
accumulate in 
the tumour 
Site-specific 
light irradiation 
to selectively 
destroy tumour 
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potentially cause cancer or lead to the induction of resistant clones (Agostinis et al. 
2011). Therefore, PDT can be repeated without development of resistance (Dolmans et 
al. 2003). Moreover, immunosuppression commonly present in conventional therapy is 
not observed in PDT but in fact, PDT is known to trigger activation of both innate and 
adaptive immune system (Castano et al. 2006; Garg et al. 2010). 
In cancer therapy regimens, PDT can be used before or after surgery or, in 
combination with chemotherapy or radiotherapy, without compromising their treatment 
modalities (Agostinis et al. 2011). The sensitivity of PDT is not affected by 
chemoresistance or radioresistance, therefore PDT is useful to treat recurrent tumours, 
especially in patients who have previously been treated by chemotherapy or 
radiotherapy, but are unsuitable for other treatment options. In addition, PDT 
procedures can be performed on an outpatient basis, which is more cost-effective and 
patient-friendly (Agostinis et al. 2011). 
PDT has several limitations. Due to the limited tissue penetration of light, PDT 
is more effective for thin, superficial tumours and for tumours situated within hollow 
organs. PDT in general is ineffective for treating metastases due to their highly localised 
effect. However, studies have demonstrated that PDT can activate the adaptive immune 
response and resulted in regression of distant untreated tumours in patients who 
received PDT (Thong et al. 2007). The common adverse effects of PDT are pain during 
treatment and photosensitivity, and because of this, local anesthesia or painkiller is 
given to manage the pain, whereas photosensitivity can be prevented by avoiding direct 
exposure to sunlight or bright indoor light for a period of time post-treatment. 
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2.2 Light in PDT 
PDT is a type of radiation therapy but unlike radiotherapy which utilises ionising 
radiation such as x-ray and gamma-ray, the radiation used in PDT is non-ionising and 
therefore does not cause tissue damage on its own. The spectrum of light relevant to 
PDT covers the limited range of the visible light between 400 to 800 nm. While non-
ionising, photon energy from visible light may still be able to induce certain molecules 
to become electronically-excited. In order to achieve optimal photosensitiser excitation, 
the ideal irradiation light wavelength used should correspond with the absorption 
maxima of the photosensitiser.  However, the nature of light penetration depth into 
biological tissue (tissue optical window) needs to be considered for successful PDT 
outcome. 
 
Figure 2.2 Tissue optical window. The absorption spectra of tissue interference 
components such as water, oxy- and deoxyhemoglobin and melanin which limit the 
light penetration of tissue. The figure was adapted from Castano et al. (2004). 
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The light penetration in tissue generally is limited by the presence of light 
interfering components of tissues such as water that absorbs infra-red light, and oxy-
/deoxyhemoglobin and melanin that absorb UV light as shown in Figure 2.2 (Castano et 
al. 2004; De Felice 2010). Therefore, tissue to some extent is much more transparent at 
longer wavelengths 600-1400 nm (red to infra-red), while blue light penetrates least 
efficiently. Even though wavelengths up to 1400 nm have good penetration, the use of 
wavelengths beyond 800 nm is restricted given its insufficient energy to initiate 
photochemical reaction (Juzeniene et al. 2006). The choice of light wavelength used 
also depends on the depth and size of lesion tissues (Agostinis et al. 2011). For an 
instance, shorter wavelengths such as blue and green light have lesser tissue penetration 
depth of approximately 0.5-2.5 mm, are much preferred for treatment of thin, superficial 
cancer such as basal cell carcinoma, melanoma, cutaneous T-cell lymphoma in order to 
minimise photodamage on healthy tissues underneath these cancers. Meanwhile, the use 
of longer red light wavelengths, which have deeper tissue penetration of about 8-10 
mm, allowed treatment of larger or deep-seated tumours as shown in Figure 2.3 (Tuchin 
1997).  
The light source for PDT can be either from lasers, incandescent- and LEDs- 
(light emitting diodes) lights, and is mostly delivered or directed to the target area using 
endoscopes coupled with fiber optics with a diffusing tip (Brancaleon and Moseley 
2002). Light dosimetry is crucial in PDT for successful eradication of cancerous lesions, 
while causing minimal injury towards normal tissues. Nevertheless, the optimum light 
dose is difficult to quantify due to the reflecting, scattering and absorbing characteristics 
of light, and the divergent tissue optical density that varies for each individual (Zhu and 
Finlay 2008; Agostinis et al. 2011).  Given the complexity of measuring these factors, in 
current clinical practice, light delivered to the target site exceeds the dose pre-
determined in prior clinical trials and is in accordance with standard light doses  (Mang 
11 
 
2008; Zhu and Finlay 2008). For example, the standard light dose used in clinical PDT 
is 200 J/cm
2
 is illuminated with light at a typical fluence rate of 150 W/cm
2
.  
 
 
Figure 2.3 Tissue penetration depth of light at violet, blue, green and red wavelengths 
(as indicated by different colour bars). The scale bar on the right shows the depth of 
light penetration through tissues which increased with longer wavelengths. While the 
light beam travel through the tissue, part of the light will be reflected, scattered and 
absorped. The figure was adapted from Agostinis et al. (2011). 
 
2.3 Photosensitisers 
A photosensitiser is a compound with the ability to absorb light and subsequently 
initiates photophysical or photochemical reactions. For instance, a photosensitiser for 
PDT can be promoted to an excited state upon absorption of light and react with oxygen 
to produce singlet oxygen. The typical chemical structure of photosensitisers consists of 
a multiple planar-aromatic moiety known as chromophore, that is conjugated with 
peripheral groups known as auxochrome (Wainwright 2009). The chromophore 
comprise of π–electron system which is crucial for the photosensitisers ability to absorb 
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visible light and to mediate the conversion of absorbed light to other forms of physical 
or chemical energy. Meanwhile, the auxochromes participate in delocalising the 
electron system around the structure, thereby varying the photophysical and 
photochemical properties of the photosensitisers. 
 
2.3.1 Ideal Photosensitiser Characteristics 
In general, certain characteristics of photosensitiser are considered ideal for PDT as 
outlined by Allison and Sibata (2010), and Garland et al. (2009). An ideal 
photosensitiser for PDT must have relatively high absorption extinction coefficients 
(>20000-30000 M
-1
cm
-1
), at wavelength between 650-800 nm in order to achieve 
sufficient excitation energy and effective tissue penetration. As discussed in Section 2.2, 
absorption bands at shorter wavelengths (< 600 nm) have lower tissue penetrationdepth, 
whereas photons with wavelengths longer than 800 nm will not have sufficient energy 
to excite a photosensitiser to its singlet state and to yield substantial reactive oxygen 
species.  Furthermore, a photosensitiser with low fluorescence quantum yield is 
preferred as fluorescence occurs through relaxation from singlet excited states, since 
high quantum yields for fluorescence means much of the energy absorbed on excitation 
does not crossover to triplet states for effective singlet oxygen generation.  Other 
properties, such as low photobleaching quantum yield as photobleaching reduces the 
availability of photosensitiser, and high singlet-to-triplet intersystem crossing 
efficiencies, are desirable for optimal singlet oxygen generation. 
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Table 2.1 Clinically approved or in trials photosensitisers for cancer treatment. 
Photosensitisers Trade name Structure Indication 
Porfimer sodium, 
(hematoporphyrin 
derivative) 
Photofrin Porphyrin Approved: early and advanced lung 
cancer, esophagus and bladder cancer 
Clinical trials: cervical, bile duct, 
brain, ovarian and breast cancer 
5-aminolevulinic acid  
(ALA) 
Levulan Porphyrin precursor Approved: esophagus cancer 
Clinical trials: skin, bladder and brain 
cancer 
ALA-ester Metvix,  
Hexvix 
Porphyrin precursor Approved: Non-melanoma skin cancer, 
basal cell carcinoma Clinical trials: 
bladder cancer  
Temoporfin, m-
tetrahydroxyphenylchlor
in (mTHPC)  
Foscan Chlorin Approved: recurrent head and neck 
cancer 
Clinical trials: lung, brain, skin and 
bile duct cancer 
Verteporfin 
(benzoporphyrin 
derivative 
monoacid ring A) 
Visudyne Chlorin Approved: age-related macular 
degeneration (ophthalmic) 
Clinical trials:  pancreatic, basal and 
squamous cell carcinoma 
Mono-(L)-
aspartylchlorin-e6 
Talaporfin, 
Laserphyrin 
Chlorin Approved: early lung cancer 
Clinical trials: liver, head and neck, 
colorectal, brain and breast cancer 
Chlorin e6-
polyvinylpyrrolidone 
(Ce6-PVP)  
Photolon Chlorin Approved: skin and mucous membrane 
cancer 
Clinical trials: nasopharyngeal cancer, 
sarcoma, brain cancer 
Tin ethyl etiopurpurin 
(SnEt2) 
Purlytin Chlorin Clinical trials: Kaposi’s sarcoma, 
metastatic breast cancer, prostate 
cancer 
Pyropheophorbide-a 
hexyl ether (HPPH) 
Photochlor Chlorin Clinical trials: head and neck cancer, 
Barett’s esophagus, lung cancer 
Padoporfin  Tookad Bacteriochlorin Clinical trials: prostate cancer 
Motexafin texaphyrin  Lutex Texaphyrin Clinical trials: lung, cervical, prostate 
cancer 
Silicon phthalocyanine  Pc4 Phthalocyanine Clinical trials: cutaneous T-cell 
lymphoma 
Rose Bengal PV-10 Fluorescein Clinical trials: metastasis melanoma, 
liver and breast cancer  
Hypericin - Anthraquinone Clinical trials: brain cancer, cutaneous 
T-cell lymphoma 
Source from http://clinicaltrials.gov and Agostinis et al. (2011) 
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In terms of bioactivity, a photosensitiser must have little or no toxicity in the 
absent of light and must be eliminated from the body immediately after treatment to 
reduce PDT side-effects such as skin photosensitivity after irradiation. Preferably, the 
photosensitiser selectively accumulates and retains in the disease tissues to avoid 
irradiation injury to surrounding healthy tissues. In pharmaceutics standpoint, the 
photosensitiser should be a pure compound with constant composition to ease dose 
standardisation and it should be easy to synthesise and manipulate for derivatisation. 
Other properties such as stability, good solubility in accepted pharmaceutical 
formulation and low tendency to aggregate following dosing are ideal. Table 2.1 lists 
the photosensitisers that have been approved or in clinical trials for anticancer PDT. 
These photosensitisers can be classified based on their chemical structures to two 
distinct groups, namely cyclic-tetrapyrrole and non-tetrapyrrole.  
 
2.3.2 Cyclic-Tetrapyrrole Photosensitisers 
To date, most of the photosensitisers used in cancer therapy or being investigated in 
clinical trials have a common cyclic-tetrapyrrole structure, which is similar to 
hemoglobin and chlorophyll. This is probably due to the fact that modern PDT has 
evolved from the use of porphyrins and ultraviolet light in image-guided surgical 
resection of neoplastic tissue (Nyman and Hynninen 2004; Wainwright 2009). This 
class of photosensitisers includes porphyrins, chlorins, bacteriochlorins, 
phthalocyanines, and related chromophore structures.  
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2.3.2.1 Porphyrins 
(a) Hematoporphyrin  
One of the earliest therapeutic successes in clinical PDT was the discovery of porfimer 
sodium (Figure 2.4), a water-soluble mixture of oligomers of up to eight units of 
hematoporphyrin formed by ester and ether linkages (Brown and Truscott 1993). A 
purified form of the porfimer sodium was marketed as Photofrin
TM
 and to date is the 
most commonly use photosensitiser in the clinic.  Photofrin was first approved in 
Canada (1993) for the treatment of bladder cancer and subsequently approved by the 
United States Food and Drug Administration (FDA) for the indication of esophageal 
cancer (1995), non-small cell lung cancer (1998) and Barrett’s esophageal disease 
(2003).   
 
Figure 2.4 Structure of hematoporphyrin. 
 
In clinical practice, porfimer sodium is activated by red light at a wavelength of 
630 nm. The disadvantage with this short wavelength is that the tissue penetration of 
light is poor, thus making porfimer sodium only suitable for superficial tumour. 
Moreover, the low absorbance of porfimer sodium at 630 nm (molar extinction 
coefficient, ε = 3000 M-1cm-1) necessitates the use of high energy and long irradiation of 
light which often leads to irradiation site discomfort and pain. Other disadvantages of 
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porfimer sodium are their prolonged skin photosensitivity of up to 10 weeks as a result 
of their complex mixture that tends to break down slowly over time (Sharman et al. 
1999). Due to the disadvantages of porfimer sodium, there has been a major effort in 
PDT research to develop second generation photosensitisers which are more effective. 
 
(b) Protoporphyrin IX 
 
Figure 2.5 Structures of protoporphyrin IX photosensitiser and its precursor 5-
aminolevulinic acid (ALA). 
                         
One notable second generation photosensitiser was 5-aminolevulinic acid 
(ALA), a non-photoactive precursor for the biosynthesis of the protoporphyrin IX 
(PpIX) photosensitiser (Figure 2.5) (Kennedy and Pottier 1992). Both ALA and PpIX 
are endogenous components that occur naturally as part of the heme biosynthesis as 
illustrated in Figure 2.6. Unlike other photosensitisers which accumulate in tumour 
through hydrophilic/hydrophobic balance, administration of exogenous ALA leads to 
build up of PpIX because of the inherent lower enzymatic activity of ferrochelatase in 
tumours which converts PpIX to heme (Kloek et al. 1998; Wachowska et al. 2011). 
 
 
heme biosynthesis 
pathway 
 
5-aminolevulinic acid (ALA)  protoporphyrin IX (PpIX) 
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Figure 2.6 The heme synthesis pathway in cells using endogenous/exogenous 5-
aminolevulinic acid (ALA) or exogenous ALA-ester as a precursor. Given the inherent 
lower ferrochelatase activity in tumours which converts protoporphyrin IX (PpIX) to 
heme, lead to a build-up of protoporphyrin IX (PpIX). Illustration was adapted from 
(Wachowska et al. 2011). 
 
ALA (Levulan
TM
) received U.S. FDA approval for the treatment actinic 
skerolosis in 1999 and esophageal dysplasia in 2007 (Wachowska et al. 2011). The 
advantages of ALA are its rapid clearance from the body and high selectivity for 
malignant lesions. The rapid systemic clearance of ALA induced-PpIX within 24 h 
through the formation of heme by healthy tissues minimises the risk of prolonged 
photosensitivity (Webber et al. 1997; Wachowska et al. 2011). However, ALA is 
hydrophilic and has limited penetration into biological barriers with lipophilic 
co
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characteristics especially the highly lipophilic stratum corneum, the outermost layer of 
epidermis, given that ALA is administered topically in PDT treatment of basal cell 
carcinoma (Fotinos et al. 2006). To overcome this shortcoming, a methyl-
aminolevulinic acid (MAL, Metvix
TM
) which is more lipophilic was synthesised (Godal 
et al. 2006). MAL was approved for the treatment of actinic keratosis and non-
melanoma skin cancers, namely basal cell carcinoma in Australia, New Zealand and 
some European countries. Nevertheless, the absorption spectrum and absorbance for 
PpIX (λabs = 630 nm, ε = 5000 M
-1
cm
-1
) is very similar to porfimer sodium and therefore 
has not improved light-tissue penetration and is always associated with pain at 
irradiation site as high energy light is applied  (Warren et al. 2009). 
 
2.3.2.2 Chlorins 
Other than porfimer sodium and PpIX (from ALA) which are porphyrin-based, the other 
clinically approved photosensitisers are all chlorin structures.  When compared to 
porphyrins, the structure of chlorins are more reduced, contain two extra hydrogens in 
one pyrrole ring. This structural change leads to a bathochromic shift in the absorption 
band (640-700 nm) and gives ε ~ 40000 M−1cm−1, allowing better photosensitizing 
efficiency and deeper tissue light penetration. 
 
(a) Temoporfin 
The first of these is 5,10,15,20-tetra(3-hydroxyphenyl)-2,3-dihydroporphyrin, 
temoporfin, which is a pure synthetic compound (Figure 2.7). Temoporfin (Foscan
TM
) is 
currently approved for PDT treatment of advanced head and neck cancer in Europe and 
has much more desirable properties compared to porfimer sodium and ALA in terms of 
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better potency, strong absorption at wavelength of 652 nm and shorter skin 
photosensitivity of 2-4 weeks (Senge and Brandt 2011).  
 
Figure 2.7 Structure of temoporfin. 
 
Temoporfin displays 100-200 fold better potency than Photofrin that even in the 
presence of very dim light will lead to severe skin photosensitivity (Allison and Sibata 
2010). The downside of temoporfin is its highly hydrophobicity causing it to precipitate 
easily upon administration (Kiesslich et al. 2007). As a consequence, temoporfin 
follows a very slow distribution pharmacokinetic attributed to its slow release from the 
aggregates to monomeric form (Hopkinson et al. 1999). This has resulted in a four-day 
delay between injection of the photosensitiser into the bloodstream and activation with 
light (Sasnouski et al. 2006). During this period, patients are highly photosensitive to 
light and therefore appropriate light exposure precautions should be followed. 
 
(b) Verteporfin 
The verteporfin, a benzoporphyrin derivative monoacid ring A (Figure 2.8), is one of 
the more ideal photosensitisers among the list with long activation wavelength at 690 
nm, rapid clearance from the body and short periods (only few hours) of skin 
20 
 
photosensitivity than Photofrin (Houle and Strong 2002). This photosensitiser is 
vascular acting and is particularly useful for treating highly vascularised lesions (Chen 
et al. 2006b). In clinical verteporfin-PDT, light treatment is initiated within 30 min of 
photosensitiser infusion. This together with its rapid body clearance thereby makes them 
suitable for use in outpatient setting. 
 
Figure 2.8 Structure of verteporfin. 
 
Verteporfin is a lipophilic compound that will self-aggregate in aqueous solution 
(Aveline et al. 1995), but following formulation with liposome (Visudyne
TM
), this 
compound becomes one of the most successful photosensitisers used for the treatment 
of age-related macular degeneration caused by abnormal blood vessel growth of the 
retina (Cruess et al. 2009). Present clinical trial data showed that verteporfin is 
particularly useful for the PDT treatment of non-melanoma skin cancer (Lui et al. 2004) 
and pancreatic cancer (Celli et al. 2011).  
 
(c) Chlorin e6 derivatives 
Two other chlorin-based photosensitisers approved for clinical applications are the 
mono-aspartyl-L-chlorin e6 (also known as talaporfin) and chlorin e6-
polyvinypyrrolidone (Figure 2.9). Talaporfin is marketed in Japan as Laserphyrin
TM
 for 
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the treatment of lung cancer (Usuda et al. 2006) whereas chlorin e6-
polyvinypyrrolidone (Photolon
TM
) is approved in Belarus and Russia for the treatment 
of skin tumours and mucosal malignancies of hollow organs (Shliakhtsin et al. 2009), 
respectively.  Both photosensitisers are highly efficient with excellent singlet oxygen 
generation and high absorbance at longer wavelengths (~660 nm, 40000 M
−1
cm
−1
). 
However, these chlorin e6-based photosensitisers have high photobleaching rate which 
reduces their availability for efficient PDT (Hongying et al. 1999).  
  
mono-aspartyl-L-chlorin e6 chlorin e6 
Figure 2.9 Structures for mono-aspartyl-L-chlorin e6 (talaporfin) and chlorin e6. 
 
Based on the literature review, it is clear that the spectroscopic and 
physicochemical properties such as absorption maxima, molar extinction coefficient, 
fluorescence quantum yield, photobleaching quantum yield, singlet oxygen generation 
quantum yield and octanol/water partition coefficient play an important role in 
determining the potency of a photosensitiser. Therefore, the spectroscopic and 
physicochemical parameters for these clinical PDT agents are summarised in Table 2.2 
for better comparison. 
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Table 2.2 Spectroscopic and physicochemical properties of clinically approved photosensitisers for cancer treatment 
Photosensitiser λabs (nm) λ (M
-1
cm
-1
) λem  (nm) Φfl ΦPB Φ∆ Log Po/w 
Porfimer sodium 
(Photofrin TM) 
630a 3000a NA NA 5.4 x 10-5 (PB)b 
0.25 
(PB + 1% TX100; 630 nm; oxygen 
depletion with FFA)c 
3.96  
(calc.)d 
Protoporphyrin IX 
(Levulan TM ) 
635a 5000a 
630 
(ex 397 nm; PBS)e 
0.011 
(ex 397 nm; PBS)e 
NA 
0.54 
(PB + 1% TX100; 630 nm; 
lysozyme inactivation; RB at 0.75)f 
NA 
Temoporfin 
(Foscan TM) 
650 (EtOH)g 
652 (H2O)g 
39000 (EtOH)g 
23000 (H2O)
g 
655 nm (PBS)h NA 
1.54 x 10-5 (PBS + 
10% FCS)i 
0.31 
(PBS + 10% FCS; >610 nm; DPBF; 
hypericin at 0.36)i 
9.24j 
Verteporfin 
(Visudyne TM) 
688 (PBS + 2% 
TX100)k 
692   (PBS)k 
31 200 (PBS + 2% 
TX100)k 
13 500 (PBS)k 
694 (PBS + 2% 
TX100)k 
695    (PBS)k 
0.049  (PBS + 2% 
TX100)k 
0.002 (PBS)k 
5.35 x 10-5 (PBS + 
2% TX100)k 
2.80 x 10-5 (PBS)k 
0.82 
(PB + 1% TX100; 692 nm; 
lysozyme inactivation; MB at 0.52)f 
7.76  
(calc.)l 
Talaporfin 
(Laserphyrin TM) 
654 (PBS)m 40000 (PBS)m 660 (PBS)m NA 8.2 x 10-4 (PBS)m 
0.77 
(D2O, oxygen depletion with FFA)
m - 1.92 
n 
Ce6 
(Photolon TM) 
663 (PBS)o 38000 (PBS)o 662 (PBS)o 0.18 (PBS)o NA 
0.75 
(PB; 660 nm; lysozyme 
inactivation; MB at 0.52)f 
0.78o 
Ref: a(Sharman et al. 1999); b(Spikes 1992); c(Kimel et al. 1989); d(Tanaka et al. 2012); e(Lozovaya et al. 1990); f(Fernandez et al. 1997); g(Grahn et al. 1997); h(Belitchenko et al. 
1998); i(Hadjur et al. 1998); j(Chen et al. 2011); k(Aveline et al. 1994); l(Macalpine et al. 2002); m(Spikes and Bommer 1993); n(Kessel 1989a); o(Isakau et al. 2008) 
Abbreviation: λabs - absorption maxima (Q-band); λ - molar extinction coefficient; λem - fluorescence emission maxima; Φfl - fluorescence quantum yield; ΦPB - photobleaching 
quantum yield; Φ∆ - singlet oxygen generation quantum yield; Log Po/w – log octanol/water partition coefficient; PB – phosphate buffer pH~7.4; EtOH – ethanol; PBS – phosphate 
buffered saline; TX100 – Triton X100; FFA – furfuryl alcohol; MB – methylene blue; RB – rose bengal; NA – not available 
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2.3.2.3 Pheophorbide-based chlorins 
 
Figure 2.10 Structure of 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide (HPPH). 
 
Pheophorbide is a chlorin characterised by a reduced exocyclic double bond leading to a 
further increased absorption to 650–700 nm compared to the chlorins. Perhaps 2-(1-
hexyloxyethyl)-2-devinyl pyropheophorbide (HPPH, Photochlor 
TM
) is currently the 
most actively investigated photosensitiser for clinical PDT (Figure 2.10). The 
photosensitiser absorbs at 665 nm with ε ~ 47000 M-1cm-1 (Lobel et al. 2001). HPPH 
has been approved for use in clinical trials and has undergone phase I/II trials for 
obstructive esophageal cancer and Barrett’s esophagus, phase I trials involving non-
melanomatous basal cell skin cancer and phase I trials for early stage non-small cell 
lung cancer. Ongoing clinical trials include phase I trials for treating dysplasia or 
carcinoma of the oral cavity and larynx, phase II trials for precancerous or early stage 
esophageal cancer, phase I trials involving lung cancer and other peural maglinancies, 
and phase I trials in patients undergoing surgery for primary or recurrent head and neck 
cancer (Ormond and Freeman 2013).  
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15
1
-hydroxypurpurin-7-lactone       
methyl ethyl ester 
15
1
-hydroxypurpurin-7-lactone    
dimethyl ester (G2) 
Figure 2.11 Structure of 15
1
-hydroxypurpurin-7-lactone derivatives. 
 
Hydroxypurpurin-7-lactone derivative is another pheophorbide-related 
photosensitiser characterised by the presence of an exocyclic lactone ring leading to a 
further increase of absorption to ~ 700 nm. So far, not much has been reported in terms 
of their photodynamic activity. The only photosensitiser from this group tested for PDT 
activity is 15
1
-hydroxypurpurin-7-lactone methyl ethyl diester, a naturally occurring 
photosensitiser isolated from plants derived from several distinct families such as 
Phaeanthus ophthalmicus (Annonaceae Family), Aglaonema simplex (Araceae Family) 
Phyllostachys bambusoides (Poaceae Family) (Kim et al. 2003; Chee et al. 2005; Tan et 
al. 2011). The photosensitiser is believed to be a degradation product of chlorophyll-a. 
Our previous studies had shown that 15
1
-hydroxypurpurin-7-lactone dimethyl ester 
(G2), a closely related analogue (Figure 2.11), was found to exhibit potential PDT 
activity by inducing the closure of capillaries and small neovessels in a chick 
chorioallantoic membrane (CAM) model (Lim et al. 2010). G2 was also shown to be a 
promising photosensitiser against head and neck cancer cells by the higher potency of 
G2 in inducing photocytotoxicity and an ability to evoke a more pronounced apoptosis 
compared with a known photosensitiser, pheophorbide-a (PhA) (Lim et al. 2011). G2 
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and its analagues will be further evaluated in present study, and more extensive 
literature review on G2 will be given in the introduction of Chapter 3. 
 
2.3.2.4 Bacteriopheophorbides 
 
Figure 2.12 Strucuture of palladium-bacteriopheophorbide (Tookad). 
 
Another class of light absorbing chromophore is based on bacteriopheophorbide, which 
have two reduced double bonds in the pyrroles compared to the porphyrins that further 
red-shifting the absorbing band. Tookad is a palladium-bacteriopheophorbide derived 
from bacteriochlorphyll a, which is isolated from bacteria (Figure 2.12). The 
photosensitiser is activated at a relatively long wavelength (763 nm) and acts mainly by 
shutting down peritumoural vasculature given its lipophilic, anionic nature (Madar-
Balakirski et al. 2010). Advantages of Tookad are its deep tissue penetration of light and 
rapid clearance from the circulation and therefore, cutaneous photosensitisation 
associated with photosensitisers such as Photofrin or Temoporfin are generally absent 
(Weersink et al. 2005). A water-soluble derivative of Tookad has been evaluated in 
phase I and II clinical trials for prostate cancer patients (Davidson et al. 2009; Betrouni 
et al. 2011).  
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2.3.2.5 Phthalocyanines 
Phthalocyanines are extended porphyrins with each of their pyrrolic ring fused with a 
benzene ring. This structural change leads to increased aromatic character that resulted 
in their intense near infra-red (NIR) absorption at λabs ~ 670-700 nm with ε ≥ 120000 M
-
1
cm
-1 
(Sekkat et al. 2012). For phthalocyanines to exhibit PDT properties, metal 
complexation, especially with a transition metal such as aluminium, zinc or silicone, is 
required to give high yields of singlet oxygen (Ali and van Lier 1999; Wainwright 
2009). Besides their NIR absorption, which is crucial for activation in deeper tissular 
regions, one interesting feature of phthalocyanines is their near absence of absorbance at 
400-600 nm that would minimise the chances of skin photosensitisation when exposed 
to sunlight (Ethirajan et al. 2008). However, the major limitations of most 
phthalocyanines are their strong tendency to aggregate and  low water-solubility (Sekkat 
et al. 2012).  
  
silicon phthalocyanine 4  aluminium phthalocyanine tetrasulfonate 
 
Figure 2.13 Structures of silicon phthalocyanine 4 (Pc4) and aluminum phthalocyanine 
tetrasulfonate (AlPcS4). 
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Aluminum phthalocyanine tetrasulfonate (AlPcS4, Photosens) and silicon 
phthalocyanine 4 (Pc4) are two phthalocyanine-based photosensitisers investigated in 
the clinic to-date (Figure 2.13). Photosens is an isomeric mixture and has been used in 
Russia to treat various cancers (Wainwright 2009). Meanwhile, Pc4 has completed 
phase I trial for the treatment of pre-malignant and malignant skin conditions. 
 
2.3.2.6 Texaphyrins 
 
Figure 2.14 Structure of motexafin lutetium. 
 
Texaphyrin is a heterocyclic macrocycles with a five nitrogen atoms core 
extended with metal complex (Figure 2.14). Motexafin lutetium is a pure, water-soluble 
texaphyrin with a large broad absorption band centered at 732 nm with ε ~ 42000 M-
1
cm
-1
. The photosensitiser has entered clinical trials for the PDT of recurrent breast 
cancer, cervical intraepithelial neoplasia and locally recurrent prostate cancer (Dimofte 
et al. 2002; Patel et al. 2008), as well as for the phototreatment of non-cancerous lesions 
such as atherosclerosis of peripheral arteries and macular degeneration (Woodburn et al. 
2002; Kereiakes et al. 2003).  
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2.3.3 Non-Tetrapyrrole Photosensitisers 
Aside from cyclic-tetrapyrrole structures, a number of naturally occurring as well as 
synthetic dyes that are non-tetrapyrrole-based have also been evaluated for their 
photosensitising ability against cancer. In fact, the fundamental of photodynamic action 
was first described in the early 1900s based on the photo-induced killing effects 
observed with non-tetrapyrrole photosensitisers namely acridine and eosin (Dolmans et 
al. 2003). Classes of non-tetrapyrroles that have been investigated for photodynamic 
activity include perylenequinones, phenothiazines, xanthenes and boron difluoride 
dipyrromethene. 
 
2.3.3.1 Perylenequinone 
 
Figure 2.15 Structure of hypericin. 
 
Hypericin (Figure 2.15) is a naturally occurring perylenequinone isolated from St. 
John's Wort (Hypericum perforatum). This photosensitiser is poorly soluble in water but 
can be dissolved following addition of alcohol (Wirz et al. 2002). Hypericin is one of 
the most powerful photosensitisers in nature with strong absorbance (ε = 44000 M-1cm-
1
) at 590 nm (Ormond and Freeman 2013). Recently, a phase II placebo-control study of 
PDT with topical hypericin on cutaneous T-cell lymphoma patients has shown 
significant improvement of the treated skin lesions (Rook et al. 2010). 
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2.3.3.2 Phenothiazinium 
 
Figure 2.16 Structure of methylene blue. 
 
Phenothiazinium-based structures are a well-known category of non-tetrapyrrole 
type of PDT agents. During the early period of research in modern PDT, 
phenothiazinium exemplary by methylene blue (Figure 2.16) was perceived as a 
standard bioactive photosensitiser, giving a reasonable yield of singlet oxygen (Φ∆ = 
0.52 in alcohol) and strong absorption (εmax ~ 82000 M
−1
cm
−1
) at 666 nm which 
corresponds with the light therapeutic window for PDT (600-800 nm) (Wainwright 
2005). Numerous methylene blue analogues have since been prepared given its ease of 
synthesis, however this class of compounds has limited therapeutic window due to low 
light-to-dark toxicity ratio (Wainwright et al. 1997; Wainwright and Giddens 2003; 
Harris et al. 2005). Nevertheless, methylene blue has found its application in 
antimicrobial PDT for treatment of chronic periodontitis and pathogen eradication in 
blood products (Wainwright 2005).  
 
2.3.3.3 Xanthene 
Xanthenes are tricyclic systems consisting of two benzene rings joined by a methylene 
group and an oxygen atom. There are three main series deriving from this chemical 
skeleton namely the fluoresceins, rhodamines and rosamines (Figure 2.17). The 
xanthene dyes are excellent singlet oxygen generator and are perhaps the most 
commonly used compounds where singlet oxygen is required in organic synthesis 
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(Wainwright 2009). This class of dyes also has a wide-ranging application as 
fluorescence probes. In terms of photodynamic action, there are only a few examples of 
xanthene being investigated even though a great range of its derivatives could be easily 
synthesised. 
   
fluorescein-type rhodamine-type rosamine-type 
Figure 2.17 Structure of xanthene photosensitisers. 
 
(a) Fluorescein 
Fluorescein is widely used as a fluorescent tracker dye for many biomedical 
applications, especially in fluorescence microscopy due its ease to synthesise, good 
solubility in aqueous environment and strong fluorescence emission. Fluorescein, 
namely fluorescein isothiocyanate (FITC), is commonly used as antibody probe in 
immunohistochemistry staining to allow visualisation of specific target proteins or 
structures within cells. In cancer PDT, the use of fluorescein was described in the early 
1900s, where von Tappeiner and colleagues performed the first PDT trial in patients 
using eosin (Figure 2.18). In this trial, four out of six patients with facial basal cell 
carcinoma treated with a 1% eosin solution and a long-term exposure either to sunlight 
or to arc-lamp light showed total tumour regression and a relapse-free period of 12 
months, as quoted by Dolmans et al. (2003). 
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eosin rose Bengal 
Figure 2.18 Structures of eosin and rose Bengal. 
 
Another noteworthy fluorescein is the rose Bengal (Figure 2.18), a water-soluble 
photosensitiser which absorbs strongly at 549 nm with ε = 100000 M-1cm-1 (Mousavi et 
al. 2009). Rose Bengal has high efficiency in singlet oxygen production leading to its 
application as a reference dye in singlet oxygen quantum yield measurement or in 
synthetic chemistry where singlet oxygen is required (Wainwright 2009). In PDT, the 
utility of this photosensitiser is limited to superficial lesions given its shorter absorption 
wavelength. A formulation of rose Bengal known as PV-10 has been studied in a Phase 
II clinical trial (NCT00521053) and is currently in preparation for a phase III 
randomised controlled study for the treatment of metastatic melanoma. Clinical 
investigation using PV-10 has also been granted to Provectus Pharmaceuticals by the 
FDA for treatment of cutaneous and subcutaneous tumours under compassionate use in 
patients whom there is no comparable or satisfactory approved alternative therapies 
(NCT01260779). 
 
(b) Rhodamines and rosamines 
Rhodamines and rosamines belong to the class of dye known as delocalised lipophilic 
cations (DLCs). In comparison to the fluorescein, both rhodamines and rosamines have 
their phenolic residues replaced by amino residues where this modification allows the 
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positive charge of these structures to be permanently delocalised onto the amino 
nitrogen. The cationic character of these DLCs leads them to be attracted to the 
negatively charge mitochondrial matrix thereby allowing mitochondrial targeting 
(Modica-Napolitano and Aprille 2001). For example, DLCs such as rhodamine-123 
(Rh123) and tetramethylrosamine (TMR) (Figure 2.19) are extensively used as 
mitochondrion-selective fluorescence probe (Modica-Napolitano and Aprille 1987; 
Minamikawa et al. 1999). 
  
rhodamine-123 tetramethylrosamine 
Figure 2.19 Structures of rhodamine-123 and tetramethylrosamine (TMR). 
 
Despite its mitochondrial targeting potential, both Rh123 and TMR are not 
efficient photosensitisers for PDT due to their relatively short wavelength of absorption 
and low singlet oxygen quantum yield of 0.01 and 0.08, respectively (Richmond and 
O'Hara 1993; Detty et al. 2004). Chromophore functionalisation has been carried out to 
improve absorption wavelength and singlet oxygen yields. For example, addition of 
alkyl or aryl to the xanthene core has been shown to red-shift the absorption wavelength 
(David et al. 2008), while halogenation resulted in increased of singlet oxygen yield 
(Pal et al. 1996). On the other hand, substitution of oxygen with lower chalcogen atoms 
such as sulfur, selenium or tellurium is associated with increased of both absorption 
wavelength and singlet oxygen production (Detty et al. 2004; Holt et al. 2006; Calitree 
et al. 2007). Introduction of heterocyclic ring at the meso-position may also altered their 
spectroscopic properties (Shandura et al. 2007). 
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2.3.3.4 Boron Difluoride Dipyrromethene  
Boron difluoride dipyrromethene (BODIPY) is a class of fluorescent dyes, which is 
composed of dipyrromethene complexed with a disubstituted boron atom, typically a 
BF2 unit. BODIPYs have many ideal photosensitiser characteristics, including high 
absorption extinction coefficients, high quantum efficiencies of fluorescence, relative 
insensitivity to environment, resistance to photobleaching (Gorman et al. 2004) and 
higher light-dark toxicity ratio compared to other non cyclic-tetrapyrole photosensitisers 
i.e phenothiazinium (Wainwright et al. 1997; Yogo et al. 2005).  
   
Nagano O’Shea Akkaya 
Figure 2.20 Examples of BODIPY photosensitisers for PDT. 
 
Recently, BODIPYs are actively being investigated as an alternative class of 
non-tetrapyrrole photosensitisers for PDT (Figure 2.20). Nagano and co-workers 
reported synthesis of a simple diiodo-substituted BODIPY with possible applications 
that included PDT and fluorescence bio-imaging probes (Yogo et al. 2005). The diiodo-
substituted BODIPY at the 4-pyrollic position produces the supposed internal heavy 
atom effect that enhanced the intersystem crossing efficiency from a singlet to a triplet 
state which promotes singlet oxygen production.  O’Shea and co-workers prepared a 
series of azadipyrromethenes with high absorption in the far-red wavelengths and 
demonstrated their efficacy in light-induced toxicity in a panel solid tumour cell line 
(Gorman et al. 2004).  One of the azadipyrromethenes was later shown to effectively 
eradicate the subcutaneously xenografts MDA-231 breast tumours in nude mice (Byrne 
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et al. 2009).  Atilgan et al. (2006) introduced another class of water-soluble BODIPY 
dyes with extended conjugation at the 5-pyrollic positions.  These photosensitisers were 
shown to have strong absorptions in the 650-680 nm therapeutic window and good 
photo-induced cytotoxicity in K562 leukemia cells at sub-micro molar concentration 
even under low fluence rate LED irradiation.  
 
2.4 Oxygen in PDT 
Molecular oxygen occurs in ground triplet state at room temperature and only become 
reactive in its singlet state. Singlet excited state oxygen is significantly more 
electrophilic and can react rapidly with unsaturated carbon-carbon bonds, neutral 
nucleophiles such as sulfides and amines, and as well as with anions (DeRosa and 
Crutchley 2002). The lifetime of singlet oxygen in organic solvents ranges from 10-l00 
μs (MacDonald and Dougherty 2001), but in cellular level, the lifetime of singlet 
oxygen reduces to approximately 3 μs due to its high reactivity with biological 
substances (Hatz et al. 2007). Because of the high reactivity and short lifetime of singlet 
oxygen, PDT-induced oxidative damage is therefore highly localised where only the 
nearest molecules and structures to singlet oxygen production site are directly affected 
(Moan and Berg 1991). 
In general, the efficacies of PDT critically depend on the concentration of 
molecular oxygen in the tumour. Several studies have demonstrated that PDT is less 
effective in hypoxic environment (Moan and Sommer 1985; Henderson and Fingar 
1987). This can be a challenge, as most solid tumours have reduced oxygen tensions due 
to their irregular microcirculation and deteriorating diffusion geometry (Hockel and 
Vaupel 2001). To overcome this, metronomic PDT where both the photosensitiser and 
light are delivered at very low dose rates over an extended period has been proposed. 
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Since oxygen consumption in PDT depends on the fluence of light, the use of lower 
fluence rates delays oxygen depletion while allowing tissue reoxygenation and has been 
shown to improve PDT efficacy (Zilberstein et al. 2001; Singh et al. 2010). 
 
2.5 Mechanism for Photodynamic Action 
2.5.1 Photophysical and Photochemistry Process of PDT 
The interactions between light, photosensitisers and oxygen involve a series of energy 
transitions in order to generate singlet oxygen as illustrated in a simplified Jablonski 
diagram (Figure 2.21). Upon light irradiation at wavelengths corresponding to the 
photosensitiser absorption maxima, ground singlet state photosensitisers will become 
electronically excited. This excited singlet state photosensitiser is very unstable and may 
discharge the absorbed energy as fluorescence. Otherwise, it will undergo intersystem 
crossing to form the more stable triplet state. To return to ground singlet state, 
photosensitiser in its triplet state may either undergo radiative deactivation by emitting 
phosphorescence or by non-radiative deactivation processes namely Type I and Type II 
reactions (Dolmans et al. 2003; Agostinis et al. 2011). 
In Type I reaction, the photosensitiser will acquire an electron by reacting 
directly with an organic molecules within cellular microenvironment to form a free 
radical. Subsequently, this reduced photosensitiser interacts with oxygen to produce 
superoxide anion radical (O2
-
). Superoxide is not particularly reactive and does not 
cause oxidative damage to biological system, but it can be catalysed by superoxide 
dismutase to hydrogen peroxide, which is in turn rapidly converted to the highly 
oxidative hydroxyl radical (•OH) by ferrous ion (Fe2+) present in the body (Castano et 
al. 2004; Agostinis et al. 2011). In the much anticipated Type II reaction, triplet state 
photosensitiser will transfer its energy to molecular oxygen to form the highly reactive 
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singlet oxygen (
1
O2), which is the key cytotoxic component in PDT. Nevertheless, these 
energy transfer process between the photosensitiser and oxygen depend on 
photophysical properties of a photosensitiser and various constant rates such as singlet-
to-triplet internal conversion efficiency, intersystem crossing efficiency, triplet state 
excited energy, triplet state excited lifetime and the efficiency of energy transfer to 
molecular oxygen that may influence the singlet oxygen production efficiency (Tanaka 
et al. 2008).  
 
 
Figure 2.21 A modified Jablonski diagram illustrates the electronic state of 
photosensitiser and oxygen during the photosensitisation processes. Upon light 
irradiation, ground singlet state photosensitiser (
1
PS) absorbed the photon energy to 
become excited singlet state (
1
PS*). In a more likely event, the excited photosensitiser 
will undergo intersystem crossing to form excited triplet state (
3
PS*) and subsequently 
transfer its energy to molecular oxygen (
3
O2) to form singlet oxygen (
1
O2), which is the 
key cytotoxic component in PDT. The diagram was adapted from Castano et al. (2004). 
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2.5.2 Mechanisms of PDT-Mediated Tumour Destruction 
Tumour ablation in PDT is contributed by three distinct mechanisms. As illustrated in 
Figure 2.22, singlet oxygen generated during PDT is capable of inducing cellular death 
of tumour, the shutting down of blood vessels feeding the tumour, and the activation of 
immunological responses against tumour cells. The latter is an important feature of PDT 
that is responsible for long-term cure and destruction of metastasised cancer. 
 
 
Figure 2.22 Mechanisms of PDT-mediated tumour destruction. Singlet oxygen 
generated during PDT is capable of inducing cellular death of tumour, shutting down of 
blood vessels feeding the tumour and activates the immunological responses against 
tumour cells. The figure was adapted from Castano et al. (2006). 
 
2.5.2.1 PDT-mediated Cytotoxicity 
PDT can evoke three cell death pathways i.e. apoptotic, necrotic, and autophagy-
associated cell death. The mode of cell death depends on the PDT doses used (both light 
and photosensitiser doses), subcellular localisation of photosensitiser and cell type 
(Castano et al. 2005). Due to the high reactivity and short life-time of singlet oxygen, 
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photodynamic damage is probably confined to targets near to or within a particular 
subcellular site and affects relatively specific molecular targets (Buytaert et al. 2007). 
In general, cell death by apoptosis are more prominent in low doses PDT, while 
cells exposed to higher PDT doses are more predisposed to necrosis. Studies on several 
photosensitisers have linked apoptosis induced by PDT is caused by photodamage to 
membrane bound BCl-2, a regulator for mitochondrial outer membrane 
permeabilisation, resulting in rapid release of cytochrome c and other pro-apoptotic 
factors (such as apoptotic-inducing factor-AIF and small mitochondria-derived activator 
of caspases-Smac) from the mitochondrion to the cytosol (Agarwal et al. 1991; Kim et 
al. 1999; Usuda et al. 2003; Kessel and Reiners 2007). This results in the activation of 
the intrinsic apoptotic pathway and initiates activation of the caspase-cascade. 
Meanwhile, high doses of PDT is thought to inactivate essential enzymes and other 
components of the apoptotic cascade such as caspases, resulting in a shift of cell death 
toward necrosis (Mroz et al. 2011). Severe photodamage of inner mitochondria 
membrane may also cause an increase in mitochondria permeability transition leading to 
release of Ca
2+
 from the mitochondrion, and subsequent overloading of intracellular 
with Ca
2+
 could promote activation calcium-dependent proteases such as calpain which 
contributes to necrotic cell death (Buytaert et al. 2007). 
 The mode of cell death is also dependent on localisation of photosensitisers in 
subcellular targets such as mitochondria, plasma membrane, lysosome and endoplasmic 
reticulum. The mitochondria has been shown to be a primary subcellular target for most 
photosensitisers used in PDT (Morgan and Oseroff 2001).  Given the complex role of 
mitochondria in regulation of apoptosis, photosensitisers which localise within this 
organelle usually activate the apoptotic pathway through cytochrome c release. 
Lysosomal photodamage is also found to induce apoptotic cell death through the release 
of lysosomal proteolytic enzymes which resulted in cleavage of the pro-apoptotic 
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protein Bid that subsequently induced the release of cytochrome c from mitochondria 
(Kessel et al. 2000; Reiners et al. 2002). Meanwhile, photo-oxidation by photosensitiser 
which localise in plasma membranes can cause loss of plasma membrane integrity, 
leading to leakage of cytosolic contents and rapid depletion of intracellular ATP, both of 
which are prominent features of necrosis (Kessel and Poretz 2000).  
In certain cell-type, oxidative stress induces by PDT may also lead to the 
stimulation of autophagic response (Dewaele et al. 2010). Studies have shown that 
photodamage to cellular organelles such as the mitochondria and endoplasmic reticulum 
may trigger macroautophagy involving the formation of a double membrane 
intracytoplasmic vacuole, known as autophagosome,  surrounding these damaged 
organelles (Kessel et al. 2006; Xue et al. 2007).  This process can be either pro-survival 
or pro-death. In cells with intact apoptosis, autophagy promotes cell survival by 
elimination of damaged organelles from activating the apoptosis pathway. In contrast, 
pronounced autophagic cell death is observed in apoptosis-deficient cells such as 
caspase-3-deficient MCF-7 breast cancer cell line (Xue et al. 2010) and Bax-deficient 
DU-145 prostate cancer cell line (Kessel et al. 2006), suggesting a pro-death function of 
autophagy. Therefore, autophagy may play a role as alternative death pathway when 
apoptosis is blocked. Autophagy also appears to play an important part in PDT-
mediated antitumour immunity, since the process can result in major histocompatibility 
class I (MHC-I) presentation of antigens derived from cytosolic proteins (van der 
Bruggen and van den Eynde 2006).  
 
2.5.2.2 Vascular Destruction     
PDT is an efficient modality in disrupting vascular circulation by inducing thrombosis 
and vasculature occlusion. In fact, PDT has been successfully used for treating vascular 
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related lesions such as intimal hyperplasia, restenosis, atherosclerotic plaques, corneal 
and choroidal neovascularisation, and port-wine stains (Krammer 2001). Given their 
efficient interactions with vascular, a series of experiments have been designed for PDT 
evaluation purposes, such as the chick chorioallantoic membrane (CAM) model and the 
murine dorsal window chamber model (Figure 2.23). CAM is a highly vascularised 
membrane that serves as the respiratory organ for developing chick embryo. It is 
frequently used in preclinical PDT research for non-invasive study of microvasculature 
and blood circulation (Lange et al. 2001). Meanwhile, the murine dorsal window 
chamber model is a chronic preparation that provides access of the interior vasculature 
surface of the skin.  This approach is relevant since all the skin layers from the stratum 
corneum composed of keratinocytes, stratum granulosum between the stratum corneum 
and the basal cells, and the facial layers of the dermis are intact in this model (Debefve 
et al. 2010; Palmer et al. 2011).  Both the CAM and the window chamber model have 
been successfully used to evaluate the PDT vascular occlusion efficacy of a number of 
photosensitisers that are undergoing clinical trials or already approved for clinical use. 
A                  B 
       
Figure 2.23 Models used to study PDT effects on vasculature. (A) Vascularisation of 
chick’s embryo chorioallantoic membrane on egg development day-9. (B) An 
illustration of the dorsal skin fold chamber implanted in a nude mouse. Figure (B) was 
kindly provided by Dr Patrycja Nowak-Sliwinska of Swiss Federal Institute of 
Technology (EPFL), Switzerland. 
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In PDT of cancer, vascular occlusion is essential in disrupting the supply of 
oxygen and nutrients to lesion tissues in order to achieve long-term cure. The initial 
vascular effect of PDT begins with light-induced damage of endothelial cells and the 
subsequent exposure of vascular basement membrane led to the formation of 
thrombogenic sites within the vessel lumen. This process promotes platelet binding and 
aggregation, and release of thromboxane that causes vessel constriction as well as 
further increases the platelet aggregation. The blood vessel is therefore shut down and 
the ensuing hypoxia and nutrient deprivation induces extensive tumour cell-death 
(Krammer 2001). The vasculature targeting of PDT largely depends on the 
photosensitiser pharmacokinetics.  For most exogenous photosensitiser, peak plasma 
concentration of the photosensitiser is usually achieved immediately after intravenous 
administration, and is followed by a rapid exponential decay in plasma concentration. 
The period of time when photosensitiser is still largely confined in the blood vessels 
provides a temporal therapeutic window for vascular targeting, and light irradiation 
during this period leads to a potent vascular damage (Chen et al. 2006a). 
 
 
2.5.2.3 Immunoactivation 
PDT is known to provoke both the innate and adaptive immune response. PDT-
mediated innate immunity is initiated immediately following tumour tissue damage by 
singlet oxygen, that results in the release of pro-inflammatory endogenous damage-
associated molecular patterns molecules (DAMPs) such as intracellular proteins and 
nuclear DNA (Korbelik 2006). This prompts the host to activate inflammatory response 
in order to protect and maintain tissue homeostasis at the affected site by removing 
damaged cells and promoting local tissue healing. The inflammatory response is led by 
the infiltration of phagocytic cells such as neutrophils, macrophages and dendritic cells 
aimed to neutralise the source of DAMPs by eliminating debris containing 
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compromised tissue elements, including injured and dead cells (Krosl et al. 1995; 
Agostinis et al. 2011). 
The induction of the earlier innate immune system is required for the subsequent 
activation of adaptive antitumour immunity. In vivo mechanistic studies revealed that 
the incubation of immature dendritic cells with PDT-treated tumour cells lysate 
activates the dendritic cells to express interleukin-12 (IL-12), which is critical to the 
development of cellular immune response. These cells will migrate to tumour-draining 
lymph nodes where they differentiate into professional antigen-presenting cells and 
stimulate the activation of tumour-specific CD8
+
 T cells that home into the tumour and 
eliminate the remaining tumour cells (Gollnick et al. 2002; Jalili et al. 2004). 
Studies have examined the ability of PDT to enhance antitumour immunity in a 
clinical setting. A study on the use of ALA-PDT to treat vulval intraepithelial neoplasia 
resulted in higher CD8
+
 T cell tumour-infiltration in patients with MHC-I positive 
tumours than non-responding patient with MHC-I negative tumours (Abdel-Hady et al. 
2001). Subsequently, a case report shows that PDT treatment of multifocal 
angiosarcoma of the head and neck resulted in spontaneous regression of distant 
untreated tumours that correlated to increase CD8
+
 T cell tumour-infiltration (Thong et 
al. 2007). In a more recent study, PDT treatment of basal cell carcinoma (BCC) was 
shown to enhance systemic immune reactivity to a BCC-associated tumour antigen, 
which may provide micro-metastatic control and long-term tumour cure (Kabingu et al. 
2009). Although, it is clear that induction of antitumour immunity after PDT may act as 
effective antitumour vaccines, this favourable result is not always observed. The 
variations may be due to the difference in tumour cells immunogenicity, the presence of 
immune suppression by regulatory T cells or the presence of dendritic cells dysfunction 
caused by the tumour (Mroz et al. 2010).  
43 
 
CHAPTER 3 
 
Evaluation of 15
1
-Hydroxypurpurin-7-Lactone Dimethyl Ester (G2) and Its 
Analogues as Photosensitiser for Photodynamic Therapy 
 
3.1 Introduction 
In the course of the screening program conducted at Cancer Research Initiatives 
Foundation, Malaysia on Malaysia’s Biodiversity for potential photosensitisers for use 
in PDT of cancer (Kamal et al. 2009; Ong et al. 2009; Kamarulzaman et al. 2011), five 
pheophorbide-related photosensitisers from an ethanol soluble extract of the leaves and 
stems of Aglaonema simplex were isolated (Chee et al. 2005). While four of the 
compounds were commonly reported degradation products of chlorophylls, the fifth 
compound, 15
1
-hydroxypurpurin-7-lactone methyl ethyl diester, was isolated for the 
first time from the Araceae plant family. The latter showed strong photo-killing potency 
against human promyelocytic leukemia cells HL-60 and human oral squamous cell 
carcinomas HSC2 and HSC3 with IC50 values ranging from 0.30-0.41 µM.  The only 
one other report of the compound as a naturally derived photosensitiser was by Kim et 
al. (2003), isolated from the leaves of bamboo plant Phyllostachys bambusoides where 
they reported rapid onset of apoptosis in the CMK-7 human leukemia cells  upon light 
activation. 
The initial in vitro studies involving 15-hydroxypurpurin-7-lactone methyl ethyl 
diester were conducted using the small quantities of naturally derived materials (Chee et 
al. 2005).  Therefore, to generate sufficient quantities for further preclinical assessment, 
a closely related analogue, 15
1
-hydroxypurpurin-7-lactone dimethyl ester, termed G2, 
was prepared through semi-synthesis from chlorophyll-a containing extracts of 
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Spirulina platensis (Figure 3.1). G2 was found to exhibit potential PDT activity by 
inducing the closure of capillaries and small neovessels in a chick chorioallantoic 
membrane (CAM) model (Lim et al. 2010). G2 was also shown to be a promising 
photosensitiser against head and neck cancer cells by the higher potency of G2 in 
inducing photocytotoxicity and an ability to evoke a more pronounced apoptosis 
compared with a known photosensitiser, pheophorbide-a (PhA) (Lim et al. 2011). Even 
though the potency data for G2 was promising, solubilisation of G2 was challenging 
throughout because of its hydrophobic nature. Precipitation of the compound was a 
major problem and formulation of G2 for intravenous injection in the CAM experiments 
was only successful with the addition of a small amount of Cremophor
@
 EL as an 
emulsifier.  
One of the strategies to improve aqueous solubility of photosensitiser is by 
attaching them to hydrophilic moieties such as amino acids (Roberts et al. 1988; Pandey 
et al. 1994; Wang et al. 2008). The conjugation of amino acids to tetrapyrrolic 
photosensitiser has been shown to improve their solubility and facilitates its entry into 
the cells (Kwitniewski et al. 2005). It has also been reported that photosensitisers 
conjugated with amino acids showed improved biological activity both in vitro and in 
vivo (Kwitniewski et al. 2005; Kwitniewski et al. 2009). With this notion, analogues of 
G2 conjugated with ionisable aspartyl (G2-Asp) and lysyl (G2-Lys) groups were 
synthesised, with the aim to optimise the drug-like properties of G2 as a quality 
candidate for clinical PDT.  
The G2 analogues evaluated in this study was synthesised and provided by Dr 
Lee Hong Boon’s group from Cancer Research Initiatives Foundation, Malaysia. G2-
Asp and G2-Lys were prepared (Figure 3.1) by dicyclohexylcarbodiimide (DCC)/ 
dimethylaminopyridine (DMAP) mediated esterification of G2 in its acid form (G2 
acid) with Boc-amino acids as previously described (Sternberg et al. 1998). In this 
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study, these G2 analogues were compared for their photophysical properties, in vitro 
photo-killing efficacy, single oxygen generation quantum yield, photobleaching, 
intracellular uptake and subcellular localisation. G2 and G2 acid were also evaluated in 
the present study with G2 used as a positive control since previous studies have 
demonstrated its efficacies (Chee et al. 2005; Lim et al. 2010; Lim et al. 2011). The 
most promising candidate compounds were further evaluated in mouse tumour allograft 
model to establish their in vivo efficacies. Even though many photosensitisers have been 
developed or are being developed for PDT center around the cyclic-tetrapyrrolic 
pharmacophore, the hydroxypurpurin structure described in this work has never been 
tested for its PDT efficacy beyond cell-based assays.   
 
Figure 3.1 Schematic diagram for the synthesis  of G2 and its derivatives. 
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3.2 Materials and Methods 
3.2.1 Materials 
3.2.1.1 Chemicals and Reagents 
Cell culture reagents including Minimum Essential Media (MEM), RPMI 1640 medium 
with L-glutamine, Pen-Strep (10000 U/ml penicillin, 10 mg/ml streptomycin), trypsin 
10× and foetal bovine serum (FBS) were purchased from Gibco, Invitrogen (Auckland, 
New Zealand). 1,3-diphenylisobenzofuran (DPBF)  fluorescein isothiocyanate dextran 
(FITC-dextran, 20 kD) and dimethyl sulfoxide (DMSO) were purchased from Sigma-
Aldrich (MO, USA) while thiazoyl blue tetrazolium bromide (MTT) was purchased 
from Amresco (OH, USA). Ethanol, isopropanol, octanol-1, and acetonitrile were 
purchased from Fisher Scientific (Leics, UK). Tiletamine-zolazepam (Zoletil) was 
purchased from Virbac (Carros, France). Ketamine (Ketamil) and xylazine (Xylazil-
100) were obtained from Troy Laboratories (NSW, Australia). Pheophorbide-a (PhA) 
was purchased from Frontier Scientific (UT, USA). ER-Tracker Blue-white DPX, 
LysoTracker Blue DND-22 and rhodamine-123 (Rh123) were purchased from 
Molecular Probes, Invitrogen (OR, USA). Saline (0.9% sodium chloride) was obtained 
from Duopharma Sdn. Bhd. (Selangor, Malaysia).  
 
3.2.1.2 Instrumentations 
All cell culture works were carried out with aseptic technique in an Airstream class II 
biological safety cabinet (ESCO, Singapore). Cultured cells were incubated in a Forma 
direct heat CO2 incubator (Thermo Fisher Scientific, OH, USA). UV-visible absorption 
and fluorescence emission spectra were recorded with the cuvette platform of 
SpectraMax M4 (Molecular Devices, CA, USA) using 1 cm pathlength quartz cuvettes. 
Meanwhile, the absorbance and fluorescence intensity of samples in a 96-well plate was 
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measured with the microplate platform of SpectraMax M4.  Photoirradiation for in vitro 
experiments was performed with a light source consisting of a Halotone 300 W halogen 
lamp (Philips Electronic, Netherlands). A water column was used to filter off the 
infrared radiation and a Roscolux #26 Light Red (>580 nm) (Rosco, NY) filter were 
placed in the irradiation path before the sample. The irradiation intensity was measured 
with a calibrated Nova-Oriel power meter (Newport Corp, CA, USA). Other equipments 
used only for specific experiment are listed under their respective methodology sections.  
 
3.2.1.3 Animal Model 
Fertilised Lohmann Brown chicken eggs were supplied by Hing Hong Sdn. Bhd. 
(Selangor, Malaysia). Female BALB/c mice aged between 4-6 weeks were obtained 
from Monash University Sunway Campus (Selangor, Malaysia) and were allowed to 
acclimatise for two weeks in the animal holding facilities in Department of 
Pharmacology, Faculty of Medicine, University of Malaya. All animal experiments 
were conducted in accordance with the protocols reviewed and approved by Dr. Haji 
Azizuddin Bin Haji Kamaruddin, Laboratory Animal Centre (LAC) Animal Care and 
Use Committee (ACUC), Faculty of Medicine, University of Malaya (reference number 
FAR/14/07/2010/LSH). Mice were maintained in individually ventilated cages rodent 
housing system (Allentown Inc., NJ, USA) in a controlled environment of 12 h light-
dark cycles with free access to food (standard pellet diet purchased from Altromin 
International, Lage, Germany) and water. Female mice were used because the hormonal 
environment essential for development of implanted 4TI mouse mammary carcinoma 
would be present.  
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3.2.2 Preparation of Compound 
G2 and its analogues were prepared and supplied by Dr Lee Hong Boon’s group from 
Cancer Research Initiatives Foundation, Malaysia. Their syntheses, purification and 
NMR characterisation are included in Appendix C. All the compounds used for in vitro 
experiments were dissolved in DMSO to make stock solutions of 10 mM, aliquoted into 
appropriate volume and stored at -20 ºC prior to use. 
 
3.2.3 Photophysical properties  
Compounds were dissolved in ethanol at 10 µM for the measurements of UV-visible 
and fluorescence emission spectra. The UV-visible spectral data was collected from 300 
to 800 nm wavelengths. The compounds were excited at their respective maximal 
absorption (λabs) for the measurement of fluorescence emission spectrum, which was 
recorded from 600 to 800 nm. Extinction coefficient (ε) for each compounds were 
determined and the fluorescence quantum efficiency (Фfl) was calculated using PhA in 
ethanol (Фfl = 0.28) as a reference (Röder et al. 2000). 
 
3.2.4 Cell Culture 
HSC2 was obtained from Health Science Research Resources Bank (Japan Health 
Sciences Foundation, Japan). The cell line was grown in MEM medium supplemented 
with 10% FBS and 1% of penicillin-streptomycin and maintained in a 25 cm
2
 tissue 
culture flask in a humidified atmosphere containing 5% CO2 and 37 ºC. When the 
culture reaches confluency of 80%, cells were washed twice with sterile PBS to remove 
all traces of serum which contains trypsin inhibitors before 1.0 ml of trypsin-EDTA 1× 
was added for 5-10 min at 37 ºC to disperse the monolayer cells. Then, 3 ml of 
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complete culture medium was added to the dispersed cells followed by repeated gentle 
pipetting to split apart the cell clumps. An aliquot of the cell suspension was transferred 
to a new 25 cm
2
 tissue culture flask containing 5 ml of fresh medium at a subculture 
ratio of 1:4 to 1:8 and incubated at 37 ºC.  
 
3.2.5 Photo-induced Cytotoxicity Assay 
Approximately 3000 cells/well in a phenol-red-free culture medium containing 10% 
fetal bovine serum were seeded in a 96-well plate. Cells were allowed to adhere 
overnight before test compounds were introduced. Photosensitiser stock solutions (10 
mM in DMSO) were diluted with medium, and concentrations varying from 0.001 to 
100.0 μM were tested on the cells. The control wells received 0.01% of DMSO, 
equivalent to the highest amount of DMSO used as vehicle in the compound-treated 
wells. Following 2 h of treatment, cells were irradiated at a fluence rate of 8.9 mW/cm
2
 
for 10 min to obtained irradiation light dose of 5.3 J/cm
2
 (as calculated using Equation 
1) using a custom-made broad spectrum irradiation light source filtered with a Roscolux 
#26 Light red (>580 nm) (Rosco, NY, USA) interference filter (Figure 3.2). 
Equation 1 
Light dose (J/cm
2
)  = 
light power (W) × irradiation time (s) 
area of irradiation (cm
2
) 
 
After irradiation, the cells were further incubated for 24 h before cell viability was 
assessed using the MTT assay (Marshall et al. 1995). Following incubation, 15 μl of 
MTT solution (5 mg/ml) was added into each well and incubated for 4 h at 37 ºC. The 
medium was then removed and 100 μl of DMSO was added to dissolve the formazan 
crystal formed. Absorbance, as a measurement of viable cell number, was read at 570 
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nm with a microplate spectrophotometer and the percentage of cell viability was 
determined using Equation 2.  
Equation 2 
% of cell viability = 
average absorbance of treated cells 
× 100 
average absorbance of control cells 
 
A dose response curve was constructed and the IC50 value (the concentration of 
compound that inhibits the proliferation rate by 50% compared with the control 
untreated cells) was interpolated from the curve. An equivalent experiment without light 
exposure was carried out concurrently to determine the dark toxicity of each compound. 
 
 
 
Figure 3.2 Schematic illustration of a custom-made irradiation light box setup which 
consists of a) an intensity-controlled halogen lamp as illumination light source; b) a 
water column to filter off the ultraviolet and infrared radiation; c) a 45° mirror to direct 
light path to the sample; d) an interference filter was placed in the irradiation path 
before the sample to attain desired irradiation wavelength and; e) a fan for system 
cooling. The irradiation intensity is measured with a calibrated power meter. 
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3.2.6 Relative Rate of Singlet Oxygen Generation 
The singlet oxygen generation of the photosensitiser was measured by monitoring the 
bleaching of DPBF, a known singlet oxygen acceptor (Kochevar and Redmond 2000). 
Photosensitisers at 0.5 μM prepared in 8 ml of 50 μM DPBF in aerated isopropanol in a 
6-well plate was irradiated at 5.3 mW/cm
2. A 200 μl of the solution was sampled into a 
covered 96-well plate in duplicates at fixed intervals over 1 h and the absorbance was 
read at 410 nm using a microplate reader. An irradiated well without photosensitiser 
was also performed as a negative control. The singlet oxygen generation rate was 
deduced from the reduction of DPBF absorbance over time and the quantum yield was 
determined by using PhA (ΦΔ = 0.52) as a reference (Hackbarth et al. 2001). 
 
3.2.7 Distribution Coefficient (Log D) 
Distribution coefficient was determined by the shake flask method (Berthod and Carda-
Broch 2004). Octanol-1 and phosphate buffered saline (PBS) (pH 7.4) were pre-
saturated with each other by shaking vigorously a mixture of both in separate bottles 
and the mixtures were allowed to settle down overnight. A stock solution of compounds 
in known concentrations (5 to 20 μM) in octanol-1 was prepared. This solution was 
shaken vigorously with a same volume of PBS (pH 7.4) in a 2 ml microcentrifuge tube. 
Another set of experiment was prepared by diluting the octanol-1 stock solution by half 
its concentration and shaking a same volume of this diluted stock solution with a second 
volume of PBS. To facilitate equilibration, tubes were centrifuged at 400 g for 10 min. 
Both the octanol-1 and aqueous phases were carefully sampled for absorbance 
measurement and the compound concentrations in both phases were interpolated from a 
standard curve of the compound determined at 400 nm. The distribution coefficient or 
Log D was then calculated using Equation 3. 
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Equation 3 
Log D = Log 
Concentration octanol-1 
Concentration PBS pH 7.4  
 
 
3.2.8 Intracellular Localisation 
Intracellular localisation of photosensitiser was analysed by confocal microscopy using 
dual staining techniques (Marchal et al. 2007). Cells grown on round glass coverslips in 
12-well plates were co-incubated with 100 nM of photosensitser together with 
organelle-specific fluorescence probes. The endoplasmic reticulum was labeled with 
100 nM of ER-Tracker Blue-White DPX, the lysosomes were stained with 500 nM of 
LysoTracker Blue DND-22, and the mitochrondria were tracked with 100 nM of Rh123, 
each for 15-30 min of incubation at room temperature. After incubation, cells were 
gently rinsed in PBS to remove free dyes, and the stained cells were observed using 
Olympus DSU spinning disk confocal microscope configured with a PlanApo 60× oil 
objective (Olympus Optical Corp. Ltd., Tokyo, Japan) and iXon EM+ digital camera 
(Andor Technology, CT, USA). Fluorescence images of Z sections at 0.2 μm were 
collected sequentially using Olympus Cell software. Organelle-specific fluorescence 
probes were respectively excited at 330-385 nm wavelengths to illuminate ER-tracker 
and LysoTracker, at 460-490 nm for Rh123 and at 400-440 nm for the G2 derivatives. 
The intracellular localisation of the photosensitiser was determined by comparing its 
fluorescence topographic profile with the topographic profile of each organelle-probe 
generated from a longitudinal transcellular axis. 
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3.2.9 Intracellular Uptake of Photosensitiser 
HSC2 cells were seeded into 96-well plate at 4000 cells/well and incubated overnight. 
Cells were treated with compounds at 10 μM for indicated periods. Following 
incubation, the content of each well was removed and the wells were washed twice with 
PBS. Each well was then incubated with 200 μl of acetonitrile:water (4:1) for 30 min at 
room temperature to lyse the cells and extract the photosensitisers. Subsequently, 100 μl 
of the extract was transferred to a black 96-well plate and their fluorescence intensity 
(excitation/emission at 400/675 nm) was measured. The concentrations of the 
photosensitiser were determined from a calibration curve. 
 
3.2.10 Photostability Studies 
 Photosensitiser photostability was studied by monitoring the photobleaching of the 
phototosensitiser following light irradiation (Rotomskis et al. 1996). Briefly, 10 μM of 
compounds in 100 μl of PBS (pH 7.4) were irradiated at 8.9 mW/cm2 for various 
durations. Following irradiation, the samples absorbance was recorded at 400 nm. 
 
3.2.1 PDT on the CAM Vasculature (in ovo) 
3.2.11.1 CAM Model Development 
The CAM experiment was performed as previously described (Lange et al. 2001). 
Freshly fertilised chicken eggs were incubated at 37.6 ºC with 65% relative humidity 
(Savimat MG
 
200, Chauffry, France) with the narrow apex down in a swinging 
incubator. On embryo development day (EDD) three, an eggshell opening of ~4 mm in 
diameter was bored at the narrow apex with a sharp curved point forceps. The purpose 
of boring a hole on the eggshell at early days of incubation is to ensure that the growing 
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CAM will not encounter a continuous surface to be attached to and will detach from the 
eggshell.  The hole was then sealed with adhesive tape to avoid contamination and 
desiccation of the egg contents.  The eggs were further incubated in stationary position 
with the narrow apex upright until EDD-9. At the time of the assay, the CAM was 
accessible without damage by carefully opened the eggshell around the window made. 
Critical steps 
 Continuous use of eggs source from one supplier decreases the variability in 
development of embryos and the degree of vascularisation (Ribatti et al. 2006). 
 The use of fertilised eggs obtained from facilities where hens do not receive any 
antibiotic, artificial hormone or nutritional supplements is recommended to avoid 
interference of such substances with the assays. 
 Eggs are best incubated soon after laying or must be maintained at 15-20 ºC prior 
to incubation. Long periods (more than 5 days) between egg laying and incubation 
decrease embryos’ survival.  
 Falling of chipped eggshell onto the CAM should be avoided since eggshell pieces 
induce inflammation. 
 Work performed on the embryos must be done under aseptic conditions as the chick 
embryo is susceptible to infections especially from Aspergillus fumigatus, 
Staphylococcus aureus and Pseudomonas aeruginosa (Ribatti et al. 2006). 
 
3.2.11.2 Microscope Setup for Photo-irradiation and Imaging  
Microscopic observation of CAM vasculature and the light irradiation during PDT were 
performed with a MVX10 macro zoom fluorescence microscope equipped with a MV 
PLAPO 2XC lens (Olympus, Japan).  Illumination was provided by a 75 W Xenon lamp 
burner (Olympus, Japan).  Light doses were adjusted with neutral density filters and 
measured with Nova-Oriel power meter (Newport Corp, CA, USA).  For exciting and 
detecting G2 analogues, a 400-440 nm excitation filter set (U-FBVW; Olympus, Japan) 
was used.  For detecting FITC, a 460-480 nm excitation filter set (U-MGFPHQ; 
Olympus, Japan) was used.  Fluorescence angiograms were acquired with a XM10 
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monochrome cooled CCD camera driven with Cell
M
 Software from Olympus Soft 
Imaging Solution (Münster, Germany).   
 
3.2.11.3 PDT on the CAM Vasculature (in ovo) 
On EDD-9, the egg opening was extended to ~30 mm in diameter.  Embryos were 
intravenously administered with a single bolus of photosensitiser in a dosing vehicle 
(CrEL 5%, EtOH 5% in saline). For control group, embryos were injected with the 
dosing vehicle only. Dosing was performed at the CAM main vasculature using 
microliter syringe affixed with a 12º beveled point 33g needle (Hamilton Company, 
NV, USA).  The needle was inserted at < 20º angle to avoid vascular damage and 
hemorrhage. One minute after injection, a site with vessels of diameter between 5-100 
µm was irradiated with light dose of 20-40 J/cm
2
. Irradiation was performed with light 
at 400-440 nm at a fluence rate of 130 mW/cm
2
 over an area of 0.02 cm
2
.  The duration 
of irradiation was determined as described in Equation 1. Subsequently, the egg opening 
was sealed with parafilm and was further incubated for 24 h before assessing the PDT-
induced damage.  
Fluorescence angiograms were performed in order to assess the PDT-induced 
vasculature damage.  Blood vessels were perfused with 10 µl of 25 mg/ml FITC-dextran 
followed by injection of Indian ink into the allantoic cavity to decrease the embryo’s 
interfering fluorescence from deeper located vessels.  The vasculature network at the 
site of irradiation was illuminated by exciting the FITC at 465-495 nm wavelengths on 
the fluorescence microscope.  The vasculature network was imaged and the extent of 
damage induced by PDT was scored using a previously defined arbitrary damage scale 
from 1 to 5 as listed in Table 3.1 (Lange et al. 2001). At least 10 embryos were assessed 
for each treatment group. 
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Table 3.1 The damage score of PDT-induced vasculature network occlusion. 
Occlusion 
score 
Findings Pre-irradiation Post-irradiation 
0 No occlusion 
  
1 
Partial closure of capillaries of 
diameter < 10 µm 
  
2 
Closure of capillary system, 
partial closure of blood vessel 
of diameter < 30 µm and size 
reduction of larger blood 
vessels 
  
3 
Closure of vessels of diameter 
< 30 µm and partial closure of 
larger blood vessels 
  
4 
Total closure of vessels of 
diameter < 70 µm and  partial 
closure of larger vessels 
  
5 
Total occlusion of vessels in 
the irradiated area 
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Critical steps 
 Embryo tolerability to the injection solution should be determined in advance. 
 Care should be taken to inject only inside the vessel and not in surrounding tissue. 
 PDT on CAM must always be performed using embryo at matching EDD. This is 
because body weight, blood volume and CAM features change during embryo 
development (Ribatti et al. 2001; Vargas et al. 2007). 
 The evaluation of PDT effects must be at exactly the same period of time post PDT, 
because the initial occlusion of vessels observed 24-h post-PDT can induce 
angiogenic stimuli, resulting in reperfusion of occluded vessels and 
neovascularisation (Zuluaga et al. 2007). 
 
3.2.12 In Vivo PDT Efficacy Studies 
Tumour allografts were initiated by injecting 5×10
5
 of 4T1 mouse mammary carcinoma 
cell in 0.1 ml RPMI 1640 media into the mammary fat-pad at the lower left quadrant of 
the mice’s abdomen (Jin et al. 2010). Treatments were initiated when tumours reached a 
volume range of 100-200 mm
3
. Mice were administered respectively with 15 mg/kg G2 
or G2-Asp dissolved in a mixture of 10% cremophor, 10% ethanol in saline as dosing 
vehicle via the lateral tail vein at 10 ml/kg. For solvent control group and unirradiated 
control group, dosing vehicle and 15 mg/kg of G2 or G2-Asp only was given, 
respectively. Following dosing at various intervals, mice were anesthetised by 
intraperitoneal injection of an anesthetic cocktail (25 mg/ml tiletamine-zolazepam, 80 
mg/ml ketamine, 20 mg/ml xylazine) and PDT was performed after the onset of 
anaesthesia. The tumour area was focally illuminated using the Lumacare LC-122A 
fiber optic light delivery system (Lumacare, Newport Beach, CA) fitted with 665/32 
bandpass filter. The total fluence delivered was 100-200 J/cm
2
 with a fluence rate of 
130 mW/cm
2
 over a 12 mm diameter irradiation spot.  Following illumination, animals 
were allowed to recover from anesthesia in a warm chamber.  Animal weights and 
tumour volume were measured thrice weekly for a month or earlier when the mice were 
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deemed necessary to be sacrificed owing to excessive tumour burden (tumour volume 
>2000 mm
3
). At least six mice were assessed for each treatment group. 
Growth of the solid tumours was monitored using in situ caliper measurement of 
two perpendicular dimensions (length and width) and tumour volume was calculated 
using the formula for a prolate ellipsoid using Equation 4. (Plowman et al. 1997; 
Hollingshead 2008).  
Equation 4 
Tumour volume (mm
3
) = 
length (mm) × width
2
 (mm) 
2 
 
The median tumour volume – time profile for each group was plotted and results 
were expressed as median ± 95% confidence interval. To determine the antitumour 
activity, terminal % T/C was calculated from the growth curve (Equation 5).  
Equation 5 
Terminal % T/C  = 
ΔT 
× 100, if  ΔT > 0 
ΔC 
or 
 ΔT 
× 100, if  ΔT < 0  
 T1 
Where ΔT and ΔC are the changes in the median tumour volume for each treated and 
control group after the treatment had ended. 
 
3.2.13 Statistical Analysis 
Statistical significance was performed using one-way ANOVA followed by 
Bonferroni’s post-hoc test (SPSS 16.0, IBM Corporation, Armonk, NY) and differences 
were considered significant when p<0.05.  
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3.3 Results and Discussion 
3.3.1 Photophysical Properties 
Figure 3.2 showed the absorption and fluorescence emission spectra for G2 analogues 
assessed at 10 µM in ethanol.  Their photophysical parameters are summarised in Table 
3.2.  The conjugation of G2 with aspartyl or lysyl as well as G2 in acid form did not 
result in a shift in the absorption and emission peaks. All the analogues have similar 
absorption spectra shape with a B-band at approximately 400 nm and a major Q-band at 
667 nm.  However, the Q-band molar extinction coefficient of G2 acid (ε = 8400) and 
G2-Lys (ε = 6500) were appreciably lower compared to G2 (ε = 34100) and G2-Asp (ε 
=31800).  Meanwhile, the fluorescence emission wavelength among the G2 analogues is 
very similar at ~ 675 nm and their fluorescence quantum yield (Φfl) in ethanol were 
ranging from 0.14-0.19 as calculated using PhA (Фfl = 0.28 in ethanol) as a reference.   
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Figure 3.2 Photophysical properties of G2 analogues at 10 μM in ethanol. A) UV-
visible spectrum for G2 analogues. B) Fluorescence emission spectra for G2 analogues 
when excited at B-band λmax. 
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Table 3.2 Photophysical parameters of G2 analogues in ethanol. 
Compounds 
B-band   
λabs (nm) 
Q-band   
λabs (nm) 
λem (nm) 
Q-band ε  
(M
-1
cm
-1
) 
Φfl 
G2 398 667 675 34 100 0.16 
G2 acid 400 666 672 8 400 0.18 
G2-Asp 397 667 675 31 800 0.14 
G2-Lys 399 667 672 6 500 0.19 
Φfl : Quantum efficiency of fluorescence was calculated using pheophorbide-a in ethanol (Фfl = 0.28) as a 
reference  
 
This observation is consistent with previous reports that also observed lower 
extinction coefficients with the conjugation of hydrophilic amino acids to porphyrins.  
(Roberts et al. 1988; Serra et al. 2010).  This reduction is undesirable because in order 
to receive sufficient excitation energy especially in deep-seeded tissues, a 
photosensitiser should have a relatively high absorption bands (>20000-30000 M
-1
cm
-1
) 
at wavelengths between 600-800 nm where light can penetrate effectively (Castano et 
al. 2004).   
 
3.3.2 Distribution Coefficient Log D    
Distribution coefficient (Log D) is defined as the equilibrium concentrations ratio of a 
compound (ionised plus unionised) dissolved in each phase of a mixture of two 
immiscible solvents, namely an aqueous buffer and n-octanol. The measurements of 
Log D values of G2 analogues were determined using the shake flask method. From the 
experiment, G2-Lys and G2-Asp had Log D values of 0.3 and -0.4 respectively, which 
were significantly lower (p<0.05) compared to the unconjugated G2 with a value of 1.3 
(Table 3.3). The lower Log D values indicated that the conjugation of G2 with aspartyl 
or lysyl amino acids had increased its solubility in the aqueous phase. The negative Log 
D value of G2-Asp reflects its preferential solubilisation in the aqueous compared to the 
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octanol phase. Meanwhile, the Log D value for G2-acid at 1.2 was similar to that for G2 
(p>0.05).   
Data from the observation showed that the attachment of aspartyl or lysyl amino 
acids was able to improve the aqueous solubility of G2 as represented by the lower or 
negative Log D values.  This is expected as Asp and Lys are highly polar, in which the 
acidic aspartyl moiety is set to lose an H
+
 (proton) at its carboxylic side chain to become 
negatively charged and engages in ionic bonding, whereas the amine side chain of the 
lysyl moiety accepts an H
+
 to become positively charged and engages in hydrogen 
bonding.    
 
3.3.3 Singlet Oxygen Generation Quantum Yields 
The ability of a photosensitiser to generate singlet oxygen determines their efficiency as 
a PDT agent. This event is essential because the singlet oxygen produced is the key 
cytotoxic agent that can directly oxidise many biological molecules. The singlet oxygen 
quantum yield of G2 analogues were quantified by monitoring the bleaching of the 
singlet oxygen scavenger DPBF at an initial concentration of 50 μM in isopropanol over 
a period of 1 h light irradiation. The irradiation was performed at 5.3 mW/cm
2
 of light 
dose at room temperature. The singlet oxygen quantum yield was determined using PhA 
as a reference. Under this experimental condition, G2 exhibited significantly higher ΦΔ 
value (p<0.05) at 0.66 which is at least 2-fold higher compared to G2 acid, G2-Asp and 
G2-Lys (Table 3.3). In the meantime, reduction of DPBF was not observed in the 
negative control well indicating that its reduction was not caused by photobleaching of 
the DPBF reagent. 
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Table 3.3 Singlet oxygen quantum yield, Log D, and photocytotoxicity of G2 analogues 
Compounds Log D
a
  ΦΔ
b
 IC50 (μM)
c 
G2 1.3 ± 0.2
§
 0.66 ± 0.03
§
 0.48 ± 0.02
§
 
G2 acid 1.2 ± 0.1
§
 0.32 ± 0.01
†
 2.8 ± 0.1
†
 
G2-Asp -0.4 ± 0.1
‡
 0.32 ± 0.03
†
 0.91 ± 0.07
§
 
G2-Lys 0.3 ± 0.1
†
 0.29 ± 0.02
†
 3.3 ± 0.4
†
 
a Distribution coefficient determined using a modified shake flask method in n-octanol and PBS (pH 7.4).  
b Singlet oxygen quantum yield in isopropanol with pheophorbide-a (ФΔ = 0.52 in EtOH) as reference.  
c IC50 (half maximal inhibitory concentration) in HSC2 cells determined using MTT assay following 24 
h incubation with compounds (light dose 5.3 J/cm2). No dark cytotoxicity was observed up to 10 μM.  
Values represent mean ± SD of three independent replicates. Means with different symbols are 
significantly different from each other (p<0.05) within each parameter. 
 
3.3.4 In Vitro PDT Activity 
To determine the photocytotoxicity of G2 analogues, HSC2 cells treated with the 
photosensitisers were irradiated with a light dose 5.3 J/cm
2
. The cell viability following 
treatment was determined 24 h later using MTT assay. The MTT assay is based on the 
conversion of tetrazolium salt to purple formazan by the mitochondrial dehyrogenase 
activity of viable cells (Mosmann 1983). In this study, G2 was the most potent 
photosensitiser with an IC50 value of 0.48 µM followed by G2-Asp, G2 acid and G2-
Lys with IC50 values of 0.91, 2.8 and 3.3 µM, respectively (Table 3.3). The reduction of 
G2-Asp  PDT potency was not significant (p>0.05), while the potency for G2-Lys and 
G2 acid were significantly reduced (p<0.05) when compared to G2. Photosensitisers 
treatment up to 10 µM without irradiation did not cause significant loss in cell viability.  
The results in this study showed that the conjugation of aspartyl or lysyl amino 
acids to G2 reduces its in vitro PDT potency. When analysed according to singlet 
oxygen generation ability, the phototoxicity of the G2 analogues decreased in 
accordance with decreasing singlet oxygen production following conjugation to aspartyl 
or lysyl group. Since the light-absorbing chromophore in the G2 analogues remained the 
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same, the decrease in the singlet oxygen generation could be linked to the lower molar 
absorption coefficient of the more polar analogues, which would in turn affect the 
amount of light energy absorbable to generate singlet oxygen. 
 
3.3.5 Cellular Uptake 
The cellular uptake of a photosensitiser may also influence cellular susceptibility to 
PDT, whereby higher level of cellular uptake is often correlated with greater 
photocytotoxicity. In the present study, the kinetic of G2 analogues cellular 
accumulation was studied in HSC2 cells by measuring the molar amount of 
photosensitisers taken up by cells following 10 µM incubation of photosensitiser in the 
dark.  From the study (Figure 3.4), G2 exhibited the highest uptake, whereby the 
accumulation of G2 increased significantly within the first 0.5 h (p<0.05) and continued 
to rise to 150 nmol/mg protein at 24 h (p<0.05). Meanwhile, the uptake rates and 
amounts for G2-acid, G2-Asp and G2-Lys within the first 24 h were low with 
concentrations detected at approximately 18 nmol/mg protein. 
When analysed together with in vitro PDT potency, greater photocytotoxicity 
was observed in analogues that showed higher level of cellular uptake. The greater 
cellular uptake by G2 compared to G2-Asp and G2-Lys is probably due to the greater 
lipophilicity of the former as lipophilic compounds can cross the membrane lipid 
bilayers more easily. While it is generally true that the uptake of compounds into cells is 
largely governed by their relative lipophilicity, several studies have shown that uptake 
of certain tetrapyrroles demonstrated non-linear correlation with their lipophilicity 
parameter (Margaron et al. 1996; Huang et al. 2010). An example is that extremely 
lipophilic tetrapyrrole tends to form aggregate in the media and thus prevent plasma 
membranes diffusion. 
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Figure 3.4 Intracellular uptake profiles of G2 analogues at 10 μM in HSC2 cells. 
Intracellular accumulation of G2 increased rapidly within the first four hours and 
continued to rise to 150 nmol/mg protein  at 24 h. Meanwhile, the uptakes for G2 acid, 
G2-Asp and G2-Lys within 24 h were approximately 18 nmol/mg protein. *Statistically 
significant differences compared to each group at their respective time point with 
p<0.05. 
 
3.3.6 Photostability 
Degradation of photosensitiser following irradiation reduces their availability to 
perform PDT due to photobleaching. Photostability study was performed by irradiating 
10 µM of photosensitisers in PBS (pH 7.4) at 8.9 mW/cm
2
 in order to mimic the in vitro 
assay settings. From Figure 3.5, G2 and G2-Asp were relatively stable to irradiation at 
wavelength between 600-800 nm. Meanwhile, G2 acid and G2-Lys were found to be 
photodegraded within the first 20 min of irradiation by 8% and 15% from their initial 
concentration, respectively. However, their degradations were minimal within the first 
10 min which corresponds with the irradiation duration used for in vitro study. 
Therefore, photostability has minimal effects in modulating the potency patterns 
exhibited by these photosensitisers. 
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Figure 3.5 Photostability assessment through UV-visible spectra of 10 μM of G2 
analogues in PBS (pH7.4) upon irradiation with light of 600-800 wavelengths at 8.9 
mW/cm
2
. 
 
3.3.7 Intracellular Localisation 
The singlet oxygen generated immediately after PDT has a short half-life and limited 
diffusion in the biological environment (Moan and Berg 1991). Therefore, different 
subcellular organelle localisation of a photosensitiser is known to produce different 
mechanisms of PDT-mediated cell toxicity and this affects its potency. The 
accumulation of a photosensitiser in the mitochondria and reticulum endoplasm is found 
to be more efficient in triggering cell death following PDT as compared to their 
accumulation in lysosomes. The mitochondrial damage by PDT has been shown to 
correlate with several cellular events associated with apoptosis i.e. rapid loss of 
mitochondrial membrane potential, cytochrome c release and the activation of cytotoxic 
caspases (Morgan and Oseroff 2001). Meanwhile in endoplasmic reticulum, PDT is 
observed to induce carbonylation of cellular proteins that leads to stress in that organelle 
and could trigger cell death (Szokalska et al. 2009). The photosensitisation of lysosomes 
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is reported to initiate autophagy response which can either promote survival or facilitate 
the death of the photodamaged cells. It is observed that lysosomal proteases were 
photoinactivated by certain photosensitisers and this had led to impaired autophagic 
processes leading to cell survival (Reiners et al. 2010). 
The intracellular localisation of the two G2 analogues namely G2 and G2-Asp 
was analysed by confocal microscopy using dual staining techniques. Only G2 and G2-
Asp were included in this study because these photosensitisers have fluorescence 
intensities high enough for live cell imaging. Co-staining images of the photosensitisers 
with organelle-specific probes namely Rh123 (for mitochondria), Lyso-tracker (for 
lysosome) and ER-tracker (for endoplasmic reticulum) were photographed and their 
localisation topographic profiles were compared (Figure 3.6).  
   In our study, the lipophilic G2 was shown to localise predominantly in the 
endoplasmic reticulum while only colocalised partially in the endoplasmic reticulum 
and lysosomes.  Meanwhile, the localisation of hydrophilic photosensitiser especially 
G2-Asp shifted to the lysosomes. No staining of the nucleus or plasma membrane was 
observed for both G2 and G2-Asp. Similar preferential for lysosomes localisation was 
also reported for chlorin-e6 with aspartyl conjugation at the similar carbon-position 
(Roberts et al. 1988).  The explanation for the observed subcellular localization may be 
attributed to the lipophilicity and the anionicity of the compounds.  Photosensitisers 
which are more lipophilic (e.g. G2) tend to accumulate in cellular compartment with 
high lipid bilayer content such as mitochondria and endoplasmic reticulum where PDT-
induced damage to these organelles is likely to amplify cell toxicity. In contrast, anionic 
photosensitisers such as G2-Asp may be too polar to diffuse across the plasma 
membrane are instead taken up by cell lysosomes through endocytosis. As lysosomes 
are less sensitive organelles than the mitochondrial, this might explain our observation 
on the better in vitro PDT activity of G2 compared to G2-Asp. 
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Figure 3.6 Intracellular localisation of G2 and G2-Asp in HSC2 cells. Spinning disk 
confocal fluorescence images and their respective fluorescence topographic profiles of 
HSC2 cells double-stained with 100 nM of G2/G2-Asp and organelle probes.  
Mitochondria were labeled with 100 nM of Rh123 and excited at 494 nm. Endoplasmic 
reticulum were labeled with 100 nM ER-Tracker and excited at 365 nm. Lysosomes 
were labeled with 500 nM of LysoTracker and excited at 365 nm.  Both G2 and G2-Asp 
was excited at 420 nm. Topographic profiles revealed that G2 localised predominantly 
in the endoplasmic reticulum, while G2-Asp localised in the lysosomes.  Objective 
magnification  60. 
G2 + Rh123 
G2 + ER tracker 
G2 + Lyso tracker 
G2  ASP+ Lyso tracker 
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3.3.8 PDT-induced Vascular Occlusion 
One method to evaluate the PDT efficacy of a photosensitiser is by determining the 
ability of the agent to induce vasculature occlusion. Only G2 or G2-Asp were selected 
to be evaluated for their vascular occlusion efficiency in CAM model given their better 
in vitro potency. In Figure 3.7, G2 at 6 nmol/embryo was shown to induce closure of 
vessels < 30 µm in diameter with an average occlusion score of 2.5 when irradiated with 
a light dose of 20 J/cm
2
. At similar drug and light doses, G2-Asp only induced partial 
closures of capillaries of diameter below 10 µm with a damage score of 1. When the 
light dose was increased to 40 J/cm
2
, G2 at 6 nmol/embryo was able to induce complete 
closure of vessels with diameter < 30 µm with an occlusion score of 3.3, while G2-Asp 
induced an occlusion score of 4,0 with total occlusion of vasculature observed for 
vessels with diameter < 70 µm. Meanwhile, the control eggs that received 20 µl of 
vehicle (2.5% CrEL, 2.5% EtOH in saline) and exposed to similar light dose showed no 
detectable vascular alteration in the treated area. This indicated that the vascular 
occlusion observed in embryos treated with G2 or G2-Asp was neither caused by the 
vehicle components nor was it a result of heat generated by the light irradiation.  
CAM is a viable model that has been successfully used to evaluate the PDT-
induced vascular occlusion efficacy of photosensitisers, some of which are currently in 
clinical trials or are already clinically approved (Hammer-Wilson et al., 2002). Data 
from the study showed that both G2 and G2-Asp were able to occlude CAM blood 
vessels following PDT, with G2-Asp achieving similar photodamage (p>0.05) 
compared to G2 when higher light dose was used. This observation could be due to the 
longer circulating half-life of the more hydrophilic G2-Asp compare to G2 because 
lipophilic photosensitiser tend to leak out of the circulatory system faster. As the 
irradiation time to achieve 40 J/cm
2
 is twice longer than 20 J/cm
2
 at a fixed fluence of 
130 W/cm
2
, there may be lesser circulating G2 by the later stage of the irradiation. 
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Figure 3.7 Representative angiographies of CAM vasculature before and 24 h after 
PDT, illustrating the vascular occlusion efficacy induced by G2 and G2-Asp at 6 
nmol/embryo. Irradiation was performed at 400-440 nm of excitation wavelength with 
20-40 J/cm
2 
of light dose. Occlusion score represents mean values from at least ten 
embryos. Score with different symbols are significantly difference from each other 
(p<0.05). Objective magnification ×4.  
 Irradiated area before PDT After PDT 
Vehicle (20 μl) 
Occlusion score  
0 
  
G2 
20 J/cm
2 
Occlusion score  
2.4 ± 0.8
†
  
  
G2 
40 J/cm
2 
Occlusion score  
3.3 ± 0.6
†,‡
 
  
G2-Asp 
20 J/cm
2 
Occlusion score 
1.1 ± 0.1
§
 
  
G2-Asp 
40 J/cm
2 
Occlusion score  
4.0 ± 1.3
‡
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3.3.9 PDT-mediated Tumour Response In Vivo 
A dose finding experiment was first conducted to determine the potential 
therapeutic  and tolerable dose levels using the typical two mice per dose level with a 
doubling dose increase or dose-halving decrease design (Workman et al. 2010). 
BALB/c mice implanted with 4T1 tumour were administered with 15 mg/kg of G2 or 
G2-Asp and PDT was performed with at fluence of 100 or 200 J/cm
2
 at drug-light 
intervals of 1 h and 24 h respectively. Observations were summarised in Table 3.4 
where each treatment group consisted of two mice. Both mice in the group that received 
PDT with 200 J/cm
2
 of light 1 hr following drug dosing resulted in functional loss of the 
lower limb close to the irradiation site, which is an unacceptable adverse effect. In 
contrast, no clear evidence of PDT-induced antitumour response was detected for mice 
in the group with 24 h drug-light interval when irradiated with 200 J/cm
2
 of light. 
Subsequently, the light dose was reduced to 100 J/cm
2
 with the drug-light interval of 1 h 
and the treated mice presented evidence of antitumour response with the observation of 
tumour cyanosis within 24 h after PDT. This was followed by the typical development 
of inflammation and eschars within day 2-3 (Figure 3.8).  
 
Table 3.4 Effects of different route of administration, light dose and drug-light interval  
on the PDT efficacy and toxicity of G2 on 4T1 murine tumour implanted BALB/c mice.  
Route 
G2 
Dose (mg/kg) 
Light dose 
(J/cm
2
) 
Drug-light 
interval (h) 
Observable 
PDT effect 
Toxicity 
Intraperitoneal 15 100 20 No No 
Intraperitoneal 15 200 20 No No 
Intravenous 15 200 20 No No 
Intravenous 15 200 20 No No 
Intravenous 15 200 1 Yes Yes  
Intravenous 15 100 1 Yes No 
Intravenous 15 50 1 Yes No 
Each treatment group consists of two mice. 
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Figure 3.8 Photographs of 4T1 syngeneic murine tumour implanted at the inguinal 
mammary fat-pad of BALB/c mice before, 24 h and 72 h after PDT (15 mg/kg of G2 + 
100 J/cm
2
 light). Evidence of antitumour response was observed with the development 
of  tumour cyanosis within 24 h after PDT and followed by the typical development of 
inflammation and eschars within day 2-3. 
 
In our tumour model, both G2 and G2-Asp at a dose of 15 mg/kg are effective to 
inhibit the growth of 4T1 when the mice were irradiated with 100 J/cm
2
 of light 1 h post 
drug injection (Figure 3.9). At the end of 14-days observation period, the tumour growth 
in mice receiving G2 + 100 J/cm
2
 and G2-Asp + 100 J/cm
2
 was inhibited with % T/C of 
41% (p<0.05) and 43%% (p<0.05), respectively compared to the vehicle control group. 
There were no statistically significant differences in tumour growth between the two 
treatment groups. However, complete tumour regression was observed in two out of 
eight mice receiving 15 mg/kg G2-Asp + 100 J/cm
2
 of light but not in the G2 + 100 
J/cm
2
 group. No tumour growth inhibition was observed in animals receiving 15 mg/kg 
of G2 or G2-Asp only. 
There was no treatment-related toxicity or significant loss of animal body weight 
observed in all treatment groups exposed to 100 J/cm
2
 of light 1 h post drug injection. 
Tumour growth was only monitored for two weeks before the experiments were 
terminated given the high risk of tumour metastasis of 4T1 tumours grown in mammary 
fat pad of Balb/C mice. A previous study conducted using the same murine tumor 
 
   
Pre-treatment 24 h post-PDT 72 h post-PDT 
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model has shown that no metastasis was detected up to 18 days following tumour cell 
inoculation (Wenzel et al. 2010). 
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Figure 3.9 Effects of G2 and G2-Asp on tumour growth of 4T1 in vivo. Treatment was 
initiated when tumours reach volume of ~ 100 mm
3
. For PDT, tumour site was 
irradiation 1 h after drug dosing with 665/32 bandpass filtered light with a light dose of 
100 J/cm
2
 and at a fluence rate of 130 mW/cm
2
. At day 14, the tumour growth in mice 
receiving G2 + 100 J/cm
2
 and G2-Asp + 100 J/cm
2
 was inhibited with % T/C of 41% 
and 43%, respectively compared to the vehicle control group. Mixture of 10% CrEL, 
10% EtOH in saline was used as dosing vehicle and number in parenthesis indicates 
number of mice in each treatment group. * Statistically significant differences compared 
to control group at each time point with  p<0.05. 
 
Data from the study indicates that G2 and G2-Asp showed similar effectiveness 
in inhibiting tumour growth although the former is two-fold more potent in vitro. A 
possible explanation for this observation is that other than direct cell-killing which may 
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dominate in the G2 treated mice, the observed tumour shrinkage was probably also 
caused by shutting down of blood vessel supplying the tumour which would be more 
prominent in the hydrophilic G2-Asp.  
 
3.4 Conclusion 
From the study, conjugation of tetrapyrrole with hydrophilic amino acids was able to 
alter their photosensitising potencies and efficacies by modifying multiple parameters, 
including absorption coefficient, singlet oxygen quantum yield, cellular uptake and 
intracellular localisation. However, these conjugates (i.e G2-Asp and G2-Lys) exhibited 
a reduced in vitro PDT potency. Further evaluation showed that G2-Asp was able to 
achieve similar potency in inducing vasculature occlusion of the CAM and in inhibiting 
tumour growth in a syngeneic mouse model compared to G2. In conclusion, the 
conjugated G2-Asp is a promising candidate to develop as a PDT agent because it has 
more ideal photophysical properties such absorption maxima at far-red wavelength (675 
nm) and molar extinction coefficient and its ability to inhibit tumour growth in the 
preclinical mouse model. Given the hydrophilic nature of G2-Asp, the photosensitiser is 
a pharmaceutically advantageous candidate as it can be formulated easily for 
administration thereby reducing the risk of vascular aggregation. 
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CHAPTER 4 
 
Evaluation of Boron Difluoride Dipyrromethene (BODIPY) as Photosensitiser for 
Photodynamic Therapy 
 
4.1 Introduction 
Boron difluoride dipyrromethene (BODIPY) chromophore is an alternative class of non-
tetrapyrrole photosensitisers that has recently emerged. BODIPYs have many 
characteristics of an ideal photosensitiser including high extinction coefficients, relative 
insensitivity to environment and resistance to photobleaching.  However, unconjugated 
BODIPYs also have high quantum efficiencies of fluorescence. Since fluorescence 
occurs through relaxation from singlet excited states, high quantum yields for 
fluorescence are undesirable since this means that much of the energy absorbed on 
excitation does not cross to the much desirable triplet states for singlet oxygen 
generation. Consequently, BODIPYs for PDT have to be modified to depress 
fluorescence and enhance singlet-to-triplet intersystem crossing. Such modifications 
include attachment of electron donating groups such as akyl, phenyl and distyryl as well 
as heavy-atom like bromine and iodine at the periphery of the BODIPY in order to 
optimise their photophysical and therapeutic properties (Gorman et al. 2004; Yogo et al. 
2005; Atilgan et al. 2006). 
 
 
Structural variation 1 Structural variation 2 
Figure 4.1 Structure variations of BODIPY evaluated. 
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This study investigates the effects of two structural variations of BODIPY 
(Figure 4.1) on their photocytotoxicity in terms of photophysical properties, in vitro and 
in vivo efficacies.  In the first variation, functionalisations such as meso-substitution as 
well as sulphonation to improve hydrophilicity were tested to fine-tune the activity of 
iodinated BODIPY-based structures such as B6 (see Figure 4.2).  As photosensitisers 
that absorb in the longer wavelengths may be activated deeper in the tissues and may 
therefore be clinically favoured, a second variation consisting of compounds with 
extended conjugation at the 4-pyrollic position, which is a structural variation that has 
not been studied prior to this, were included in this study.  First, the PDT efficacy of 
these BODIPY-based photosensitisers on a panel of leukemia and solid tumour cell 
lines, with particular attention on their structure-activity relationship was evaluated.  
The most active derivative was further investigated for intracellular localisation, cell 
cycle arrest and onset of apoptosis experiments, as well as in a preclinical model using 
the chick chorioallantoic membrane (CAM) for PDT efficacy in terms of vascular 
occlusion. Compound B6 which has been shown to be a highly efficient and photostable 
photosensitiser (Yogo et al. 2005) was used as positive control. 
The BODIPYs evaluated in this study were provided by Prof Kevin Burgess’s 
group from the Department of Chemistry, Texas A&M University, Texas, USA. 
BODIPY series with structural variation 1 can be prepared with ease (Scheme 1) by 
condensation of acyl chlorides with pyrroles. The resulted dipyrromethene 
hydrochloride salt intermediates were then reacted with boron trifluride etherate in the 
presence of triethylamine to yield the desired BODIPY structures. BODIPYs with 
structural variation 2 were prepared by direct conjugation of electron withdrawing 
groups (EWG) at the pyrrroles through palladium mediated C-H functionalisation 
(Scheme 2) (Loudet and Burgess 2007). The preparation of BODIPY series is feasible 
given the easy access to various substituted pyrroles commercially. 
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4.2 Materials and Methods 
4.2.1 Materials 
4.2.1.1 Chemicals and Reagents 
SYTOX Green was purchased from Molecular Probes, Invitrogen (OR, USA). 
Methylene blue and ribonuclease A (RNase A) were purchased from Sigma (MO, 
USA). Annexin V-FITC Apoptosis Detection Kit 1 was purchased from BD 
Biosciences (CA, USA). Other chemicals and reagents used were as described in 
Section 3.2.1.1. 
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4.2.1.2 Instrumentations 
Flow cytometry analyses were performed using FACSCalibur flow cytometer with 488 
nm argon laser (Becton Dickinson, CA, USA) and data were acquired on CellQuest 
software. Other equipment used were as described in Section 3.2.1.2. 
 
4.2.2 Preparation of Compounds 
A total of fifteen BODIPYs used in this study were prepared and supplied by Prof 
Kevin Burgess’s group from the Department of Chemistry, Texas A&M University, 
Texas, USA. Their syntheses, purification and NMR characterisation were previously 
described by Loudet and Burgess (2007); Li et al. (2008); and Wu and Burgess (2008a). 
All the compounds used for in vitro experiments were dissolved in DMSO to make 
stock solutions of 10 mM, aliquoted into appropriate volume and stored at -20 ºC prior 
to use. 
  
4.2.3 Photophysical Properties 
Absorbance spectra were obtained on a Varian 100 Bio UV-Vis spectrophotometer at 
room temperature.  Extinction coefficients were determined from Beer’s Law plots 
using three data points. 
 
4.2.4 Cell Culture and Photo-induced Cytotoxicity Assay 
HL-60, HSC2 and HK1 cell lines were used to evaluate the photocytotoxicity of 
BODIPY in vitro. HL-60 human promyelocytic leukemia cells were obtained from 
American Type Culture Collection (VA, USA) and maintained in RPMI 1640 medium 
supplemented with 10% heat inactivated FBS and 1% of penicillin-streptomycin. A 
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confluent HL-60 culture was subcultured by transferring an aliquot of 0.5 ml cells to a 
new 25 cm
2
 tissue culture flask containing 5 ml of fresh medium. HK1 nasopharyngeal 
epithelial carcinoma cell line was a gift from University of Hong Kong Culture 
Collection (University of Hong Kong, Hong Kong) and grown in MEM medium 
supplemented with 10% FBS and 1% of penicillin-streptomycin.  HK1 cells were 
maintained similarly to HSC2 (refer Section 3.2.3). The photocytotoxicity experimental 
procedure and conditions were similar as described in Section 3.2.4, unless specified. 
For HL-60 cells, approximately 15000 cells/well in a phenol-red-free culture medium 
containing 10% fetal bovine serum were seeded in a 96-well plate. PDT was performed 
with 4.1 J/cm
2
 of fluence with light with a fluence rate of 6.8 mW/cm
2
 for 10 min.  
 
4.2.5 Comparative Singlet Oxygen Generation Measurements 
8 ml of aerated 2-propanol containing 50 μM of DPBF and the photosensitiser (0.5 μM 
or 5 μM) in a 6-well plate was irradiated at 6.8 mW/cm2 of filtered light of >510 nm 
wavelength with a Roscolux medium yellow no. 10 filter (Rosco, NY) at room 
temperature for 1 h. Aliquots of 200 μl were removed from the mixture at various fixed 
intervals, and the absorbance of DPBF was measured at 410 nm. Irradiation of DPBF-
isopropanol solution in the absence of photosensitiser as a negative control and solution 
containing methylene blue as a comparative control was also carried. The singlet 
oxygen production rate for each photosensitiser was determined from the reduction 
DPBF absorbance recorded over time. in relative to methylene blue.  
 
4.2.6 Intracellular Localisation 
As described in Section 3.2.8. BODIPY were excited at 520-550 nm wavelength.  
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4.2.7 Annexin V-FITC Apoptosis Analysis 
The event of apoptosis was determined using Annexin V-FITC Apoptosis Detection Kit 
1 according to manufacturer’s protocol. Briefly, cells grown in 60 mm dishes at 50% 
confluency were treated with test compounds. For PDT active compound, cells were 
irradiated with 4.1 J/cm
2
 of broad spectrum light following 2 h of incubation. At various 
treatment intervals, floating cells in the medium were pooled together with the adherent 
cells after trypsinisation and were washed twice with cold phosphate buffered saline 
PBS). The cells were resuspended with 1× binding buffer at 1×10
6
 cells/ml. A 100 μl of 
cell suspension was transferred to a flow cytometry tube followed by addition of 5 μl of 
annexin V-FITC. The cells were gently mixed and incubated for 15 min at room 
temperature in the dark before analysed on a flow cytometer. The fluorescence data of 
1×10
4
 cells were collected with the FL1 detector containing 530/30 band-pass filter to 
collect annexin-FITC fluorescence. 
 
4.2.8 Cell Cycle Analysis 
Cells grown in 60 mm dishes at 50% confluency were treated with test compounds. 
Cells were then irradiated with 4.1 J/cm
2
 of broad spectrum light following 2 h of 
incubation. At various treatment intervals, floating cells in the medium were pooled 
together with the adherent cells after trypsinisation and were washed twice with cold 
PBS. Cells were then fixed in 70% ice-cold ethanol (v/v in PBS) overnight at 4 ºC. 
Following fixation, the cells were washed twice in cold PBS. The pellet was then 
resuspended in PBS solution containing 20 μg/ml RNase A and 1 μM SYTOX Green 
for and incubated for 30 min at room temperature before analysed on a flow cytometer. 
The DNA-SYTOX Green fluorescence of 1×10
4
 cells were collected with the FL1 
detector containing 530/30 band-pass filter. 
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4.2.9 In Ovo CAM Model 
As described in Section 3.2.10. For exciting and detecting BODIPY, a 520-530 nm 
excitation filter set (U-MNG; Olympus, Japan) was used. Irradiation was performed 
with light dose of 20 or 40 J/cm
2
 at 520-550 nm wavelength achieved at an irradiation 
fluence rate of 130 mW/cm
2
 over a 0.02 cm
2
 of irradiation area.   
 
4.2.10 Stastical Analysis 
Statistical significance was performed using one-way ANOVA followed by 
Bonferroni’s post-hoc test (SPSS 16.0, IBM Corporation, Armonk, NY) and differences 
were considered significant when p<0.05. 
 
4.3 Results and Discussion 
4.3.1 Structural Variations and Photophysical Properties 
Two structural variations around the BODIPY core of compound B1 were investigated 
in this study (Figure 4.2).  The first (compounds B2-6) investigated the effectiveness of 
various iodinated derivatives in order to maximise the ‘heavy atom effect’.  To fine-tune 
the activity of iodinated BODIPY-based structures, additional functionalisations such as 
meso-substitution with alkyl or aryl groups as well as sulphonation to improve 
hydrophilicity were tested.  Compound B5 contains a carboxylic acid handle and could 
be easily attached to other molecules later if required.  For the second variation 
(compounds B7-15), the effect of extended conjugation at the 4-pyrollic position was 
examined.  Extended conjugation at the 4-pyrrolic positions increases the absorption 
wavelength of the compounds to the red, permitting the use of longer excitation 
wavelength that penetrates deeper into biological tissues for effective treatment. 
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Table 4.1 summarises the photophysical data of compounds B1-15.  The 
absorption and emission wavelengths of compounds B1-15 range from 500 nm to 600 
nm.  As expected for compounds B8-15, extending the conjugation with an acrylate 
shifts the λabs  to the red by 20-30 nm while attaching two acrylates red-shifts the λabs by 
50-60 nm, compared to compound B1.  The λabs values for iodinated compounds B3, B5 
and B6 are also red-shifted compared to compound B1 but not for compounds B2 and 
B4 which are aryl-iodinated at the meso position.  In addition, all compounds have high 
extinction coefficients and high quantum efficiencies of fluorescence except for a few 
structures.  Among the exceptions, compounds B3, B5 and B6 have much lower 
quantum efficiency of fluorescence and a correspondingly higher singlet oxygen 
generation rate (Table 4.2) compared to the other BODIPY’s studied here, probably as a 
result of the enhanced intersystem crossing efficiency from the lowest singlet excited 
state to the triplet state contributed by the internal heavy-atom effect.  As in the case of 
λabs values above, compounds B2 and B4 which contain a para-iodo-aryl group at the 
meso position did not demonstrate the same loss in fluorescence yields or the same 
increase in singlet oxygen generation rate as compound B3, B5 and B6 probably 
because the iodo-aryl group is twisted relative to the BODIPY plane (Burghart et al. 
1999), overall causing the aryl iodine atom to only, at most, elicit an intramolecular 
external heavy-atom effect (Gorman et al. 2004). 
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Figure 4.2 Structures of BODIPY. 
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Table 4.1 Photophysical properties of BODIPY derivatives 
Compd. 
λabs 
(nm) 
ε 
(M
-1
cm
-1
) 
λem 
(nm) 
Φfl
 a
 Ref. dye 
b
 Solvent 
B1 505 83000 516 0.80 1 EtOH 
B2 504 82000 510 0.64 1 CHCl3 
B3 537 89000 552 0.05 2 CH2Cl2 
B4 498 100000 509 0.34 1 H2O 
B5 525 93000 540 0.03 2 EtOH 
B6 534 110000 548 0.02 1 MeOH 
B7 494 81000 504 0.95 1 EtOH 
B8 531 27000 570 0.42 2 EtOH 
B9 529 -
c
 560 0.25 2 EtOH 
B10 527 63000 549 0.73 2 EtOH 
B11 559 13000 580 0.51 3 EtOH 
B12 528 62000 551 0.73 2 EtOH 
B13 560 30000 580 0.52 3 EtOH 
B14 517 63000 527 0.78 2 EtOH 
B15 530 72000 539 0.92 2 EtOH 
a Φfl represents quantum efficiency of fluorescence.  
b Reference dyes used for quantum yield determination (solvent, Φfl
 ): 1. fluorescein (0.1 M NaOH, 0.92), 
2. rhodamine 6G (EtOH, 0.94), 3. rhodamine B (EtOH, 0.97).  
c Value not determined. 
 
4.3.2 In Vitro Photocytotoxic and Comparative Singlet-oxygen Generation   
The in vitro photocytotoxic activity of compounds B1-15 against a promyelocytic 
leukemia cell line (HL-60), an oral squamous carcinoma cell line (HSC2) and a 
nasopharyngeal carcinoma cell line (HK1) following irradiation with 4.1 J/cm
2
 of a 
broad spectrum light was determined using a modified MTT assay.  Parallel assays 
without light irradiation were also carried out to determine cytotoxicity in the dark.  
Results were expressed as IC50 – the concentration of compound (in µM), that inhibits 
proliferation rate by 50% as compared to control untreated cells (Table 4.2).  The parent 
compound, denoted as B1, was also prepared and tested for comparison.  From the 
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assay, all compounds had negligible or undeterminable unirradiated cytotoxicity up 100 
µM.  Upon irradiation with 4.1 J/cm
2
 of light, compounds B1-6, B10-15 demonstrated 
photosensitised cytotoxicity with IC50 values in the sub-micromolar to tens of 
micromolar range. Compounds B5 and B6, which had two iodine atoms directly 
attached to the BODIPY core showed the highest activity among the analogues, with 
IC50 values that are up to 100 times lower than that of compound B1 (0.045 µM vs 4.4 
µM in HL-60). In contrast, compounds B7-9 displayed poor activity with 
undeterminable IC50 up to 100 µM. 
The influence of the iodine atom on the photocytotoxic activity of the 
compounds was evident from studying compounds B1-6.  Meso-substitution with an 
para-iodo aryl group in compound B2 does not alter the photocytotoxicity significantly 
compared to compound B1, while further substitution with iodine atoms on the two 
pyrrolic 4-carbon to yield either compound B3 from B2 or compound B6 from B1, 
improved the activity by ten-and hundred-fold respectively in all three cell lines, 
alluding to the importance of iodine atom substitution on the pyrrollic carbons rather 
than on the meso-aryl position. Compound B5, which has an additional carboxylic acid 
tether at the meso position has similar to marginally better activity than compound 6 in 
all three cell lines.  An attempt to improve the water-solubility of compound B2 by 
substituting with sodium sulphonate to yield compound B4 resulted in ten times loss in 
activity.   
For the effect of extended conjugation at 4-pyrrolic positions on photocytotoxic 
activity of BODIPYs, compounds B7-15 were studied. Extending the 4-pyrollic carbon 
with a single aldehyde (B7) or the hydrophilic allylic carboxylic (B8) and allylic 
suphonic acid (B9) resulted in loss of activity to greater 100 µM IC50 values. Single 
extensions at the 4-pyrrolic position with acrylate esters affected the activity differently 
depending on the length of the alkyl ester group, where the methyl compound B10 
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showed no change in activity while n-butyl compound B12 demonstrated ten-fold 
improvement in activity compared to compound B1. For compounds with double 
extension with the same groups at the 4-pyrollic positions, the methyl compound B11 
remained unaltered in its activity compared to compound B1 but interestingly, the n-
butyl compound B13 showed ten-fold loss in activity compared to B1 or hundred-fold 
loss compared to the singly-extended counterpart B12. The explanation for structure-
activity relationship of the n-butyl acrylate esters compared with the methyl acrylate 
esters is not obvious. Compounds B14 and B15 which failed attempts to prepare the 
analogous ring-constrained conjugated structures were also tested and showed similar 
activities compared to compound B1, further indicating the minor role that 4-pyrrolic 
extended conjugation or the lack of it plays in modulating the photocytotoxicity of the 
BODIPY structures.  
Subsequently, the relative rate of singlet oxygen generation was measured for 
compounds B1-15 by monitoring the reaction of known singlet oxygen acceptor DPBF 
with photosensitisers generated singlet oxygen . This was achieved by following the 
loss of DPBF absorbance at 410 nm at initial concentration of 50 µM over a time period 
of 1 h.  A light source filtered at 510 nm wavelength was used to minimise the 
photobleaching of DPBF. As a result, this would have caused an under-estimation of 
singlet oxygen generation rate of the compounds with λabs lower than 510 nm as the 
light transmission through the filter begins to drop below 510 nm.  Each of the 
compounds was tested at an equivalent concentration of reference sensitiser methylene 
blue. The results from this study ranged from 0.01- to over 24-fold of singlet oxygen 
generation rate compared to that of methylene blue. Importantly, the rate of reactive 
oxygen generation measured generally correlated to the potency of these compounds 
and may then be the main factor affecting the photocytotoxicity of these BODIPY 
compounds. 
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Table 4.2 Comparative singlet oxygen generation and in vitro photo cytotoxicity 
induced by BODIPY 
BODIPY Φ∆ 
a 
Activity IC50 (µM) 
b 
HL-60 HSC2 HK1 
0 J/cm2 9.6 J/cm2 0 J/cm2 9.6 J/cm2 0 J/cm2 9.6 J/cm2 
B1 0.48 >100 4.4±0.4 >100 8.7±2.0 76.8±10.6 6.2±1.2 
B2 0.15 >100 2.7±1.2 >100 5.1±0.8 >100 5.7±0.1 
B3 13.9 10 0.42±0.06 10 0.5±0.1 95.5±7.9 0.69±0.08 
B4 0.07 >100 54±8 >100 59±6 >100 59.0±7.1 
B5 24.6 >100 0.045±0.004 >100 0.10±0.06 55.8±0.8 0.57±0.1 
B6 23.9 >100 0.062±0.011 >100 0.64±0.06 >100 0.57±0.06 
B7 0.07 >100 >100 >100 >100 >100 >100 
B8 0.01 >100 >100 >100 >100 >100 >100 
B9 0.00 >100 >100 >100 >100 >100 >100 
B10 0.57 >100 4.8±0.7 >100 5.4±0.6 >100 5.3±0.6 
B11 0.41 >100 5.2±0.6 >100 11.1±7.4 >100 8.5±0.5 
B12 0.73 >100 0.49±0.07 >100 0.6±0.1 99.6±0.6 1.1±0.6 
B13 0.17 >100 58±7 >100 38±16 >100 >100 
B14 0.24 >100 4.9±0.6 >100 4.1±0.2 >100 5.0±0.6 
B15 0.29 >100 3.8±0.7 - - >100 4.8±0.9 
a Φ∆ - Comparative singlet oxygen generation rate of photosensitisers in relative to methylene blue.   
b IC50, the concentration of compound, which inhibits the proliferation rate by 50% as compared with 
control untreated cells.  Values represent the mean ± SD of three determinations assessed 24 h using 
standard MTT assay. Cells were incubated with compound for 2 h prior to irradiation with 9.6 J/cm2. 
 
 
4.3.3 Photosensitiser Cellular Localisation 
To ascertain the intracellular localisation of the BODIPYs, compound B5, owing to its 
good potency data, were chosen and examined by spinning disk confocal microscopy 
using dual staining techniques.  Co-staining images and topographic profiles of HSC2 
cell line loaded with compound B5 and a mitochondria-specific dye Rh123 revealed an 
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almost identical overlap, suggesting that compound B5 localised particularly well in 
mitochondria (Figure 4.3 A and B).  In comparison, compound B5 displayed only 
partial co-localisation with endoplasmic reticulum and lysosomes, according to the 
confocal images and topographic profiles of compound B5 with ER-Tracker (Figure 4.3 
C and D) and with LysoTracker (Figure 4.3 E and F) respectively.  Staining of the 
cytoplasmic or nuclear membrane by compound B5 was not detected, indicating that it 
does not react non-specifically with biological membranes. Furthermore, the nucleus 
remained free of compound B5 (dark nuclear area) signifying that this class of 
compounds would not be expected to directly damage DNA. 
Mitochondria perform vital cellular functions and are involved in multiple 
signaling cascades in regulation of metabolism, cell cycle control development and cell 
death (McBride et al. 2006).  In PDT, the mitochondrion is an important target.  During 
mitochondria-photosensitisation in PDT, cytochrome c is released from mitochondria to 
directly affect rapid cell death through downstream effector pathways of apoptosis, 
bypassing other upstream apoptotic signaling pathways that require synthesis of new 
proteins.  This mechanism of action is particularly useful in the treatment of cancer 
types which are chemo-resistant due to mutations in upstream pro-apoptotic signaling 
pathways (Morgan and Oseroff 2001). 
     
  
 
 
 
 
 
 
 
Merge 
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A       B 
 
C       D 
 
E       F 
 
 
Figure 4.3 Intracellular localisation of B5 in HSC2 cells. Spinning disk confocal images 
(A, C, E) and fluorescence topographic profiles (B, D, F) of HSC2 cells double-stained 
with 100 nM of compound B5 and respective organelle probes. (A, B) Mitochondria 
were labeled with 100 nM of Rh123 and excited at 494 nm. (C, D) Endoplasmic 
reticulum were labeled with 100 nM ER-Tracker and excited at 365 nm. (E, F) 
Lysosomes were labeled with 500 nM of LysoTracker and excited at 365 nm. 
Compound B5 was excited at 575 nm.  From the fluorescence profiles, B5 localised 
almost exclusively in the mitochondria and partially in the endoplasmic reticulum and 
lysosomes. Line indicates the longitudinal transcellular axis analysed to generate the 
topography fluorescence profiles. Objective magnification  60. 
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4.3.4 Cell Cycle Arrest and Apoptosis 
To study the mechanism of action of compound B5 that contributed to its 
photocytoxicity, the effect of compound B5 on cell cycle and apoptosis of HSC2 cell 
line were investigated using flow cytometric method.  The cell cycle profile of HSC2 
cells treated with compound B5 was analysed in a time course experiment.  At the 
concentration of 0.25 µM, compound B5 was found to induce G2/M arrest in HSC2 
cells as early as 2 h following light irradiation (Figure 4.4).  HSC2 cells in G2/M phase 
gradually increased significantly (p<0.05) from 26.1% in the control group to 39.8%, 
48.4%, 55.5%, respectively, at 2, 4 and 6 h after light irradiation.  Concomitant with the 
increased of G2/M phase cells proportion, HSC2 cell in G1 phase reduced significantly 
(p<0.05) from 57.7% to 46.3%, 33.8% and 26.4%, while the proportion of HSC2 cells 
in S phase remained fairly constant.  At 8 and 12 h, the proportion of cells arresting in 
G2/M phase was reduced to 48.8% and 26.0%, respectively after light irradiation.  
Following the reduction of proportion of cells arresting in G2/M phase, an increase of 
sub-G1 cells population from 8 h to 12 h (4.4% (p>0.05)  to 10.6% (p<0.05)) was 
observed.  The cells proportion treated with compound B5 without irradiation remains 
unchanged compared to control. 
In the present study, the maximal level of G2/M cell-cycle arrest was observed at 
6 h after PDT.  Thereafter the recovery of the cell cycle profile to one with a reduced 
G2/M peak may be due to the redistribution of cells to sub-G1, indicating the onset of 
apoptosis of arrested cells.  A similar G2/M arrest was also observed in hypericin-based 
PDT, a naturally occurring photosensitiser currently undergoing research (Vantieghem 
et al. 2002; Lee et al. 2006). Photosensitisation of HeLa cervical cancer cells with 
hypericin resulted in phosphorylation of mitochondria Bcl-2 that correlated with G2/M 
cell cycle arrest, followed by the onset of apoptosis (Vantieghem et al. 2002). 
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A 
 
B 
 
Figure 4.4 Cell cycle arrest induced by B5. A) A representative histograms of event of 
HSC2 cell cycle phase at various intervals post-irradiation analysed using flow 
cytometry after treatment with 0.25 µM of compound B5 and irradiated with a light 
dose of 9.6 J/cm
2
. B) Mean percentage of  proportion of cell population in pre-G1, G1, S 
and G2/M phases, an increased of cell population arrested in G2/M phase cell cycle was 
observed from 2-6 h following light irradiation. Thereafter, from 8-12 h the G2/M 
population decreased with a redistribution of cells to sub-G1 phase. *Difference with 
p<0.05 compared to 0 h control at each cell cycle phase. 
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Figure 4.5 Apoptotic cell death induced by B5. Representative histograms of the event 
of annexin V- fluorescein isothiocyanate (FITC) binding to phosphatidylserine as an 
indicator of apoptosis in HSC2 cells treated with 0.5 µM of compound B5 and irradiated 
with a light dose of 9.6 J/cm
2
. Onset of apoptosis was observed at 12 h following PDT. 
M1 represents viable cell population, M2 represents apoptotic cell population and DC 
represents unirradiated dark control. *Difference with p<0.05 compared to 0 h control . 
 
In addition to cell cycle analysis, the onset of apoptosis was also quantified in 
flow cytometry experiments by measuring the externalisation of membrane 
phosphatidylserine through annexin V-FITC staining, an event which is considered 
characteristic of cells undergoing apoptosis (Figure 4.5).  Flow cytometric analysis of 
HSC2 cells treated with 0.5 µM of compound B5 showed the onset of apoptosis by 12 h 
following irradiation with 20.7% of the cells stained positive for annexin V compared to 
less than 10% at 0 h or 4 h time-points (p<0.05).  The proportion of cells undergoing 
apoptosis continued to increase rapidly to 47.4% by 16 h (p<0.05) and at 24 h the 
apoptotic cell proportion was at 89.9% (p<0.05). The induction of apoptotic cell death 
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by BODIPY was probably due to their mitochondria localisation characteristic. This is 
consistent with other photosensitisers which localised in the mitochondria, where 
photosensitisation of the organelle induces permeabilisation of mitochondrial outer 
membrane that subsequently leads to prominent increase apoptotic cell population 
(Agarwal et al. 1991; Kim et al. 1999; Usuda et al. 2003; Kessel and Reiners 2007). 
 
4.3.5 PDT-induced Vascular Occlusion 
One of the ways PDT causes damage during cancer treatment is by shutdown of blood 
vessels feeding the tumour (Chen et al. 2006a). Hence, the ability of compound B5 to 
exert vasculature disruption was investigated using in ovo chick embryo chorioallantoic 
membrane (CAM) as a model.  In the present study, the ability of compound B5 to 
induce occlusion of blood vessels in the CAM by PDT was performed at 2-4 µg/embryo 
with a light dose of 20-40 J/cm
2
.  The degree of vascular occlusion was scored 24 h 
after treatment according to Table 3.1.  The score for photosensitiser-mediated PDT-
induced vascular occlusion is shown in Figure 4.6 and the angiograms representing the 
vascular occlusion score are shown in Figure 4.7.  As expected, the degree of vascular 
occlusion increased with drug and light dose.  The average CAM vasculature damage 
score when irradiated at 20 J/cm
2
 on embryos treated with 2 and 4 µg/embryo of 
compound B5 were at approximately 2 and 3 respectively.  When the light dose 
increased to 40 J/cm
2
, the damage score increased accordingly to 3.5 and 5.  Meanwhile, 
the control eggs that received 20 µl of vehicle (CrEL 2.5%, EtOH 2.5% in saline) and 
exposed to a similar light dose showed no detectable vascular alteration in the treated 
area.  This indicated that the vascular occlusion observed in embryos treated with 
compound B5 was neither caused by the vehicle components nor was it thermally-
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induced.  On the other hand, treatment with compound B5 alone without irradiation did 
not induce any vascular occlusion as non-irradiated areas remained perfused after 24 h. 
 
 
Figure 4.6 Effects of drug concentration and light dose on vascular occlusion efficacy 
of B5 in the CAM model. The average of vasculature damage score was drug and light 
dose dependent, where the damage scores when irradiated at 20 J/cm
2
 on embryos 
treated with 2 and 4 µg/embryo of B5 were at approximately 2 and 3 respectively.  
When the light dose increased to 40 J/cm
2
, the damage scores increased accordingly to 
3.5 and 5. Occlusion score represents mean values from at least ten embryos. Damage 
score with different symbols are significantly different from each other (p<0.05).  
 
In this study, B5 was formulated in CrEL based on earlier experiences on other 
similar lipophilic photosensitisers. CrEL consists of a complex mixture of hydrophobic 
and hydrophilic molecules for effective solubilisation of lipophilic drugs, and it has 
been used in combination with EtOH to solubilise lipophilic antineoplastic drug such as 
paclitaxel (Strickley 2004) and photosensitisers such as TOOKAD, phthalocyanine- and 
purpurin-based photosensitisers (Kessel 1989b; Whitacre et al. 2000; Rück et al. 2005). 
Although the use of CrEL is associated with anaphylactic hypersensitivity reaction and 
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neurotoxicity in patients (Gelderblom et al. 2001), it is still accepted in early 
formulations for preclinical studies given its efficiency in solubilising lipophilic entities 
and its ease of preparation. Our earlier study also demonstrated that administration of 20 
µl per embryo of 2.5% CrEL, 2.5% of EtOH in saline as a dosing excipient is well 
tolerated by chick embryos (Lim et al. 2010). This formulation is therefore used to 
deliver the photosensitiser evaluated in the present study. 
CAM as the main respiratory organ of the chick embryo is a well-vascularised 
membrane that is suitable as a model for PDT.  It is easily accessible, inexpensive and 
relatively easy to handle for photosensitiser administration, light irradiation, 
fluorescence analysis of administered photosensitiser, and microscopy examination of 
PDT-induced vascular damage (Lange et al. 2001; Vargas et al. 2007).  CAM is a viable 
model which has been successfully used to evaluate the photodynamic-induced vascular 
occlusion efficacy of some photosensitisers that are either in clinical trials as well as 
those that are already clinically approved such as Tookad, Photofrin, lutetium 
texaphyrin, 5-aminolevulinic acid and verteporfin (Hammer-Wilson et al. 2002; Rück et 
al. 2005).  For example, a PDT experiment in the CAM model using verteporfin at a 
dose that is similar to the recommended clinical dosage has been shown to cause 
complete occlusion of the large neovessels, an observation that correlates well with 
clinical setting (Lange et al. 2001).  In addition, in a BALB/c mouse model where PDT 
treatment by verteporfin resulted in suppression of tumour growth, antivascular effects 
were also observed, whereby a decrease in the blood volume at the tumour site was 
noted (Kurohane et al. 2001; Ichikawa et al. 2004). In the PDT treatment of cancer, 
complete closure of larger vessels is desirable as to disrupt the delivery of oxygen and 
nutrients to the fast-growing tumour tissues. The results from the study demonstrated 
these effects can be achieved with compound B5 at 7.0 nmol/embryo and 40 J/cm
2
 of 
light dose. 
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Figure 4.7 Representative angiographies of blood vessels supplying the CAM at 
beginning and 24 h after PDT illustrating the vascular occlusion efficacy induced by 
compound B5 at 2 µg/embryo and 4 µg/embryo. Irradiation was performed at 510-560 
nm of excitation with 20-40 J/cm
2
 light dose. CrEL 2.5%, EtOH 2.5% in saline was 
used as a control vehicle. Objective magnification is ×4. 
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4.4 Conclusions 
We have demonstrated the in vitro photocytotoxic activity of BODIPY derivatives 
against cell lines from leukemia and two types of solid tumour. Structure-activity 
relationship study indicated the importance of having iodine atoms directly substituted 
on the BODIPY pyrollic carbon-4 position rather than at the meso-aryl position, in 
accordance with the high singlet oxygen generation rate of these compounds.  Extended 
conjugation at the 4-pyrollic positions shifts the λabs to the red but did not confer extra 
potency except for the compound with a single n-butyl acrylate ester (B12).  
Hydrophilic analogues substituted with groups such as carboxylic acid, sulphonic acid 
or sodium sulphonate generally drastically diminished the activity.  An exception here 
was the doubly-iodinated compound B5 with an aliphatic carboxylic acid which showed 
up to 100-fold lower IC50 value in HL-60 compared to the parent compound B1, 
perhaps due to the structural difference where the carboxylic acid group is not directly 
conjugated with the BODIPY core. Fluorescence microscopy studies showed that 
compound B5 localised exclusively within the mitochondria.  This, together with data 
from cell cycle analysis and onset of apoptosis studies, suggests that compound B5 
probably induced cell death through mitochondria-dependent apoptosis rather than 
through damage to nucleic materials.  In addition, an emulsion of compound 5 was able 
to occlude the vasculature network in the CAM model, further showing its potential as 
an effective PDT agent.  Overall, our results showed that BODIPY structures especially 
compound B5 have potential to be explored as a clinically useful agent for PDT of 
cancer.
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CHAPTER 5 
 
Evaluation of Rosamines as Photosensitiser for Photodynamic Therapy and as 
Anticancer Agents 
 
5.1 Introduction 
Rosamines belong to the class of dyes known as delocalised lipophilic cations (DLCs). 
In comparison to fluorescein, both rhodamines and rosamines have their phenolic 
residues replaced by amino residues where this modification allows the positive charge 
of these structures to be permanently delocalised onto the amino nitrogen. The cationic 
character of these DLCs leads them to be attracted to the negatively charge 
mitochondrial matrix thereby allowing mitochondrial targeting (Modica-Napolitano and 
Aprille 2001). For example, DLCs such as Rh123 and tetramethylrosamine (TMR) are 
extensively used as a mitochondrion-selective fluorescence probe (Modica-Napolitano 
and Aprille 1987; Minamikawa et al. 1999). 
Despite its mitochondrial targeting potential, TMR with its relatively short 
absorption wavelength λabs of 552 nm and low singlet quantum yield of 0.08 low are not 
an efficient photosensitiser for PDT (Detty et al. 2004). Therefore, chromophore 
functionalisation has been carried out to increase absorption to the red wavelength and 
singlet oxygen yields, for example, alkylation or halogenation to the core; substitution 
of oxygen with heavier chalcogen atoms; and heterocyclic substitution at meso position. 
(Pal et al. 1996; Detty et al. 2004; Holt et al. 2006; Calitree et al. 2007).  
The series of rosamine evaluated in this study consists of cyclic-amine 
substituents and represents a new class of rosamines not reported prior to this. Like the 
BODIPY, the synthesis of simple rosamine analogues is relatively straightforward 
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(three main steps), thus facilitating compound series preparation. The starting material 
of xanthone ditriflate was prepared in solution by triflation of the phenols, followed by 
animation of the triflate with piperidine to give symmetrical cyclic-amines substitution 
(Scheme 1) or by stepwise addition of piperidine and morpholine to give unsymmetrical 
cyclic-amines substitution (Scheme 2) (Wu and Burgess 2008b). The resulted 3,6-
diamino-xanthen-9-one was reacted with organolithium or Grignard reagents to yield 
the desired rosamine structures. These compounds were synthesised and provided by 
Prof Kevin Burgess’s group from the Department of Chemistry, Texas A&M 
University, Texas, USA. 
 
 
 
The research reported here was first undertaken to probe how substitution of 
rosamine with various peripheral cyclic-amines and various groups at the meso position 
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would affect their photodynamic efficiency in terms of photophysical properties and in 
vitro efficacy. However, preliminary in vitro data showed that the rosamines evaluated 
here have poor photodynamic activity but several of these derivatives displayed potent 
antiproliferative activity with IC50 values in the nanomolar range. Despite their low 
PDT efficacy, this class of compounds has not been further reported for its anticancer 
potency and given their structural novelty, we subsequently evaluated their potential 
utility as a mitochondrial targeting anticancer agent. 
The reprogramming of energy metabolism has recently been listed as one of the 
emerging hallmarks of cancer and mitochondria are recognised as a potential targets for 
anticancer therapy (Hanahan and Weinberg 2011; Hainaut and Plymoth 2013). 
Mitochondria are the energy generators that maintain cell life and essential cell 
functions, including multiple signaling cascades that regulate cells, for instance, 
metabolism, cell cycle control, development, and cell death  (McBride et al. 2006). 
Therefore, shutting down the mitochondria will disrupt essential cellular functions and 
will subsequently lead to cell death.  In cancer chemotherapy, mitochondria-targeting 
drugs are known to interfere with cancer cell metabolisms by pertubing the 
mitochondrial transmembrane potential, inhibiting the electron redox chain complexes, 
interfering the mitochondria transmembrane permeability, and targeting mitochondrial-
DNA (Biasutto et al. 2010; Wang et al. 2010). The most common types of 
mitochondria-targeting drugs are lipophilic, cationic drugs; these are selective for 
cancer cells because they tend to have higher mitochondrial membrane potentials than 
normal epithelial cells (Lampidis et al. 1985; Modica-Napolitano and Aprille 2001).   
 
Consequently, we examined the cytotoxicities of rosamines with particular 
attention to structure-activity relationship. Rh123 which is a well-studied delocalised 
lipophilic cation was included as a positive control. Selected rosamines were further 
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investigated for their intracellular localisation, induction of cell cycle arrest and cell 
death and their effect on the cellular redox systems. The in vivo antitumour activity of 
the most potent rosamine was then evaluated in a syngeneic mouse tumor model. 
Selected rosamines were also evaluated in the NCI-60 human tumour cell lines screen 
for cancer cell type selectivity, activity correlation with specific genes mutations, and 
comparison of the mode of action by COMPARE analyses.  
 
5.2 Materials and Methods 
5.2.1  Materials 
5.2.1.1 Chemicals and Reagents 
Complex I, Complex II, Complex IV and ATP Synthase Enzyme Activity Microplate 
Assay Kit were purchased from MitoSciences (OR, USA). ). JC-1 was purchased from 
Molecular Probes, Invitrogen (OR, USA). Protein assay dye reagent concentrate was 
obtained from Bio-Rad Laboratories (CA, USA). Ethylene glycolbis(aminoethylether)-
tetra-acetic acid (EGTA), 3-(N-morpholino)propanesulfonic acid (MOPS), sucrose and 
Tris were purchased from Fisher Scientific (Leicestershire, UK). Other chemicals and 
reagents used were as described in Section 3.2.1.1 and 4.2.1.1. 
 
5.2.1.2 Instrumentations 
As described in Section 4.2.1.2 
 
5.2.1.3 Animal Model 
Mouse model used was as described in Section 3.2.1.3 
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 5.2.2 Preparation of Compound 
A total of 21 rosamines were prepared and supplied by Prof Kevin Burgess’s group 
from the Department of Chemistry, Texas A&M University, Texas, USA. Their 
syntheses and NMR characterisation were previously described by Wu and Burgess 
(2008b). All the compounds used for in vitro experiments were dissolved in DMSO to 
make stock solutions of 10 mM, aliqouted into appropriate volume and stored at -20 ºC 
prior to use.  
 
5.2.3 Photophysical Properties 
Absorbance spectra were obtained on a Varian 100 Bio UV-Vis spectrophotometer at 
room temperature.  Extinction coefficients were determined from Beer’s Law plots 
using three data points. 
 
5.2.4 Cell Culture and Cytotoxicity Assay 
MCF-7, HCT116, HL60, HSC2 and HK1 cell lines were used to evaluate the 
photocytotoxicity/cytotoxicity of rosamine in vitro. The experimental procedure and 
conditions were similar as described in Section 4.2.4, unless specified. Both MCF-7 
breast carcinoma and HCT-116 colon carcinoma cell lines were obtained from 
American Tissue Culture Collection (VA, USA) and maintained in RPMI 1640 medium 
supplemented with 10% heat inactivated FBS and 1% of penicillin-streptomycin. 
 
5.2.5 Intracellular Localisation 
As described in Section 3.2.8. Rosamine was excited at 520-550 nm wavelength. 
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5.2.6 Analysis of Cell Cycle and Annexin V-FITC Apoptosis 
As described in Section 4.2.7 and 4.2.8. 
 
5.2.7 Mitochondria Isolation and Detergent Solubilisation 
Functional mitochondria were isolated from mouse liver by differential centrifugation 
method (Frezza et al. 2007). Briefly, a mouse (~30 g) was starved overnight before 
sacrificed by cervical dislocation. The liver was harvested promptly and rinsed with ice-
cold mitochondria isolation buffer (10 mM Tris-MOPS, 1 mM EGTA/Tris, 0.2 M 
sucrose, pH 7.4) until blood-free. The liver was then cut into small pieces in a beaker 
using scissors while keeping in an ice-bath. The buffer was replaced with 5 ml of fresh 
isolation buffer and the liver was homogenised with a Polytron probe (Ultra-Turrax T8, 
Ika-Werke, Germany) until smooth. The homogenate was centrifuged at 1000 g for 15 
min at 4 ºC. The pellet was discarded and the supernatant was centrifuged at 12000 g 
for 15 min at 4 ºC to pellet the mitochondria. The mitochondria were washed twice with 
4 volumes of isolation buffer containing 1× protease cocktail inhibitor. The 
concentration of the mitochondrial protein was determined using the Bradford (Biorad 
protein assay) method. The mitochondria were frozen in 10 mg/ml aliquots at -80 ºC.  
Detergent solubilisation of the mitochondria proteins was done prior to 
measurement of the oxidative phosphorylation complexes activity. Mitochondria were 
diluted to 5.5 mg/ml with PBS and solubilised by addition of a 1/10th volume of 
detergent provided to give the final protein concentration of 5 mg/ml. The mixture was 
incubated on ice for 30 min and centrifuged at 17000 g at 4 ºC for 20 min. The 
supernatant was collected and diluted to the appropriate concentrations for each 
oxidative phosphorylation complexes activity. 
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5.2.8 Measurement of Oxidative Phosphorylation Complexes Activity 
The measurement of mitochondria oxidative phosphorylation activities for Complex I, 
II, IV and ATP-synthase were carried out using the microplate immunocapture ELISA 
assay kit according to their respective manufacturer’s protocols (Nadanaciva et al. 
2007). Briefly, the plate pre-coated with appropriate immunocapture antibody was 
incubated with mitochondria extract at recommended concentration to allow 
immobilisation of their respective complexes. Complex activity was measured by 
addition of substrates solution mix provided by the kit and compound was added at 
concentration ranging from 0.01-10 µM in triplicate. Control wells treated with only 
0.1% DMSO (v/v) and wells without mitochondria extract incubation were included as 
background reference. The kinetic of the complexes activity was recorded with 
SpectraMax M4 microplate spectrophotometer reader using the suggested measurement 
parameters. 
 
5.2.9 JC-1 Analysis of Mitochondrial Membrane Potential 
The mitochondrial membrane potential was measured based on the potential-dependent 
accumulation of the cationic JC-1 dye which results in a shift of fluorescence emission 
from green (∼525 nm) to red (∼590 nm) due to the formation of J-aggregates (Reers et 
al. 1991). Therefore, mitochondrial depolarisation is indicated by a decrease in the 
red/green fluorescence intensity ratio. Briefly, cells were collected and suspended in 1 
ml warm media at approximately 1×10
6
 cell/ml. In a control tube, 1 μl of 50 mM 
carbonyl cyanide 3-chlorophenylhydrazone was added and incubated at 37 ºC for 5 min. 
Then, 10 μl of 200 μM JC-1 was added into the cells and incubated at 37 ºC for 30 min. 
Cells were washed twice with warm PBS, resuspended in 500 μl of PBS and analysed 
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on a FACSCalibur flow cytometer using 488 nm excitation with 530/30 nm and 585/42 
nm bandpass emission filters. 
 
5.2.10 NCI-60 Human Tumour Cell Line Screen 
NCI-60 cell-lines panel screening was performed by the National Cancer Institute’s 
Developmental Therapeutics Program. Sulforhodamine B assay was used to assess the 
cytotoxicity of test agents in a panel of 60 cell lines (Boyd and Paull 1995). Briefly, the 
human tumour cell lines of the cancer screening panel were grown in RPMI 1640 
medium containing 5% FBS and 2 mM L-glutamine. For a typical screening 
experiment, cells were inoculated into 96 well microtiter plates in 100 µl at plating 
densities depending on the doubling time of individual cell lines. After cell inoculation, 
the microtiter plates are incubated at 37° C, 5% CO2 and 100% relative humidity for 24 
h. Following incubation, aliquots of 100 µl of compound at different dilutions were 
added to the appropriate microtiter wells and were further incubated for 48 h.  At the 
assay end-point, cells were fixed with trichloroacetic acid followed by Sulforhodamine 
B staining for cellular protein content. Sulforhodamine B absorbance was read at 515 
nm of wavelength as a measurement of cell density. 
 
5.2.11 In Vivo Antitumour Efficacy 
Female BALB/c mice aged 6-8 weeks with a minimum weight of 17 g were used in the 
experiment. Tumour allografts were initiated by subcutaneous injection of 5×10
5
 4T1 
mouse mammary carcinoma in 0.1 ml RPMI 1640 media into the inguinal mammary 
fat-pads of mice (Jin et al. 2010). Tumour growth was monitored and treatments were 
initiated when tumours reached volume of approximately 200 mm
3
. To assess the 
tumour growth inhibition, 4T1 tumour bearing mice were randomised into groups with 
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at least eight animals per group. Compound was prepared at 0.3 mg/ml in normal saline 
and treatment was administered intravenously at 5 mg/kg on staging day or 3 mg/kg 
every other day for six treatments (q2dx6). For control group, normal saline was given.. 
Animal weights and tumour volume were measured three times weekly for 14 d. At 
least eight mice were assessed for each treatment group. 
Growth of the solid tumours was monitored using in situ caliper measurement of 
two perpendicular dimensions (length and width) and tumour volume was calculated 
using the formula for a prolate ellipsoid using Equation 4 (Section 3.2.12). Relative 
tumour volume (RTV) was calculated for every tumour volume using Equation 6 
(Plowman et al. 1997).  
Equation 6 
Relative tumour volume, RTV = 
tumour volume at any given time, Vt 
tumour volume at staging day, V0 
 
The median RTV – time profile for each group was plotted and results were 
expressed as median ± 95% confidence interval. To determine the antitumour activity, 
terminal % T/C was calculated from the growth curve (Equation 5, Section 3.2.12) and 
tumour growth delay to attain a specified number of doublings compared to control 
group (Equation 7).  
 Equation 7 
Tumour growth delay  = 
T - C 
× 100 
   C 
  
Where T and C are the median days for the treated and control groups respectively, to 
attain a specified number of doublings from its staging day tumour volume 
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5.2.12 Stastical Analysis 
Statistical significance was performed using one-way ANOVA followed by 
Bonferroni’s post-hoc test and differences were considered significant when p<0.05. 
Statistical analysis for mean data obtained from NCI screen were performed using one-
sample t-test and Student’s t-test (SPSS 16.0, IBM Corporation, Armonk, NY). 
 
5.3 Results and Discussion 
5.3.1  Structural Variations and Photophysical Properties 
The rosamines investigated in present study were cyclic-amines substituted around the 
compound TMR core which represent a new structural variation not reported before 
(Table 5.1). Rosamines R1-R6 were functionalised with various heterocylic amine 
substitution patterns aimed to increase the chomophore aromaticity which is postulated 
to red-shift the absorption wavelength.  Meanwhile, rosamines R7-R21 were prepared 
to examine the effects of meso-substitution with alkyl (R7), aryl (R8-R9), heterocyclic 
(R10-R12), aryl-halide (R13-R16), methoxy-aryl (R17-R19) and of hydrophilic 
substituents such as the phenolic R20 and the carboxylic R21 moieties on the 
spectroscopic properties of rosamine.  
The photophysical data of the rosamines were summarised in Table 5.1.  As 
expected, heterocylic amine substitutions (R1-R6) resulted in a red-shift of λabs and 
higher molar extinction coefficient compared to TMR (ε = 83000 M-1cm-1 at 552 nm). 
Rosamine substituted with hydrophobic cyclic-amines such as pyrrolidine (R1), 
piperidine (R2) and Boc-piperazine (R5) exhibited higher far-red absorbance than 
rosamine substituted with hydrophilic cyclic-amines that contain exposed oxygen or NH 
isosteres (R3, R4 and R6). For the effect of meso-substitution, conjugation with 
heterocyclic (R10-R12) or phenyl halide (R13-R16) moieties further red-shifted the 
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λabs, while varying substitution with alkyl (R7), unsubstituted-aryl (R8-9), methoxy-aryl 
(R17-19) or hydrophilic substituents such as the phenolic R20 and the carboxylic R21 
moieties had little effect on the λabs value when compared to R2. Substitution of 
hydrophilic moieties such as furan R11, di-2-methoxy aryl R19, phenolic R20 and the 
aryl carboxylic R21 resulted in decreased molar extinction coefficient. 
 
5.3.2 In Vitro Antiproliferative Assay   
The in vitro antiproliferative activity of compounds R1-R21 against a promyelocytic 
leukemia cell line, HL-60 was determined using a 24 h endpoint MTT assay.  Results 
were expressed as IC50 in µM, concentration of compound that inhibits proliferation rate 
by 50% as compared to control untreated cells.  From the assay, compounds R1-R3, R5, 
R8-R19 demonstrated their antitumour activity with IC50 values in the sub-micromolar 
range. In contrast, compounds R4, R6, R7, R20 and R21 displayed moderate to poor 
activity from single-digit micro-molar IC50 values to undeterminable IC50 up to 100 µM. 
Meanwhile, there were no significant decreases in IC50 values when HL60 cells were 
irradiated with 5.3 J/cm
2
 of broad spectrum light after 2 h of rosamine treatment 
compared to unirradiated cells, except for R9 which demonstrated 6-fold decreased in 
IC50 value following irradiation. However, this effect was negligible compared to strong 
photosensitisers such as BODIPYs that demonstrated up to 1000-fold increase in photo-
induced cytotoxicity. Therefore, the rosamines evaluated here were considered poorly 
photo-active, but given their potent cytotoxicity and structural novelty, their potential 
utility as an anticancer agent was evaluated instead. We thereby examined their 
cytotoxicities with particular attention to structure-activity relationship. 
Table 5.1 The structure-activity relationship and in vitro antiproliferative activities of 
rosamine analogues in HL-60 cells 
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Cmpd R1 R2 R3 
λabs 
(nm) 
ε 
(M-1cm-1) 
a IC50 (µM)
  
0 J/cm2 5.3 J/cm2 
R1 
  
 
558 127400 0.72±0.09 0.49±0.19 
R2 
  
 
565 123600 0.76±0.03 0.40±0.04 
R3 
  
 
559 111000 0.35±0.01 0.56±0.08 
R4 
  
 
554 106900 8.3±2.2 7.2±1.9 
R5 
  
 
555 120800 0.62±0.07 0.52±0.09 
R6 
  
 
558 - 53.3±0.3 75.6±7.8 
R7 
   
555 101900 3.9±1.5 4.7±1.5 
R8 
   
566 95900 0.82±0.04 0.63±0.13 
R9 
   
565 106000 0.47±0.13 0.08±0.01 
R10 
   
582 107600 0.10±0.04 0.07±0.02 
R11 
   
592 86900 0.13±0.01 0.15±0.02 
R12 
   
576 87600 0.23±0.02 0.27±0.02 
R13 
   
570 119100 0.17±0.01 0.14±0.01 
R14 
   
570 110800 0.50±0.04 0.49±0.04 
R15 
   
570 115400 0.09±0.01 0.06±0.01 
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Table 5.1, continued 
R16 
   
565 80 900 0.17±0.05 0.18±0.03 
R17 
   
562 116700 0.66±0.17 0.57±0.08 
R18 
  
 
566 118000 0.95±0.01 0.25±0.11 
R19 
  
 
565 87300 0.25±0.22 0.06±0.01 
R20 
  
 
557 
71000 
(EtOH) 
2.9±1.9 4.3±1.8 
R21 
  
 
557 
84800 
(EtOH) 
>100 >100 
Rh123 
  
 
508 
111000 
(EtOH) 
7.8±06 7.8±0.2 
TMR 
   
b 552 
b 83000 
(MeOH) 
ND ND 
a Values represent the means ± SD of three determination assessed 24 h post-treatment using MTT assay. 
b Data obtained from literature (Detty et al. 2004) 
 
The influence of the cyclic-amine substituents on the antiproliferative activity of 
the compounds was evident from studying compounds R1-R6.  Regardless of the size 
of the ring, the derivatives containing hydrophobic cyclic-amines from pyrrolidine (R1), 
piperidine (R2) to Boc-piperazine (R5) exhibited moderate antiproliferative activity 
with IC50 values of 0.62-0.76 µM.  On the other hand, the derivatives with cyclic-
amines that contain exposed oxygen or NH isosteres as in the case of compounds R4 
and R6 had 10- to 70-fold higher IC50 of 8.3 or 53.3 µM respectively.  The 
unsymmetrical rosamine R3, which had a combination of piperidine and morpholine 
substituents interestingly, had the lowest IC50 value among compounds R1-6, alluding 
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to the possible importance of an amphilic structure with contrasting hydrophobic and 
hydrophilic halves. 
For the effect of meso-substitution on antiproliferative activity of rosamines, 
compounds R7-21 were studied.  Similar to compounds R4 and R6 above, the 
derivatives with hydrophilic substituents such as the phenolic R20 and the carboxylic 
R21 had higher IC50 values than the unsubstituted meso-aryl R9.  Having an aryl 
subtituent at the meso position, whether directly (R9-19) or through an alkyl spacer 
(R8), was important for antiproliferative activity and was convincingly demonstrated in 
the lower activity observed in compound R7 which had only a simple methyl 
substituent at the meso position. Among the aryl substituted compounds, the 
heterocyclic (R10-R12) and the phenyl-halide (R13-R16) structures had the lowest IC50 
values compared to a simple phenyl-substituted compound R9, while 4-methoxy aryl 
(R17), mono-2-methoxy (R18) and di-2-methoxy (R19) aryl substitutions did not 
confer additional activity. 
Subsequently, the in vitro antiproliferative activity of the most active 
compounds, R9-16, were assessed against a panel of cell lines derived from human 
solid tumours including breast carcinoma (MCF-7), colon carcinoma (HCT-116), oral 
squamous cell carcinoma (HSC2) and nasopharyngeal carcinoma (HK1).  A 48 h 
endpoint MTT assay which is more typical of cytotoxicity studies was used.  The 
antiproliferative activity of Rh123 was also simultaneously determined for comparison. 
The IC50 values for these rosamines across the panel of cancer cell lines tested 
ranged from 0.07-1.2 µM and on average were at least 10-folds more potent than Rh123 
(Table 5.2). From this study, compound R10 which had a thiofuran showed the highest 
activity among the analogues with average IC50 of 0.11 µM. SAR study revealed that 
rosamines bearing phenyl halide or heterocyclic moieties were significantly (p<0.05) 
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more potent than phenyl substituted rosamine R9.  Halide substitution resulted in 
improvement of cytotoxicity; this was expected because substitution of H by halide is 
commonly used to increase compound lipophilicity that improves lipid-bilayer 
membrane permeability (Gerebtzoff et al. 2004).  Within the halide series, cytotoxicities 
increased in the following order R13 > R14 > R15 (Cl > Br > I), although not 
statistically significant (p>0.05). The compounds with meso-heterocyclic substituents 
R10 and R11 were more potent than the aromatic halides R13-R15.  Of the two 
compounds with meso-heterocycles the thiofuran-substituted R10 was slightly more 
active than R11, the furan-substituted one. 
 
Table 5.2 Antiproliferative activities of rosamine analogs against a panel of cancer cell 
lines. 
  
Rosamine 
Activity IC50 (μM)
a
 
MCF-7 HCT-116 HSC2 HK1 Mean
b
 
R9 1.2 ± 0.7 0.60 ± 0.41 0.09 ± 0.00 0.61 ± 0.07 0.63
†
 
R10 0.18 ± 0.02 0.07 ± 0.02 0.09 ± 0.01 0.10 ± 0.00 0.11
§
 
R11 0.31 ± 0.14 0.10 ± 0.03 0.09 ± 0.00 0.31 ± 0.08 0.20
‡,§
 
R12 0.17 ± 0.10 0.07 ± 0.02 0.22 ± 0.11 0.53 ± 0.00 0.25
‡,§
 
R13 0.15 ±0.04 0.22 ± 0.14 0.09 ± 0.01 0.25 ± 0.01 0.18
‡,§
 
R14 0.29 ± 0.04 0.30 ± 0.08 0.19 ± 0.11 0.34 ± 0.00 0.28
‡,§
 
R15 0.59 ± 0.12 0.39 ± 0.07 0.35 ± 0.05 0.29 ± 0.03 0.41
‡
 
R16 0.26 ± 0.07 0.24 ± 0.07 0.22 ± 0.10 0.44 ± 0.01 0.29
‡,§
 
Rh123 5.6 ± 0.6 7.9 ± 1.0 4.5 ± 2.2 5.9 ± 0.2 6.0

 
a IC50, the concentration of compound, which inhibits the viability by 50% as compared with control 
untreated cells. Values represent the mean ± SD of three determination assessed 48 h post-treatment using 
methylthiazolyldiphenyl-tetrazolium bromide assay. b Values with different symbols are significantly 
different from each other (p<0.05).  
 
Compound R16 has a more polar combination of amine substituents than the 
symmetrical bispiperidine R15, and was proved to be more cytotoxic (Table 5.2).  This 
is consistent with our earlier data for R3 unsymmetrically substituted with piperidine 
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and morpholine which showed nearly 2-fold lower IC50 values compared with the 
symmetrical hydrophobic structure containing only piperidine R2 (Table 5.1).  
Meanwhile for the meso-thiofuran R10, substitution of one of the piperidine groups 
with morpholine gives R12, which has a slightly decreased activity, contrary to our 
expectations.   
 
5.3.3 Intracellular Localisation 
TMR with its cationic characteristic is known to be attracted to the negatively charge 
mitochondrial matrix leading to its localisation in the mitochondria. We would like to 
investigate whether the rosamines investigated in this study would retain their 
mitochondrial targeting properties following cyclic-amine substitutions. Therefore, the 
intracellular localisation of R15 in HSC2 cells was examined by confocal microscopy 
using dual staining techniques (Figure 5.1). R15 was chosen as a representative 
compound given its higher fluorescence quantum yield to allow better visualisation. 
Co-staining images and topographic profiles of cells containing R15 and a 
mitochondria-specific dye Rh123 revealed an almost identical overlap, suggesting that 
R15 localised particularly well in mitochondria (Figure 5.1 A and B).  In comparison, 
R15 displayed only partial co-localisation with endoplasmic reticulum and lysosomes, 
according to the confocal images and topographic profiles of R15 with ER-Tracker 
(Figure 5.1 C and D) and with LysoTracker (Figure 5.1 E and F) respectively.  Staining 
of the cytoplasmic or nuclear membrane by R15 was not detected, indicating that it did 
not react non-specifically with biological membranes. Furthermore, the nucleus 
remained free of R15 (dark nuclear area) signifying that this class of compounds would 
not be expected to directly damage DNA.  
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A      B 
 
 
C      D 
 
 
E      F 
 
 
Figure 5.1 Intracellular localisation of R15 in HSC2 cells. (A, C, E) Confocal images 
and (B, D, F) fluorescence topographic profiles of HSC2 cells double-stained with 100 
nM of R15 and organelle probes. (A, B) Mitochondria were labeled with 100 nM 
Rh123, excited at 494 nm. (C, D) Endoplasmic reticulum were labeled with 100 nM 
ER-Tracker, excited at 365 nm. (E, F) Lysosomes were labeled with 500 nM 
LysoTracker, excited at 365 nm. R15 was excited at 575 nm. Topographic profiles 
revealed that R15 localised predominantly in mitochondria but partially in both 
lysosomes and endoplasmic reticulum. Line segment indicates the longitudinal 
transcellular axis analysed to generate the topography fluorescence profiles. Objective 
magnification  60. 
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5.3.4 Apoptosis and Cell Cycle Arrest 
The induction of apoptosis was quantified in flow cytometry experiments measuring the 
externalisation of membrane phosphatidylserine through annexin V-FITC staining, an 
event considered to be characteristic of cell undergoing apoptosis (Figure 5.2). Flow 
cytometric analysis of HSC2 cells treated with 0.5 µM of R15 showed the onset of 
apoptosis by 8 h of incubation with 16% of the cells stained positive for annexin V 
compared to less than 10% at 0 h or 4 h time-points.  The proportion of cells undergoing 
apoptosis continued to increase rapidly to 58% within 24 h (p<0.05). Meanwhile, the 
cell cycle profile of HSC2 treated with 0.25 µM of R15 was examined in a time course 
experiment.  From Figure 5.3 (A and B), HSC2 cell population in S phase was shown to 
increase significantly (p<0.05) from 17.9% in the control group to 29.4%, 28.5%, 
30.2%, respectively, at 12, 16 and 24 h after treatment. This findings indicate that the 
apoptosis cell death induced were associated with S-phase cell cycle arrest by R15. 
 
 
Figure 5.2 Apoptotic cell death induced by R15. A representative histograms of event 
of annexin V-FITC binding to PS as an indicator of apoptosis in HSC2 cells treated with 
0.5 M of R15 at different duration. Onset of apoptosis was observed 8 h following 
treatment. M1 represents viable cell population, M2 represents apoptotic cell 
population. *indicates difference is with p<0.05 compared to 0 h control. 
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A 
 
B 
 
Figure 5.3 Cell cycle arrest induced by R15. (A) A representative histograms of event 
of HSC2 cell cycle phase after treated with 0.25 µM of compound R15 for various 
intervals analysed using flow cytometry. (B) Mean percentage of  proportion of cell 
population in G1, S and G2/M phases, following subtraction of sub-G1 phase population. 
An increased of cell population arrested in S phase cell cycle was observed from 12-24 
h following treatment. *Difference with p<0.05 compared to 0 h control at each cell 
cycle phase. 
 
 
* 
* 
* 
* * 
* 
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5.3.5 Rosamines Interfered the Energy Redox  
Accumulation of cytotoxic lipophilic cations is known to alter mitochondrial 
transmembrane potentials (Don and Hogg 2004; Toogood 2008).  The alteration of 
mitochondrial membrane potential caused by rosamines were monitored based on the 
accumulation of potential-dependent JC-1 dye which resulted in a shift of fluorescence 
emission from green (∼525 nm) to red (∼590 nm) due to the formation of J-aggregates.  
From the study, approximately 21% of the HSC2 cells treated with R10 at 0.1 μM were 
affected in the first hour and the percentage increased drastically to 34% in 8 h. 
Meanwhile, for HSC2 cells treated with R15 at 0.1 μM, 9% of the cell population 
exhibited the onset of mitochondrial transmembrane potential loss within 1 h after 
treatment and gradually increased to 19% (p<0.05) in 8 h (Figure 5.4). For the untreated 
control cells, the population of depolarized cells at 8 h remained at approximately 8 %. 
Meanwhile, cells treated with 5 μM of CCCP for 5 min resulted in loss of membrane 
potential in 70% (p<0.05) of cell population. CCCP is an oxidative phosphorylation 
decoupling agent which acts as a positive control for the experiment.  
 
 
Figure 5.4 Loss of mitochondrial transmembrane potential in HSC2 cells treated with 
R10 and R15 at 0.1 μM for various intervals analysed using flow cytometry. Cells 
treated with 5 μM of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) for 5 min was 
included as a positive control. *Difference with p<0.05 compared to control at 0 h. 
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Since the rosamines were shown to primarily localise in the mitochondria and 
they induced loss of mitochondrial membrane potential, their effect on the oxidative 
phosphorylation pathway was therefore investigated.  By using immunocapture ELISA 
microplate assay, the mitochondrial redox carriers namely Complex I, Complex II, 
Complex IV and ATP-synthase were monitored for their enzyme kinetics upon 
treatment with R10 and R15.  From Figure 5.5, the activity of Complex II was partially 
inhibited by R10 with IC50 value of 9.6 ± 0.1 μM whereas for R15, inhibition was 
observed but with undetermined IC50 value. Meanwhile, both R10 and R15 displayed 
inhibition of ATP synthase activities with IC50 values of 3.0 ± 0.8 μM and 3.9 ± 0.3 μM 
respectively.  The activity of Complex I and Complex IV were not affected by the 
rosamines at treated concentrations (highest at 10 μM).  This data indicates that these 
rosamines act by compromising the mitochondrial bioenergetics function primarily by 
inhibiting ATP synthase, a proton-driven enzyme that produces ATP from ADP and 
inorganic phosphate.  Similar biochemical interaction was observed in Rh123 and this 
effect is expected as the compound has close structural similarity with the rosamine 
(Modica-Napolitano et al. 1984). 
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Figure 5.5 Inhibition of mitochondrial oxidative phosphorylation complexes. The dose-
response inhibition of mitochondrial oxidative phosphorylation Complex 1 (A), 
Complex II (B), Complex IV (C) and ATP synthase (D) activities by rosamine R10 
(solid line) and R15 (dotted line). IC50 values depict concentrations that inhibit the 
complexes activity by 50%. ND - indicate non-determined IC50 values based on the 
concentration used. 
 
5.3.6 In Vivo Antitumour Effect of Rosamines  
R10 was selected for further evaluation in in vivo tumour model given its in vitro 
potency and ability to achieve aqueous solubility large enough for preparing an 
intravenous injection. As illustrated in Figure 5.6, tumour growth attenuation was 
observed at experimental end-point (day 14) when the mice received a single bolus of 5 
mg/kg of R10 i.v. compared to the control group (p-value=0.08). The tumour growth 
attenuation effect is further enhanced (p-value=0.029) when the mice received a 
rosamine treatment regimen of 3mg/kg, once every two day, for six times (q2d×6). The 
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median day for 4T1 tumour in attaining two-doubling growth (RTV=4) were 
approximately 9, 11 and 13 days in control mice, mice receiving 5 mg/kg and 3 mg/kg 
(q2d×6) respectively. The percentage of two-doubling tumour growth delay (T-C)/C in 
mice treated with 5 mg/kg and 3 mg/kg (q2d×6) of R10 were determined to be 22% and 
38%, respectively.  
0 2 4 6 8 10 12 14
0
2
4
6
Vehicle control
5 mg/kg (single)
3 mg/kg (q2dx6)
*
Day
M
e
d
ia
n
 r
e
la
tiv
e
 t
u
m
o
r 
vo
lu
m
e
 
Figure 5.6 In vivo antitumour effects of rosamine. The relative tumour volume (RTV) – 
time profile of 4T1 murine breast carcinoma in BALB/c mice following intravenous 
dosing of R10 or saline as vehicle control. Each point represents median ± 95% 
confidence interval of RTV to staging day (n = 8). The terminal % T/C value for mice 
receiving 5 mg/kg and 3 mg/kg (q2d×6) of R10 were 72% and 66% respectively. The 
two doubling tumour growth delay (T-C)/C (dotted line, RTV=4) for mice receiving a 
single bolus of 5 mg/kg and multiple doses of 3 mg/kg (q2d×6) of R10 were 22% and 
38%, respectively. T and C refer to RTV for treatment and control groups, respectively. 
*Difference with p<0.05 compared to control animal.  
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Meanwhile, the terminal percent test/control (% T/C) values calculated at the 
end of experiment were 72% and 66% in mice receiving 5 mg/kg and 3 mg/kg (q2d×6) 
respectively. The antitumour efficacy of R10 was modest as the % T/C attained after 
treatment had ended was not ≤ 40% activity, the minimal rating for a compound to be 
considered active (Plowman et al. 1997). Loss of body weight (Figure 5.7) was 
observed in mice treated with R10 throughout the experimental period, however the 
reduction at any time were not statistically significant compared to the untreated mice. 
None of the mice suffered weight loss of more that 15%, the cut-off limit set in the 
experiment (Workman et al. 2010). From this study, the in vivo anticancer effect 
showed by R10 is modest, probably because 4T1 was an aggressive tumour cell line and 
the dose of compound R10 used was not high. However, the use of a higher 
concentration was not possible because of unacceptable adverse effects such as weight 
loss, diarrhea and sudden death which were observed at 10 mg/kg dose. 
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Figure 5.7 Effects of rosamine on mice body weight. Percentage of mean body weight 
of mice receiving 5 mg/kg or 3 mg/kg (q2d×6) of R10 compared to untreated mice. 
Body weight loss was observed in treatment groups but none of these mice experienced 
weight loss of more than 15%.  
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Even though these rosamines (i.e 2 and 5) are more cytotoxic against cancer 
cells compared with normal epithelial cells (previously published data (Lim et al. 
2009)), their effects on normal cells could still lead to undesirable side effects as a result 
of increase lactic acid accumulation in cells following decreased ATP synthase activity 
and a shift in metabolic pathways from aerobic to anaerobic metabolism.  Accumulation 
of lactic acid has been shown to cause depressive cardiovascular function, cardiac 
arrhythmias and multiple organ failure. Therefore, risk minimisation measures to deal 
with lactic acidosis such as those employed in the management of patients prescribed 
with metformin, a commonly used antidiabetic drug with similar toxic side effects, need 
to be outlined to prevent this serious complication (Kraut and Madias 2012; Renda et al. 
2013). 
Another documented side effect commonly associated with DLC such as 
rosamines is selective accumulation of these compounds in cardiac muscle cells that can 
lead to fatal deterioration in the function of the heart muscle (Kurtoglu and Lampidis 
2009). Studies have shown that cardiac muscle cells are similar to cancer cells in 
exhibiting high negative plasma membrane potentials and therefore have increased 
uptake of DLC. In connection to this, doxorubicin which is a positively charged 
antracycline antitumour agent, is also shown to target the cardiac muscle cells and 
causes serious and occasionally fatal cardiotoxicity in a significant number of treated 
cancer patient (Aiken et al. 2009). However, following liposomal encapsulation of 
doxorubicin, cardiotoxicity was diminished in cancer patients receiving the formulation 
with no loss of efficacy (Kesterson et al. 2010). It therefore remains to be investigated 
whether a similar encapsulation approach (i.e. encapsulation of rosamine with liposomal  
formulation) may limit the toxicity to sufficiently allow higher dose to be safely used in 
preclinical study. 
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5.3.7 NCI-60 Screen 
Screening of compounds against the NCI-60 cell line panel gives a wealth of 
information on the growth inhibitory effects of molecules across a wide variety of 
human tumour cell lines including cell type specific effects (selective growth inhibition 
or cytotoxic properties), correlation with specific genes or protein expression levels, and 
comparison of the mode of action with compound of known action by COMPARE 
(Computerised Pattern-recognition algorithm) analysis (Weinstein et al. 1997). 
 
5.3.7.1 Compounds Selection and Submission 
A total of seven rosamines namely R10-R16 were submitted online to NCI 
Development Therapeutic Programme (DTP) for request to be tested against 60 
different human cancer cell lines, representing leukemia, melanoma and cancers of the 
lung, colon, central nervous system, ovary, breast, prostate, and renal subpanel. The 
seven compounds which consist of two analogs class with different heterocyclic and 
phenyl-halide substitution at the para position were selected based on their potency 
from in-house screening. From the seven rosamines, three were shortlisted by the DTP 
staff for testing based on defined guidelines i.e. compound ability to add diversity to the 
NCI small molecule collection, and compounds with drug-like properties designed 
utilising the concept of privileged scaffolds or structures based on computer-aided 
design. 
 
5.3.7.2 NCI In Vitro Screen 
In NCI in vitro screen, three response parameters (GI50, TGI, and LC50) were 
determined for each cell line. The GI50 value (growth inhibitory activity) corresponds to 
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the concentration of the compounds causing 50% decrease in net cell growth, the TGI 
value (cytostatic activity) is the concentration of the compounds resulting in total 
growth inhibition and the LC50 value (cytotoxic activity) is the concentration of the 
compounds causing net 50% loss of initial cells at the end of the incubation period 
(48 h). A mean graph for each parameter was tabulated to illustrate the rosamine-
activity pattern, with bars representing the response deviation of individual tumour cell 
lines from the overall mean value for all the cells tested. Positive values project to the 
right of the vertical line represent cellular sensitivities to the test agent that exceed the 
mean. Whereas, negative values project to the left represent cell line sensitivities to the 
test agent that are less than the average value (Figure 5.8 - 5.10). 
From the mean graphs, mean GI50 values  generated from the NCI-60 cell lines 
screen indicated that R10, R11 and R13 exhibited similar 50% growth inhibitory 
potency with Log10GI50 (M) values  of -7.16, -7.28  and -7.02, respectively (GI50 = 
0.069 µM, 0.052 µM and 0.095 µM, respectively). Meanwhile, the mean value that 
induced total growth inhibition (Log10TGI) for R10, R11 and R13 was achieved at 
concentration (M) of -6.58, -6.51 and -6.52, respectively (TGI = 0.26 µM, 0.31 µM and 
0.30 µM, respectively). The mean concentration (M) for R10, R11 and R13 to induce 
50% killing of initial cells (Log10LC50) was achieved at -5.94, -5.78 and -5.95 
respectively (LC50 = 1.2 µM, 1.7 µM and 1.1 µM, respectively). From the activity 
pattern, all the three rosamines were particularly more effective against a colorectal 
cancer subpanel across the three response parameters (except for HCT-15). The renal 
cancer subpanel was also more sensitive to R11 in all the three response parameters. 
Meanwhile, the leukemia subpanel is less sensitive towards rosamines treatment at TGI 
and LC50 concentrations compared with other tested cell lines.  
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Figure 5.8 NCI mean graphs that illustrate the pattern activity at GI50 (50% growth 
inhibition), TGI (total growth inhibition) and LC50 (50% lethal concentration) response 
parameters in the NCI-60 cell line screen for R10. 
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Figure 5.9 NCI mean graphs that illustrate the pattern activity at GI50 (50% growth 
inhibition), TGI (total growth inhibition) and LC50 (50% lethal concentration) response 
parameters in the NCI-60 cell line screen for R11. 
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Figure 5.10 The mean graphs that illustrate the pattern activity at GI50 (50% growth 
inhibition), TGI (total growth inhibition) and LC50 (50% lethal concentration) response 
parameters in the NCI-60 cell line screen for R13. 
 
For better illustration of tumour-type selectivity, box and whisker plots were 
constructed (Figure 5.11-5.13). Dotted line across the plot represents overall mean value 
of all the tested cell lines and the significant differences (p<0.05) between cell-type 
subpanel mean and overall mean values were determined using one sample t-test. The 
leukemia subpanel was significantly less sensitive towards rosamines treatment at TGI 
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and LC50 concentrations compared with other tested cell lines. Meanwhile, significant 
increase in sensitivity was observed in the melanoma subpanel treated with R10 at LC50 
value; in renal and colon subpanel treated with R11 at TGI and LC50, respectively; and 
in melanoma treated with R13 at LC50 value. 
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Figure 5.11 Cytotoxicity of R10 on NCI-60 cancer subtypes. Box and whisker plots of 
R10 cytotoxicity against NCI-60 cancer subtypes at GI50, TGI and LC50 values. 
*Difference with p<0.05 compared to mean value across panel of cell lines (dotted line) 
determined using one-sample t-tests. 
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Figure 5.12 Cytotoxicity of R11 on NCI-60 cancer subtypes. Box and whisker plots of 
R11 cytotoxicity against NCI-60 cancer subtypes at A) GI50, B) TGI and C) LC50 
values.  *Difference with p<0.05 compared to mean value across panel of cell lines 
(dotted line) determined using one-sample t-tests. 
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Figure 5.13 Cytotoxicity of R13 on NCI-60 cancer subtypes. Box and whisker plots of 
R13 cytotoxicity against NCI-60 cancer subtypes at A) GI50, B) TGI and C) LC50 
values.  *Difference with p<0.05 compared to mean value across panel of cell lines 
(dotted line) determined using one-sample t-tests. 
 
5.3.7.3 COMPARE Analysis 
The NCI COMPARE analysis allows the probable mode of action to be inferred by 
comparing the drug-activity patterns against standard anticancer agents with known 
targeting characteristics (Shoemaker 2006).  COMPARE (computerised pattern-
recognition algorithm) analysis utilises the mean graph profiles generated from the NCI-
60 cell line screen to determine and express the degree of activity patterns similarity 
with Pearson Correlation Coefficient (PCC) values. PCC values >0.6 are considered to 
indicate similarities on the basis of chemical structure and mechanism of action to 
known agents (van Osdol et al. 1994; Weinstein et al. 1997).  
In Table 5.3, COMPARE analyses indicated that both the rosamines R10 and 
R13 shared strong similarities in activity patterns with methyl violet (NSC271967), a 
cationic triarylmethane dye which has been formerly used in medicine for its 
antimicrobial, antifungal and antihelmintic properties. This class of dyes had been 
shown to promote mitochondrial respiratory inhibition by inhibiting ATP synthesis, 
dissipating mitochondrial membrane potential and inducing mitochondrial permeability  
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Table 5.3  COMPARE analysis of R10, R11 and R13 with standard agents at GI50 
values 
Rosamine 
(NSC No.) 
PCC
a
 Compound/Class (NSC No.) Mechanisms of action 
(Ref)
b
 
R10 
(751817) 
0.72 Methyl violet dye (NSC271967) 
 
Mitochondrial 
respiratory inhibitor 
(Spikes and Bommer 
1993) 
 0.611 Aclacinomycin HCl (NSC654508) 
 
Topoisomerase II 
inhibitor (Nitiss et al. 
1997) 
 0.598 (NSCS140380) 
  
Antifolate (Andrea and 
Kalayeh 1991) 
    
R11 
(751818) 
0.728 Acridine thioether (NSC751818) 
 
Topoisomerase I/II 
inhibitors (Santelli-
Rouvier et al. 2004) 
 0.657 Acridine thioether (NSC699927) 
 
Topoisomerase I/II 
inhibitors (Santelli-
Rouvier et al. 2004) 
 
 
 
 
130 
 
Table 5.3, continued  
 0.657 (NSC698379)
 
Unknown  
    
R13 
(751819) 
0.767 Methyl violet dye (S271967)  
 
Mitochondrial 
respiratory inhibitor 
(Kowaltowski et al. 
1999) 
 0.644 Methyl violet BASIC BLUE 1 
(S83193) 
 
Possible mitochondrial 
respiratory inhibitor 
(Kowaltowski et al. 
1999) 
 0.585 Methyl violet BASIC VIOLET 3 
(NSC 3090) 
 
Mitochondrial 
respiratory inhibitor 
(Kowaltowski et al. 
1999) 
a PCC – Pearson correlation coefficient and PCC values >0.6 are considered to indicate a significant 
similarity to known agents (Weinstein et al., 1997). b Ref – reference. 
 
transition (Moreno et al. 1988; Kowaltowski et al. 1999).  Thus the NCI-60 cell lines 
screen indicated the compounds tested had a signature unique to energy metabolism-
targeting anticancer agents. Data from the COMPARE analysis further confirmed our 
earlier findings, indicating that rosamines interfered with energy redox. Furthermore, 
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both the rosamines share basic structural similarity with triarylmethane dye, deferring 
only in the presence of an oxygen bridge. 
Meanwhile, the activity patterns for R10 also showed strong correlation with 
aclacinomycin, whereas R11 was strongly correlated with acridine thioethers, where 
both aclacinomycin and acridine thioethers are topoisomerase I/II inhibitors (Nitiss et al. 
1997; Santelli-Rouvier et al. 2004). These findings suggest that another possible 
anticancer mechanism of rosamines is through the inhibition of topoisomerase activity. 
It is thought that the planar structure of R10 and R11 is the contributing factor for their 
topoisomerase inhibition. 
 
5.3.7.4 Cancer Genes Mutations and Drug Activity 
Recent studies have indicated that mutations in cancer genes may influence cellular 
sensitivity to chemotherapy. For examples, p53 mutations correlate significantly with 
resistance to platinum-based chemotherapy in ovarian cancer patient (Reles et al. 2001), 
and PIK3CA mutations have been correlated with altered sensitivity to taxanes in 
human cancer cell lines and with treatment outcome of patients (Santarpia et al. 2008). 
Data from the NCI-60 screen can be used to correlate activity to specific genes mutation 
or differential protein expression level (Weinstein et al. 1997). A database such as the 
Catalogue of Somatic Mutations in Cancer (COSMIC) provides a comprehensive list of 
genetic mutations for the NCI-60 cell-panel 
(http://www.sanger.ac.uk/genetics/CGP/NCI60). Using the information obtained from 
COSMIC, the effects of mutations in 7 individual genes and 5 gene combinations on 
drug-activity were tested. The 7 individual genes consist of TP53, CDKN2A, PTEN, 
KRAS, BRAF, APC and PICK3CA which represent the most common mutations found 
in the NCI-60 cell-panel (Ikediobi et al. 2006).  Meanwhile, the 5 gene combinations 
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were selected to assess the effect of mutations of multiple genes involved in the same 
pathway on drug activity (Ikediobi et al. 2008). For example, compound that may act on 
proliferative signaling pathway, cell lines mutant for either RAS and/or BRAF were 
group together. The following are the gene combinations and their related pathway in 
parenthesis:  RAS and/or BRAF (MAPK signaling pathway in regulating cell 
proliferation); RB1 and/or CDKN2A (retinoblastoma pathway in regulating cell 
proliferation); KRAS and/or PIK3CA (PI3K/AKT pathway in suppressing senescence); 
PIK3CA and/or PTEN (phosphoinositide 3-kinase pathway which regulates growth, 
survival, and proliferation); and KRAS and/or PIK3CA and/or PTEN (mTOR signaling 
pathway which promotes cell survival).   
From the analysis (Figure 5.14 - 5.16), no statistically significant differences 
(Student’s t-test, p<0.05) were observed in the activity of rosamines against cell lines 
with mutations either in individual genes or in combinations compared to cell lines with 
correspond wild-type genes. This finding indicates that the anticancer activity of 
rosamines was not affected by present of mutations and that they do not particularly 
target any signaling pathway involves in tumourigenesis. Since we have shown that 
rosamines inhibit the oxidative phosphorylation pathway, it would be interesting to 
investigate if different cellular bioenergetics of the NCI-60 cell lines such as 
mitochondrial respiration and glycolysis levels would affect rosamines activity. 
However, at present time, there is no report on the cellular bioenergetics of NCI-60.  
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Figure 5.14 Box and whisker plots of the -log10 (GI50) values of R10 tested in wild 
type (Wt) and mutant (Mt) cell lines of the NCI-60 for twelve gene categories. Larger -
log10 (GI50) values indicate increased sensitivity to the drug compound. 
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Figure 5.15 Box and whisker plots of the -log10 (GI50) values of R11 tested in wild 
type (Wt) and mutant (Mt) cell lines of the NCI-60 for twelve gene categories. Larger -
log10 (GI50) values indicate increased sensitivity to the drug compound. 
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Figure 5.16 Box and whisker plots of the -log10 (GI50) values of R13 tested in wild 
type (Wt) and mutant (Mt) cell lines of the NCI-60 for twelve gene categories. Larger -
log10 (GI50) values indicate increased sensitivity to the drug compound. 
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5.4 Conclusions 
The photophysical properties of rosamine could be fine-tuned by minor modification 
such as cyclic-amine and meso-aryl substitutions hence rendering them ideal as 
photosensitiser in contrast to tetrapyrrole-based photosensitiser. However, these 
modifications did not improved the photodynamic efficiency of rosamine but enhanced 
their non-PDT induced cytotoxicity. Therefore, their in vitro antiproliferative activities 
against a panel of cell lines from leukemia and solid tumours were investigated instead.  
SAR study indicated the importance of having hydrophobic substituents at the 
peripheral cyclic-amines as well as at the meso-aryl groups.  Structures with aryl 
substituents at the meso position, either directly attached or througha -CH2- spacer 
conferred extra activity.  The most active compounds R10 and R15 were at least 10-fold 
more potent than Rh123, a structurally similar compound whose anticancer properties 
have been extensively investigated. 
Fluorescence microscopy studies showed that rosamine localises exclusively 
within the mitochondria.  This, together with data from cell cycle analysis and onset of 
apoptosis studies, suggests that rosamine-induced cell death through mitochondria-
dependent apoptosis rather than through damage to nucleic materials.  The anticancer 
effects of these compounds were associated with their ability to compromise 
mitochondrial membrane potential and to inhibit the oxidative phosphorylation 
complexes primarily the ATP synthase (Figure 4.18). This observation was further 
confirmed by COMPARE analysis of the NCI-60 screen data that rosamine activity had 
a strong correlation in growth inhibitory pattern with that exhibited by a mitochondrial 
respiratory inhibitor i.e. crystal violet. 
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Figure 5.17 The inhibition of rosamines on the oxidative phosphorylation pathway 
complexes i.e Complex II and ATP synthase  which were associated with cell death and 
loss of mitochondrial transmembrane potential.    
 
Although the in vivo antitumour effects of R10 was moderate against 4T1 
murine mammary tumour, it may be worthwhile to test the compound in colon cancer 
models for example models based on HCT-116 and HT-29 cell lines as both were more 
sensitive to R10 based on the NCI-60 cell line screen. Without a doubt, proper strategies 
need to be devised to deliver and enhance tumour uptake of rosamines for example by 
integration to carrier molecules to improve safety and therapeutic outcome. Overall, our 
results suggest that these compounds offer a unique potential for the design of 
mitochondrial targeting agents that either directly kill or deliver cytotoxic drugs to 
selectively kill cancer cells. 
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CHAPTER 6 
 
General Discussion and Recommendation of Future Research 
 
6.1 General Discussion 
The discovery and development pathway of photosensitisers in general is very similar to 
that for conventional therapeutics. The major difference lies in the incorporation of 
photo-property assays into the development schedule. As with conventional 
therapeutics, one of the major reasons for new compound synthesis is to improve 
selectivity, and therefore therapeutic efficacy. New compounds may have altered 
hydrophilic/lipophilic balance that may improve cellular uptake and pharmacology 
/pharmacokinetic profiles. New compound synthesis may also affect the 
photosensitising properties of the compounds. The main goal of photosensitiser design 
is to develop photosensitisers with the most ideal characteristics as mentioned in Section 
2.3.1. 
Throughout the modern era of PDT research, the discovery and development of 
photosensitiser had evolved around porphyrins. As discussed in Section 2.3.2, much of 
these efforts focus on optimising or synthesis of tetrapyrrole-based chromophores such 
as chlorins, bacteriochlorins and phthalocyanines as potential improvements for 
anticancer application. However, challenges in synthesis and purification of 
tetrapyrroles have restricted modulation of their photophysical and biological properties 
through chemical derivatisation during drug development. Therefore, there is an interest 
among photodynamic research groups in discovering other tetrapyrrole and non-
tetrapyrrole photosensitisers that might be more synthetically accessible. 
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One of the approaches of discovering new photosensitiser chromophore is 
through natural product screening. It cannot be denied that natural product has made 
invaluable contribution to drug discovery for potential anticancer agents and as source 
for photosensitiser discovery used in modern PDT. However, bio-assay guided isolation 
for photosensitiser from natural resources often leads to identification of known or 
derivatives of cyclic tetrapyrrolic based photosensitiser. In our attempts to tap into 
Malaysia natural resources for new photosensitisers, approximately 300 plant extracts 
that exhibited photocytotoxicity were subjected to dereplication by using liquid 
chromatography mass spectrometry coupled with principal component analysis (LCMS-
PCA) technique. From the study, only eight photosensitisers were identified and 
importantly, they were all based on the cyclic tetrapyrrole structure. These 
photosensitisers were probably degradation products from the ubiquitous plant 
chlorophylls (Kessel 1992).   
On the other hand, biological stains mainly used as fluorescence probes or 
histological stains may be an alternative source for photosensitiser drug discovery. Such 
examples include the class of compounds belonging to acridine, phenothiazinium, 
xanthene and BODIPY (see Section 2.3.3). Typically, they have high absorption 
extinction coefficients, high quantum efficiencies of fluorescence, relative insensitivity 
to environment and resistance to photobleaching. As fluorescence occurs through 
relaxation from singlet excited state, high quantum yield for fluorescence is undesirable 
since much of the energy absorbed on excitation would not cross to the triplet states. 
However, fluorescence quantum yield could be converted to singlet-to-triplet 
intersystem crossing quantum yield (to facilitate generation of reactive singlet oxygen) 
through compound modification. More importantly, their ease in synthesis (through 
chromophoric extension and auxochromic functionalisation) and purification allows for 
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large quantities of pure photosensitiser to be prepared, thereby making them more 
commercially viable. 
In Chapter 3, we had shown that conjugation of G2 with ionisable amino acids 
was able to alter their photosensitising efficacies by modifying multiple parameters i.e 
absorption coefficient, singlet oxygen quantum yield, cellular uptake, photostability and 
intracellular localisation. These G2-derived photosensitisers had absorption wavelength 
> 660 nm wavelength which allow deeper access into biological tissue for effective 
treatment of larger or deep-seated lesion. Although both the lysine and aspartic acid 
conjugation successfully increased the aqueous solubility of G2, the conjugation had 
resulted in the loss in vitro PDT efficiencies especially with lysine. When evaluated in 
physiological setting, G2-Asp however was able to achieve equivalent in vivo PDT 
efficacies as G2 in both the CAM model and the in vivo mouse tumour model. Given 
the hydrophilic nature of G2-Asp, the photosensitiser is a pharmaceutically 
advantageous candidate as it can be formulated easily for administration and reduces the 
risk of vascular aggregation.  
In Chapter 4, we had shown that BODIPY is a good chomophore candidate to be 
developed as a photosensitiser since their photophysical properties such as λabs and 
molar extinction coefficient of BODIPY could be fine-tuned by minor modification to 
the chromophore core for examples; iodination on the BODIPY pyrollic carbon resulted 
in red-shift λabs and higher singlet oxygen generation, while extended conjugation at 
similar position shifts the λabs to the red. BODIPY was found to induce cell death 
through mitochondria-dependent apoptosis following photosensitisation and was able to 
occlude the vasculature network in the CAM in vivo model. These findings further 
substantiated its potential to be explored as a clinically useful agent for PDT of cancer. 
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The BODIPY studied here had a relatively short absorption wavelength ranging 
from 500-580 nm. Although photosensitisers with excitation > 600 nm wavelength 
allow deeper access into biological tissue for effective treatment of larger or deep-seated 
lesion, these shorter wavelength absorbing BODIPYs may be preferred in treatment of 
superficial lesion tissues such as  basal cell carcinoma,  melanoma or mucosal 
carcinoma of hollow organs. For example, rose Bengal with 549 nm excitation 
wavelength has been used successfully for the treatment of metastatic melanoma in a 
Phase II clinical trial and is currently being investigated in Phase I trial for treatment of 
cutaneous and subcutaneous tumours under compassionate use. In addition, in a clinical 
PDT study for superficial cancer in the esophagus and bronchi with porfimer sodium, 
treatment regime with light corresponding to the 514 nm excitation wavelength 
exhibited similar effectiveness as that with 630 nm in terms of tumour eradication but, 
significantly, with less damage of the deep tissues which could cause perforation on the 
esophagus (Grosjean et al. 1998). 
Another group of compounds that we evaluated for PDT efficacy belongs to a 
new class of rosamine derivatives (Chapter 5).  Like the BODIPY, their photophysical 
properties such as λabs and molar extinction coefficient could be modulated by minor 
modification to the chromophore core for examples; cyclic-amine substitution 
particularly with piperidine drastically improved the compound absorptivity, while, 
substitution of meso-aryl with heterocyclic or phenyl-halide red-shifted the λabs. Such 
modifications however were not sufficient for the compounds to produce potent photo-
induced cytotoxicity. Probably this could be due to the lack of conversion yield of the 
compounds to triplet excited state following light irradiation, a process that controls the 
singlet oxygen production. To overcome this, conjugation of heavy atom such as 
chlorine, bromine and iodine to the chromophore core, or substitution of the oxygen 
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bridge with heavier chalcogen atoms may enhance the crossing of singlet to triplet state, 
a phenomenon known as “heavy atom effects”. 
Despite lack of photodynamic efficacies, several of the rosamines having 
hydrophobic cyclic-amines and meso-aryl substituents exhibited potent cytotoxic 
effects. These compounds were found to localise in the mitochondria and induced 
apoptotic cell death which was associated with membrane potential loss and inhibition 
of oxidative phosphorylation enzymes activity. Nevertheless, the lead rosamine (R10) 
evaluated in in vivo model only exhibited modest antitumour activity probably due to 
insufficient drugs concentration administered. However the use of higher drug doses in 
the study was limited by adverse side-effects. As in the case of doxorubin as discussed 
in Section 5.3.7, liposomal formulation possibly may reduce the adverse side-effects 
and higher drug doses could then be used to evaluate its antitumour efficacies. 
It is interesting to point out that both the BODIPY and rosamine localised 
particularly well in the mitochondria. Numerous studies have shown that the 
mitochondrial membrane potential of carcinoma cells is higher than in normal epithelial 
cells and that the accumulation and retention of lipophilic cations correlated with the 
mitochondrial membrane potential (Lampidis et al. 1985; Modica-Napolitano and 
Aprille 2001). The increase in mitochondrial membrane potential in carcinoma cells had 
led to selective accumulation of toxic lipophilic cations, thereby providing a rationale 
for treatment selectivity. This is feasible because mitochondria are the main energy 
generators which maintain cell life and are involved in diverse cellular events by being 
an integral part of multiple signaling cascades in regulation of metabolism, cell cycle 
control, development, and cell death (McBride et al. 2006). Furthermore, 
reprogramming of energy metabolism has been identified as one of the emerging 
hallmarks of cancer and mitochondria are recognised as a potential anticancer targets 
(Hanahan and Weinberg 2011).  
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Targeting the mitochondria is a viable strategy because the lack of selectivity of 
current conventional cancer chemotherapy that acts by interrupting DNA replication, 
i.e. by inhibiting the synthesis or function of new nucleic materials, or by causing 
irreparable damage to vital nucleic acids through intercalation, alkylation or enzymatic 
inhibition had resulted in unwarranted side-effects. On the other hand, contemporary 
chemotherapeutic strategies that target signaling pathways or particular gene products 
tend to be limited to cancers driven by a dominant oncogene and are often vulnerable to 
resistance through the multiplicity of tumourigenesis signaling pathways (Lemmon and 
Schlessinger 2010).  For example, most of the HER-2 positive metastatic breast cancer 
patients who initially responded to treatment with trastuzumab developed secondary 
trastuzumab resistance within a year after the treatment began (Nahta and Esteva 2007).  
Similar observations have been made for BRAF-targeted vemurafenib for melanoma 
therapy (Alcala and Flaherty 2012) and EGFR-targeted gefitinib or erlotinib for the 
treatment of non-small cell lung cancer (Ayoola et al. 2012). In contrast, mitochondria 
is a cellular targets that all cancer cells have in common, especially those in metastatic 
cancers and therefore, shutting down the mitochondria either by photosensitisation or 
toxic lipophilic cations insult, will disrupt essential cellular functions that subsequently 
can lead to cell death. 
Over the years, the used of PDT for cancer treatment has increased 
tremendously as clinicians started to recognise the advantages that PDT holds over 
conventional therapy for cancer such as surgery, chemotherapy and radiotherapy. The 
non-invasive procedure of PDT is specifically useful for treating lesions which are 
anatomical challenging, for favorable cosmetic outcomes and repeat treatments can be 
performed when necessary without the risk of resistance development. In a recent match 
cohort comparison study, it has shown that PDT is able to achieve disease control and 
survival at comparable rates to trans-oral surgery in treating patients with early stage 
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oral cavity squamous cell cancer (Karakullukcu et al. 2013). Because of the tissue 
sparing properties of PDT, this has rendered the used of PDT as an alternative treatment 
for early stage cancer especially attractive in patients with extensive malignant lesions. 
It is hope that in the future, PDT may become an integrated part of the mainstays for 
cancer therapy.  
 
6.2 Recommendation of Future Research 
Data from G2 study showed that complete tumour regression was observed in two out 
of eight mice treated with G2-Asp. Therefore, it would be interesting to investigate 
whether higher number of complete tumour regression could be achieved by performing 
multiple PDT. Unlike chemotherapy and radiotherapy, PDT has no cumulative toxicity 
or does not cause the development of resistance clones. In addition, the photosensitiser 
pharmacokinetics parameters for example uptake/clearance in tumour tissues need to be 
understood further to ascertain the optimal time interval between drug administration 
and light irradiation. 
Data from our study offer invaluable SAR information for synthesis of second 
generation BODIPY and rosamines with improved PDT efficacies. For BODIPY, the 
relatively short λabs could be increased by benzylation at the position as shown in Figure 
6.1. Attachment of electron donating groups (i.e. benzyl) is known to red-shift the 
absorption though with the expense of increasing lipophilicity. Highly lipophilic 
photosensitisers tend to have poor aqueous solubility and might pose a challenge in drug 
delivery during clinical development. Therefore, attachment of hydrophilic substituents 
such as carboxylates or sulphonates may be considered to improve their solubility. 
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Figure 6.1 Potential structural modification (in red) on BOBIPY chromophore  to 
improve its PDT efficacies.  
Meanwhile for the cyclic-amine rosamines, their photosensitising efficacy i.e. 
singlet oxygen production could be increased by heavy chalcogen atoms substitution at 
the central heteroatom or by halogenation of carbon adjacent to the core. The additions 
of akyl or aryl moieties to the chromophore will extent the λabs to the red. It is also 
essential to consider the addition of hydrophilic substituents such as carboxylates or 
sulphonates to improve the hydrophilicity of these rosamines (Figure 6.2). 
 
Figure 6.2 Potential structural modification (in red) on rosamine chromophore to  
improve its PDT efficacies. 
146 
 
For downstream development of BODIPY as photosensitiser, it would be 
interesting to investigate their efficacy in in vivo tumour model. Since the BODIPY 
studied here possessed slightly shorter excitation wavelength and that non-invasive 
delivery of light was almost limited to the skin and oral cavity, it is recommended to 
evaluate their efficiency in superficial embedded tumour model. For this, we would 
propose the use of dimethylbenz[a]anthracene (DBMA) -induced hamster cheek pouch 
tumour model which is a well-characterised squamous cell carcinoma model that 
histologically mimics human oral cancers. Furthermore, the check pouch can be readily 
inverted for local irradiation and macroscopic follow up. As for the rosamines, it is 
suggested that their in vivo antitumour efficacies are evaluated in the sensitive HCT-116 
and HT-29 tumour cell lines based on the NCI-60 in vitro screen data. Further 
formulation would be required to reduce the toxicity of the rosamines, which may also 
improve their potency and pharmacokinetic properties. 
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Abstract 
 
Photodynamic therapy (PDT) is now a well-recognised treatment modality for cancer 
and precancerous lesions. One class of photosensitisers that is currently investigated for 
PDT is the boron-dipyrromethene difluoride (BODIPY). BODIPYs have many ideal 
photosensitiser characteristics including high extinction coefficients, high fluorescence 
quantum efficiencies, relatively insensitive to environment and resistance to 
photobleaching. In this study, two structural variations of BODIPY were investigated 
for their efficacies as photosensitisers. In the first variation, functionalisations such as 
meso-substitution and sulphonation to improve hydrophilicity were tested to fine-tune 
the activity of iodinated BODIPY. The second variation consisted of compounds with 
extended conjugation at the 4-pyrollic position which had not been studied before. The 
PDT efficacies of BODIPYs were evaluated by means of singlet oxygen generation rate 
and in vitro microculture MTT assay. The most potent BODIPY was further 
investigated for its intracellular localisation using confocal microscopy technique, cell 
cycle and apoptosis by flow cytometry and vascular occlusion efficiency in a 
chorioallantoic membrane (CAM) model. Among the 16 BODIPY structures studied, 
the iodinated compound 5 was the most effective in terms of photo-induced cytotoxicity 
and singlet oxygen production. The compound was also shown to localise exclusively in 
the mitochondria, induced G2/M-phase cell cycle block and apoptosis. In addition, a 
formulated preparation of compound 5 was found to extensively occlude the CAM 
vascular network following PDT, a feature that correlate with tumor regression in 
mouse tumor models. In conclusion, iodinated BODIPY structures such as 
compound 5 have promising potential to be developed as new PDT agents for cancer 
treatment. 
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Abstract 
 
Reprogramming of energy metabolism has recently been identified as one of the 
hallmarks of cancer and therefore, mitochondria offer a unique target for cancer therapy.  
Previously, we had demonstrated the antiproliferative activity of a new class of 
mitochondria-targeting known as rosamines. These compounds were shown to was 
found to localize exclusively within the mitochondria and induced apoptosis as the 
major mode of cell death.  We now described the in vitro cytotoxicity efficacy of a 
second generation rosamine analogs, the studies to identify the molecular targets of 
these molecules and their in vivo efficacy in a mouse allograft model.  Experiments 
conducted on analogues KB14 and KB15 indicated inhibition of Complex II and ATP 
synthase activities of the mitochondrial oxidative phosphorylation pathway machinery 
which results in the loss of mitochondrial transmembrane potential.  In vivo animal 
experiments showed that KB15 was able to inhibit the tumour growth of Balb/C mice 
implanted with 4T1 mouse mammary carcinoma cells by 23% compared to the 
untreated control.  Our data suggests that rosamine analogues such as KB15 are good 
lead structures for the design of mitochondrial-targeting agents. 
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Abstract 
 
This study aims to improve the physicochemical properties and biological effectiveness 
of 151-hydroxypurpurin-7-lactone dimethyl ester (G2), a semisynthetic photosensitiser, 
for the PDT treatment of cancer. The strategy undertook was by conjugating G2 with 
amino acids moieties such as aspartic acid and lysine. The photophysical properties, 
singlet oxygen generation, distribution coefficiency (LogD) and photostability of these 
analogues and their in vitro bioactivities such as cellular uptake, intracellular 
localization and photo-induced cytotoxicity were evaluated. In addition, selected 
analogues were also investigated for their PDT-induced vasculature occlusion in CAM 
model and antitumour efficacies in Balb/C mice bearing 4T1-mouse mammary tumour. 
From the study, conjugation with Asp improved the aqueous solubility G2 without 
affecting its photophysicochemical characteristics.  G2-Asp showed similar in vitro and 
in vivo antitumour efficacies compared to the parent compound.  Given the hydrophilic 
nature of G2-Asp, the photosensitiser is a pharmaceutically advantageous candidate as it 
can be formulated easily for administration and reduces the risk of vascular aggregation. 
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